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1. Palladium- and Copper-Mediated N-aryl 
Bond Formation Reactions for the Synthesis 
of Biological Active Compounds 
 
N-Arylated aliphatic and aromatic amines are important substituents in many 
biological active compounds. In the last years, transition metal mediated N-aryl 
bond formations have become standard procedures for the introduction of 
amines to aromatic systems. N-arylation of simple aromatic halides by simple 
amines works with many described methods in high yield, the reactions may 
require detailed optimisation if applied to the synthesis of complex molecules 
with additional functional groups, such as natural products or drugs. In this 
review we discuss and compare the three main N-arylation methods and their 
applications in the synthesis of biological active compounds: Palladium-
catalysed Buchwald-Hartwig-type reactions, copper-mediated Ullmann-type and 
Chan-Lam-type N-arylation reactions. The discussed examples show that 
palladium-catalysed reactions are favoured in large scale applications and 
tolerate sterical demanding substituents on the coupling partners better than 
Chan-Lam conditions. Chan-Lam N-arylations are particular mild and do not 
require further ligand addition, which facilitates the work-up. However, reaction 
times can be very long. Ullmann- and Buchwald-Hartwig-type reactions have 
been used in intramolecular reactions providing access to complex ring 
structures. All three N-arylation methods have specific advantages and 
disadvantages that should be considered when selecting the reaction conditions 
for a desired C-N bond formation in the course of a total synthesis or drug 
synthesis. 
                                                 
∗
 Fischer, C, König B, Beilstein J. Org. Chem, 2011, 7, 59-74. 
* 
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1.1. Introduction 
Palladium- and copper-mediated N-arylations are essential tools in organic 
synthesis. Due to the widespread importance of aryl-N bond formation many 
synthetic methods emerged over the years. Beside the traditional Ullmann[1-2] 
and Goldberg[3-5] procedures, the palladium-catalysed reaction discovered by 
Buchwald[6-7] and Hartwig[8-9] has been a major breakthrough in this field. More 
recently, Chan[10] and Lam[11-12] introduced the copper-mediated arylation of N-
nucleophiles using stoichiometric copper(II) acetate and boronic acids. Collman 
improved the procedure using catalytic amounts of [Cu(OH)TMEDA]2Cl2, 
omitting the base and working at room temperature.[13-14] Beside palladium and 
copper, also nickel catalysis allows the arylation of primary and secondary 
amines.[15-16] However, the three methods (Ullmann-Goldberg, Buchwald-
Hartwig and Chan-Lam) have become standard procedures for N-aryl bond 
formation, illustrated by many examples and its wide applications in organic 
synthesis. 
The chelating phosphines BINAP, DPPF[17] and DtBPF[18,] commonly used for 
the Buchwald-Hartwig amination, were recently displaced by the biaryl-
(dialkyl)phosphine or arylphosphinepyrrole ligands.[18-20] Industrial upscale of 
these methods have already been applied in 100 kg scale for arylpiperazines 
and different diarylamines [21]. In addition, Nolan et al. and Organ et al. reported 
Pd-N-heterocyclic carbene (NHC) catalysed Buchwald-Hartwig amination 
protocols that provide access to a range of hindered and functionalized aryl 
amines.[22-24] Aryl bromides are most frequently applied as substrates for the 
coupling of primary and cyclic secondary amines.[17] In the presence of a weak 
base like caesium carbonate many functional groups are tolerated, while 
NaOtBu causes limitations for base labile functional groups. Electron neutral- 
and electron-poor aryl bromides are easily converted as substrates,[17] and 
ortho-substituents on the aryl halide are tolerated. In contrast, electron-rich aryl 
bromides give only poor results. Recently, the modular synthesis of indoles by a 
palladium-catalysed cascade process provided an efficient entry to the 
synthesis of substituted indoles.[25] 
Although copper is less toxic and less expensive than palladium, the required 
harsh conditions, the limited range of suitable substrates and moderate yields 
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prevented the use of Ullmann-type reaction at its full potential for a long time. 
Aryl halides activated by electron-withdrawing groups can only be converted at 
high temperatures (210 °C) using stoichiometric amounts of copper. The 
discovery of efficient copper/ligand systems enabled the use of catalytic 
amounts of metal under milder conditions (90-100 °C) and resulted in good 
yields.[4, 26] Copper-diamine catalysed N-arylation facilitated the arylation of 
pyrroles, pyrazoles, indazoles, imidazoles, triazoles, benzimidazoles and 
indoles.[27-29] Beside arylhalides as the aryl donor, arylsiloxanes,[30] aryl 
stannanes,[31] iodonium salts,[32] aryl lead (IV) triacetates[33] and pentavalent 
organobismuth reagents[34] were used as aryl donors for copper-mediated C-N 
couplings. 
Further improvement of N-arylation conditions were achieved by the use of 
arylboronic acids. The reagents are not sensible to air, the reaction proceeds at 
room temperature[35-36] and in aqueous solution.[37] However, the reactions are 
very slow and require several hours or even days to complete.[38] 
In general, there is a wide variety of protocols describing the metal-mediated 
arylation of amines,[17, 37, 39] amides,[38] imides,[38] imidazoles,[14, 37, 40] 
benzimidazoles,[40-41] sulfonamides,[38] pyrroles[42] and lactams.[43] The three 
typical methods for N-arylation were extensively reviewed concerning scope 
and limitation of these reactions.[4, 44-48] 
However, the application of palladium- and copper-mediated N-arylation 
reactions in the synthesis of complex molecules such as natural products or 
drugs is, in comparison to standard small molecule N-arylation, not always 
straight forward and requires specially optimized conditions. Since amine- and 
amide substituted aromatics and heteroaromatics are typical structures in 
medicinal chemistry and natural product synthesis, a broad application of 
catalytic C-N arylation is highly desirable. 
Copper-mediated C-N arylation reactions in natural product syntheses were 
recently reviewed by Evano et al. They discussed different examples of total 
synthesis using the arylation of alkylamines, amides, carbamates, N-
heterocycles, enamines and intramolecular N-arylation reactions.[45] 
Here we compare the success of the different C-N arylation reactions as applied 
to the synthesis of more complex structures and discuss selected examples of 
palladium- and copper-mediated reactions for the synthesis of bioactive 
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compounds in terms of scope and limitation. If available, we will directly 
compare the different methods and advantages of specific reaction conditions. 
The review should help synthetic chemists to select the most suitable catalytic 
C-N arylation method for their target molecule. 
 
1.2. Results and Discussion 
1.2.1. Pd-Catalysed Synthesis of Biological Active Molecules 
A typical example for the application of palladium-catalysed N-aryl bond 
formation, is the synthesis of highly selective D3 receptor ligands (4). Piperazine 
1 and a substituted aryl bromide (2) (see Scheme 1.1) are coupled in the initial 
step of the synthesis. 
 
 
Scheme 1.1: Synthesis of selective D3 receptor ligands. 
 
The electron-withdrawing substituents (nitrile and chloro) on the aryl bromide 
assisted the reaction and the reported yields of compound 3 are in the range of 
65 - 90 %. This method represents conditions of early catalyst generations and 
allowed the synthesis of a library of 18 compounds, which were investigated to 
identify a possible structure-activity relationship.[49] 
Federsel et al. used a piperazine derivative (6) and an aryl halide (5) for the 
preparation of a CNS-active substituted chiral aminotetralin (7) (see Scheme 
1.2) [50]. The 5-HT1B receptor antagonist 8 was developed for the treatment of 
certain neuronal disorders. Different syntheses have been developed in which 
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Pd(OAc)2 proved to perform better than the dba complex. BINAP turned out be 
the privileged ligand without any effect of its enantiomeric purity. The use of 
Pd(OAc)2 was advantageous on reactions of larger scales due to low cost and 
easy handling. The choice of base was crucial. NaOMe and NaOEt showed 
only low conversion in comparison to NaOtBu. The reaction tolerated up to 0.06 
% water. Thus, the conditions could be optimized for the final use in a pilot plant 
in which batches of 125 kg were synthesised in a robust and reproducible 
manner.[51] 
 
 
Scheme 1.2: Synthesis of a novel 5-HT1B receptor antagonist. 
 
Compound A-366833 (12) was found to be a broad-spectrum analgesic having 
an improved safety profile relative to other pyridine-containing analgesics. The 
efficient synthesis of this compound used a palladium-catalysed coupling for the 
final step connecting 3-bromo-5-cyanopyridine (9) with the protected (1R,5S)-
3,6-diazabicyclo[3.2.0]heptane 10. The use of Cs2CO3 instead of the 
conventional base tBuONa increased the yield of compound 11 from 47 % to 73 
% (Scheme 1.3).[52] The enantioselective synthesis of A-366833 allowed large-
scale preparation required for preclinical investigations. 
 
 
Scheme 1.3: Synthesis of A-366833, a selective α4β2 neural nicotinic receptor 
agonist. 
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Oxcarbazepine (13) (Trileptal) is one the of most prescribed drug for the 
treatment of epilepsy due to improved tolerability profile compared to 
carbamazepine. Additionally, its analgesic properties and successful treatment 
of mood disorders and mania make it an important drug. In 2005, a new method 
containing a cyclization step by intramolecular N-arylation of compound 14 
improved the access to compound 15 due to better availability of the starting 
material and a simple palladium source. Optimized conditions for the palladium 
catalysis yielded the tricyclic skeleton 15 in 91 % and minimized the amount of 
dehalogenated byproduct to 4 % (see Scheme 1.4). The beneficial effect of 
added water may be due to better dissolving of K3PO4. Scale-up to gram 
amounts was possible without significant decrease in yield. The copper-
mediated Ullmann-type reactions and heterogeneous palladium catalysis failed 
for this reaction.[53] 
Intramolecular palladium-catalysed N-arylations were applied to substituted 
arenes and thiophenes in good to excellent yields. Electron-rich bromides gave 
best results, while pyridine derivatives were unreactive.[54] 
 
 
Scheme 1.4: A new route to oxcarbazepine. 
 
Another intramolecular approach enabled the stereoselective synthesis of 
atropisomeric N-(2-tert-butylphenyl)lactam as an intermediate for 
norepinephrine transporter (NET) inhibitors (16). NET inhibitors were developed 
to treat a variety of mental disorders such as depression and attention deficit 
hyperactivity disorder (ADHD). 
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Screening different ligands, SERGPHOS appeared to give the highest 
stereoselectivity of compound 18 for the N-arylation of compound 17 (see 
Scheme 1.5).[55] Other conditions were not varied in this case. 
 
NH
O
I
tBu
R1
N O
5.0 mol% Pd(OAc)2,
7.5 mol% (R)-SERGPHOS,
2.0 eq Cs2CO3,
toluene, 80 °C, 24 h
R1 = tBu (98 % ee)
R1 = H (93 % ee)
N O
R
N
H
NET inhibitor 16
tBu
R1
95 %
17 18
 
Scheme 1.5: Synthesis of key intermediates for norepinephrine transporter 
(NET) inhibitors. 
 
Another example for BINAP not being the favoured ligand is the synthesis of the 
fungal natural product demethylasterriquinone A1 (19). Asterriquinones show 
different biological functions including anti-tumour activity and are used as 
insulin mimetics. The palladium-catalysed coupling of the styrene 20 with 
sterical demanding N-nucleophiles (21) gave the indole building blocks 22 for 
the natural product synthesis (see Scheme 1.6). In this case, PtBu3 was the 
appropriate ligand. As starting materials cyclic and aromatic amino compounds 
as well as substituted styrenes were tolerated (yields 61 % - 85 %). Only nitro-
substituted styrene resulted in poor conversion (34 %).[56] 
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N
N
O
O
OH
HO
demethylasterriquinone A1 19
Br
Cl
N
R
5 mol%Pd(OAc)2,
12 mol% HBF4
.PtBu3,
2.5 eq NaOtBu,
toluene, 130 °C, 4 h
H2N-R
1 eq 3 eq
61-85 %
20 21 22
 
Scheme 1.6: N-Annulation yielding substituted indole for the synthesis of 
demethylasteriquinone A1. 
 
The synthesis of the natural product murrazoline is also an example for 
connecting a sterical demanding N-nucleophile at two positions. Murrazoline 
(23), a carbazole alkaloid isolated from the shrub Murraya, is used in folk 
medicine for the treatment of analgesia and anesthesia, eczema, rheumatics 
and dropsy. It is known to be a potent platelet aggregation inhibition. The 
double N-arylation of compound 25 was carried out under standard conditions, 
using compound 24, and revealed the best yield of compound 26 for the 
dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine ligand (27) (59 %, see 
Scheme 1.7) compared to the ligands 28 and 29.[57] 
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Scheme 1.7: Palladium-catalysed double N-arylation contributing to the 
synthesis of murrazoline. 
 
The synthesis of vitamin E amines 35, possessing antiproliferative activity, 
could be realized by the easy and efficient procedure by coupling compound 30 
or to 31 or to 33 according to Scheme 8. Enantiopure tocopheramines (32) and 
tocotrienamines (34) were synthesised using an N-aryl amination as key step. 
Here, the leaving group was triflate instead of the typically used halides. The 
yields of the reaction range from 10 % to 80 %.[58] 
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O
R1
TfO
R2 R3
NH2
O
R1
H
N
R2 R3
+
5 mol%Pd(OAc)2,
6.5 mol% BINAP,
1.3 eq NaOtBu/CsCO3,
argon atmosphere
toluene, 85 °C, 16 h
1 eq
30
1.2 eq
31
O
R1
H2N
R2 R3
R1 = H, CH3
R2 = H, CH3
R3 =
O
R1
TfO
R2 R3
+
PhPh
NH
O
R1
N
R2 R3
Ph Ph
5 mol% Pd(OAc)2,
6.5 mol% BINAP,
1.3 eq NaOtBu,
toluene, 80 °C, 16 h
1.2 eq
33
1 eq
30
R1 = H, CH3
R2 = H, CH3
R3 =
vitamin E amine 35
32
34
 
Scheme 1.8: Synthesis of vitamin E amines. 
 
An example showing the application of both methods, the palladium- and the 
copper-catalysed N-arylation, is the synthesis of the natural product martinellic 
acid (36) and its derivative (see Scheme 1.9). The two alkaloids martinellic acid 
(36) and martinelline (37) possess antagonist activity towards bradykinin B1 and 
B2 receptors. The key step of the synthetic sequence is the connection of an 
amino acid derivative to the aromatic core. 
Miyata et al. report nearly quantitative yield of compound 40 (99 %) for the 
palladium strategy converting (S)-ethyl 5-oxopyrrolidine-2-carboxylate 39 and 2-
bromobenzaldehyde O-benzyl oxime 38 and only moderate yield using CuI (53 
%).[59] Targeting the same product, Ma et al. used copper-catalysis some years 
before. The coupling of 1,4-diiodobenzene 41 and (S)-ethyl 3-amino-6-
hydroxyhexanoate 42, and subsequent esterfication resulted in an overall yield 
of 72 % for the two steps to compound 43.[60-61] The specific yield for the 
copper-catalysed reaction step was not reported. 
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Scheme 1.9: Improved synthesis of martinellic acid. 
 
1.2.2. Cu-Catalysed Synthesis of Biological Active Molecules 
Copper-catalysed N-arylation reactions were applied to introduce diversity into 
new ABCB1 transporter modulators. The tariquidar (44) derived compounds 
showed logP dependant inhibition activity of the ABCB1 transporter, which 
represents an important component of the blood brain barrier and is a major 
limitation in cancer chemotherapy. 
Primary and cyclic secondary amines were coupled to compound 45 in 
moderate to good yields of compounds 49 and 50. Secondary acyclic amines 
48 were unreactive although a variety of different conditions was tested, 
including the variation of base, ligand and copper source. Scheme 1.10 shows 
the optimized conditions for coupling with morpholine (46) and 2-(2-
methoxyethoxy)ethanamine (47). Palladium-catalysed reactions failed due to 
the low solubility of the bromide compound in toluene.[62] 
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N
H
O
N
O
O
NH
O
N
O
O
N
H
O
N
O
O
NH
O
N
Br
20 mol% CuBr.SMe2,
40 mol% proline,
2.5 eq K3PO4,
DMSO, 90 °C, 44 h
40 mol% CuI,
75 mol% 2-isobutyryl-
cyclohexanone
1.6 eq K3PO4,
DMF, 90 °C, 48 h
R, R' =
R = H,
R' =
O
O
O
R, R' =
tariquidar 44
75 % 40 %
+ NHRR'
N
H
O
N
O
O
NH
O
N
R'RN
O
O
45
46
49
R = H,
R' = O O 47
R, R' =
O
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R, R' = O O 48
 
Scheme 1.10: New tariquidar-derived ABCB1 inhibitors. 
 
Another class of compounds related to anti-tumour treatment are β-carbolin-1-
ones (52) due to their inhibition of cell proliferation. These compounds were 
accessible using an intramolecular coupling between an aryl bromide and an 
acylated amine (51). In comparison to the Goldberg reaction conditions (CuI, 
NaH, DMF at 90 °C for two hours), the change of the solvent to DME was 
crucial for good yields up to 72 % (see Scheme 1.11). Additionally, the reaction 
was sensible to the amount of NaH. Substituents on the aryl bromine affected 
the yield marginally.[63] 
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Scheme 1.11: β-Carbolin-1-ones as inhibitors of tumour cell proliferation. 
 
A second example for intramolecular coupling is the synthesis of promazine 
drugs (56) interesting due to their clinical use for psychotropic medication. The 
CuI/L-proline-catalysed cascade process, developed by Ma et al., revealed the 
best yields for 2-methoxyethanol as solvent, compared to DMSO, dioxane and 
others. The reaction conditions tolerated electron-rich and electron-deficient 
substituents on the aniline 53 and on the 2-bromobenzenethiol 54 in different 
substitution patterns and is supposed to run over the intermediate 55. The 
catalytic synthetic sequence is an inexpensive and efficient route to the target 
compounds (see Scheme 1.12).[64] A three component coupling reaction of 2-
bromobenzenethiol (57), a primary amine (58) and 1-bromo-2-iodobenzenes 
(59), also targeting promazine derivatives (60) was successfully established 
using palladium catalysis (see Scheme 1.13). The method benefits from 
controlled regiochemistry and the applicability for various aliphatic and aromatic 
amines (58). Although the reaction scope was limited to 1-bromo-2-
iodobenzenes 59 a scale up to multigram quantities was possible.[65] 
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Scheme 1.12: Copper-catalysed synthesis of promazine drugs. 
 
 
Scheme 1.13: Palladium-catalysed multicomponent reaction for the synthesis 
of promazine drugs. 
 
A key intermediate 64 of imatinib (61), a standard anti-cancer drug treating 
chronic myelogenous leukaemia and gastrointestinal tumours, was prepared in 
a copper-mediated N-arylation of compounds 62 and 63 in 82 % yield (see 
Scheme 1.14). Screening different reaction conditions, Cu(I) turned out to be 
the best copper source compared to Cu(0) and Cu(II). In the series of aryl 
halides, aryl iodides 63 were most active. The presence of air and water gave 
only slightly lower yields. Also other heteroarylamines gave good yields.[39] 
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Scheme 1.14: Key intermediate for imatinib. 
 
The copper-catalysed domino-indole synthesis facilitated the access to the new 
Chek1/KDR kinase inhibitor 67 from phenylethynyl naphthalenes (65) and tert-
butyl carbamate (66) (see Scheme 1.15). The broad scope of this method 
improved the synthesis of diversely substituted indoles. Beside N-H indoles, N-
acyl and N-aryl indoles were accessible. For this attempt, DMEDA turned out to 
be the crucial ligand.[66] 
 
 
Scheme 1.15: Effective Chek1/KDR kinase inhibitor synthesis. 
 
Examples for the synthesis of complex biological active compounds are 
reblastatin (68) and autolytimycin (69). The potent inhibitors of heat shock 
protein 90, an important therapeutic target for cancer treatment, were accessed 
by a copper-mediated macrocyclisation step of compound 70 to compound 71 
in high yield (82 %, Scheme 1.16).[67] The same method was employed in the 
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total synthesis of glendanamycin and other 8- to 14-membered lactam-
containing natural products.[68] 
 
 
Scheme 1.16: Macrocyclisation as final step of heat shock protein inhibitor 
synthesis. 
 
A number of biological targets, such as blocking cytochrome C oxidase, made 
N-aryhistidines (74) important drug candidates. The quite simple looking copper 
triflate catalysed conversion of aryl halides (72) with an N-acylhistidine (73) 
revealed total regioselectivity on the imidazole ring, but suffered from 
complicated work-up procedures due to difficult separation from stoichiometric 
quantities of the ligand. Sufficient reactivity was only observed for aryl iodides, 
nevertheless resulting in low overall yields including the subsequent ester 
cleavage step (Scheme 1.17).[69] 
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Scheme 1.17: Synthesis of N-arylimidazoles. 
 
According to the well-known benzolactam V8 (78) synthesis[70] Ma et al. proved 
the accelerating effect of α- (76) and β-amino acids (80) to aryl aminations 
(Scheme 1.18 and Scheme 1.19). Lotrafiban (SB-214857) (79), a potent 
GPIIb/IIIa receptor antagonist inhibiting platelet aggregation, was efficiently 
obtained by an Ullmann-type aryl amination reaction. Despite the disadvantage 
of long reaction time (2 days), the intermediate 81 was obtained in enantiopure 
form.[71] 
A very similar intermediate 85, published at the same time, was synthesised by 
the coupling of L-aspartic acid (83) to an aryl bromide (82) in 55 % yield and 90 
% ee (Scheme 1.20). Under these reaction conditions CuI turned out to be the 
copper source causing the least racemization.[72] 
 
 
Scheme 1.18: Benzolactam V8 synthesis. 
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Scheme 1.19: Synthesis of an intermediate for lotrafiban (SB-214857). 
 
 
Scheme 1.20: Intermolecular effort towards lotrafiban. 
 
1.2.3. Chan-Lam Arylation Reactions of Biological Active 
Molecules 
A key intermediate for the potent matrix metalloproteases (MMPs) inhibitor 
AG3433 (89) was synthesised by coupling an electron-deficient pyrrole (86) with 
an aryl boronic acid (87) in excellent yield of compound 88 (93 %, see Scheme 
1.21). Screening numerous boronic acids showed that only boronic acids 
containing electron-donating or weakly electron-withdrawing substituents were 
suitable for this purpose. Pyrroles lacking the substituent in the 2-position, 
which is supposed to support the reaction by a chelating effect with the copper 
ion, did not succeed in the coupling reaction. Further disadvantages were the 
required stoichiometric amount of copper and the long reaction time of three 
days.[42] 
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Scheme 1.21: Matrix metalloproteases (MMPs) inhibitor synthesis. 
 
For detailed insight into structural requirements of active antimycobacterial 
purines (90), an easy access to 9-N-arylpurines (93) was required. Complete 
regioselectivity and in most cases high chemoselectivity was achieved by 
reacting 9-N-purines (91) with an excess of arylboronic acid (92) in the 
presence of copper(II) acetate, molecular sieves and phenanthroline (Scheme 
1.22). Bakkestuen et al. showed that electron-donating and electron-
withdrawing substituents on the aryl boronic acid were tolerated. However, 
adenine was unreactive under these conditions, probably due to low solubility of 
the starting material.[73] 
 
 
Scheme 1.22: Regioselective 9-N-arylation of purines. 
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Slight changes of the procedure, the use of a protic solvent, enabled the 
conversion of adenine (97) and cytosine (94) (Scheme 1.23). These conditions 
tolerated electron-donating and electron-withdrawing substituents at the o-, m-, 
p-position of phenylboronic acid 98 and resulted in moderate to excellent 
yield.[74] 
 
 
Scheme 1.23: N-Arylation of adenine and cytosine. 
 
9-N-Arylpurines (102, 105) are used as a new class of inhibitors against 
enterovirus, which are responsible for a variety of acute human diseases like 
respiratory infections, meningitis, pancreatitis and others. The conditions 
reported by Bakkestuen et al. [73] gave only low yield (26 %). Here, DMF as 
solvent and the absence of molecular sieves improved the yield (Scheme 1.24). 
The reaction conditions were compatible for different purine bases (100, 103) 
and a variety of functional groups at the arylboronic moiety (101, 104). Thus, a 
single reaction step from commercial precursors allowed the synthesis of new 
enterovirus inhibitors with activity in the low µM range.[75] 
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Scheme 1.24: 9-Arylpurines as enterovirus inhibitors. 
 
A very recent example of 7-N-arylation of purines is the synthesis of highly 
substituted xanthine derivatives (109) as fluorescent and potent kinase 
inhibitors. The conditions of Bakkestuen et al. were modified and resulted in 
yields up to 60 % for the optimized conditions using pyridine as base and 
heating the reaction mixture to 40 °C for 24 h (Scheme 1.25). Beside the p-
methoxy substituent at the boronic acid 107, p-methyl and m-fluorine were 
tolerated. The xanthine compounds showed good antiproliferative activity and 
exhibited a significant fluorescence response.[76] 
 
 
Scheme 1.25: Xanthine analogues as kinase inhibitors. 
 
The peroxisome proliferators-activated receptors (PPARs), members of the 
nuclear hormone receptor super-family, are important targets in the treatment of 
diabetes and dyslipidemia. Azetidinone acid derivatives 110 were discovered as 
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new subtype selective PPARα/γ agonists. For detailed structure-activity 
relationships (SAR) studies, diversity was introduced very efficiently by a 
copper-mediated N-arylation of azetidinones (111) with different aryl boronic 
acids (112) in nearly quantitative yields of compound 113 (Scheme 1.26).[77] 
The palladium-catalysed N-arylation of 2-azetidinones was only described for 
unsubstituted azetidinones before.[78] 
 
 
Scheme 1.26: Synthesis of dual PPARα/γ agonists. 
 
N-Aryltriazole ribonucleosides (118) with potent antiproliferative activity against 
drug-resistant pancreatic cancer were found by coupling 3-aminotriazole with 
various boronic acids. Corresponding to the method developed for N-aryltriazole 
acylonucleoside analogues,[79] the N-arylation was performed in the presence of 
stoichiometric Cu(OAc)2, pyridine and freshly activated molecular sieves in 
CH2Cl2 at room temperature and open air for three days (Scheme 1.27). There 
was no clear trend on the effect of electron-donating or electron-withdrawing 
substituents of the aryl boronic acid 116 on the course of the reaction. However, 
sterical hindered, ortho-substituted arylboronic reagents were unreactive. 
Although the coupling resulted only in moderate yield, a new anticancer drug 
candidate with improved potency on human pancreatic cancer cells, in 
reference to gemcitabine (114) treatment, was found.[80] 
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Scheme 1.27: N-Aryltriazole ribonucleosides with antiproliferative activity. 
 
1.3. Conclusion 
Palladium- and copper-mediated N-arylation have been shown to be powerful 
methods for inducing aryl and heteroaryl substituents. However, for substrates 
of a more complex structure the performance and applicability of the different 
reactions is often difficult to predict. The three reaction types, palladium-
catalysed and copper-catalysed N-arylations of aryl halides, and copper-
catalysed N-arylations using boronic acids show some distinct differences. 
Palladium-catalysed N-arylation reactions typically require reaction 
temperatures of 80-130 °C and extended reaction times up to 40 h. In most 
cases, the reactions must be conducted in an inert atmosphere; toluene is a 
favourite solvent and BINAP a commonly used ligand. Strong bases are 
required and water is added to dissolve them. Substituents in the starting 
material, which are labile to basic conditions, are not tolerated. With low catalyst 
loading and good availability of the palladium sources, reactions on larger scale 
are possible. Sterical demanding N-nucleophiles, as well as cyclic and aromatic 
amino compounds are suitable coupling partners to aryl bromides. 
In contrast to palladium catalysis, Ullmann-type coupling reactions tolerate air 
oxygen. However, reaction temperatures (90-115 °C) and reaction times (48 h) 
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are comparable to the palladium-catalysed processes. Ligand-free and ligand-
assisted reaction conditions have been applied in the synthesis of biological 
active compounds. DMEDA, proline and phenantroline are the most commonly 
used ligands. In some cases, the up to stoichiometric amount of ligand made 
work-up procedures difficult. In general, CuI is the most efficient catalyst. The 
reaction conditions tolerate primary, cyclic secondary aliphatic amines, electron-
rich and electron-poor anilines and heteroarylamines. Macrocyclisation using 
amides and aryl bromides are possible. Both, the palladium-catalysed and the 
Ullmann-type N-arylation reactions were successfully applied for inter- and 
intra-molecular reactions. An advantage of the Ullmann-type reactions is the 
lower price of catalyst metal salts and ligands. 
The mildest conditions for N-arylation reactions are provided by the Chan-Lam 
arylation, but conversion at room temperature resulted in long reaction times up 
to four days. The general absence of ligands is an additional advantage 
facilitating the product purification. However, one to two equivalents of 
Cu(OAc)2 and large excess of the boronic acid are required. Boronic acid 
reagents tolerated electron-donating and electron-withdrawing substituents in 
ortho-, meta- and para-position, but sterical demanding substituents were found 
unreactive. Many commercial precursors for the starting materials used in 
Chan-Lam arylations are available. 
 
None of the three reactions is clearly superior as method for N-arylations. 
Depending on the substrate that should be converted and the summarized 
constraints, the preferred method must be selected. In many cases optimization 
or adaptation of the standard protocols to the specific substrate is required. 
Nevertheless, the modern N-arylation methods have become an indispensable 
tool in organic chemistry and facilitate the synthesis of complex natural products 
and drugs significantly. 
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2. Fluorescently Labelled ABCG2 Modulators 
 
The membrane located ABCG2 transporter plays a major role in multi-drug 
resistance. However, the transport mechanism for this transporter is still 
unknown. Starting from the recently discovered tariquidar-derived selective 
ABCG2 modulator 1, different fluorescent labelled ABCG2 modulators were 
synthesised. The modified modulators show emission in the red part of the 
spectrum and reveal quantum yields up to 31.2 %. Moderate potency was 
obtained by the replacement of the tetrahydroisoquinoline part of the tariquidar-
derived lead-structure by a pyrylium label. All synthesised derivatives showed 
selectivity for ABCG2 over ABCB1. Studies at the physiological expressed 
ABCG2 concentrations on rat brain capillaries revealed that the parent 
compound 1 is also influencing the rat ABCG2 transporter, confirming the 
results of previous in vitro experiments with MCF-7/Topo cells and Hoechst 
33342 as substrate. Due to lower affinity of the fluorescent labelled compounds 
this could not be proven for the fluorescent modulators. 
 
                                                 
∗
 All synthesis and spectroscopical investigations were done by Carolin Fischer, compounds 6 
and 8 were a kind gift of Prof. Dr. Otto Wolfbeis, inhibition assays for ABCB1 and ABCG2 were 
performed by Peter Höcherl and Matthias Kühnle, convocal laser scanning microscopy was 
done with the help of Nathalie Pop, studies on rat brain capillaries were done by Anne 
Mahringer (University of Heidelberg). 
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2.1. Introduction 
The large family of ABC (ATP-binding cassette) transporter proteins is involved 
in numerous physiological processes including absorption, distribution and 
elimination of xenobiotics.[1] Prominent members of these efflux pumps are 
ABCB1 (P-gp, MDR1) and ABCG2 (BCRP, MXR, ABCP1), which are 
physiologically located in the membranes of epithelial and endothelial cells, e. g. 
in the capillaries of the blood-brain barrier.[2] These transporters use the energy 
of ATP-hydrolysis to decrease the intracellular concentration of a wide variety of 
structural different substances.[3] They are responsible for lowering the oral 
bioavailability and brain penetration of drugs, e.g. in the chemotherapy of 
malignant brain tumours.[4] Additionally, ABCG2 is considered to be one of the 
major transporters causing multi-drug resistance (MDR) in cancer cells.[5-7] 
Overexpression of ABCG2 results in resistance against a large number of 
different anti-cancer drugs for example mitoxantrone, topotecan, etoposid and 
flavopiridol.[8] As elevated expression of ABCG2 was also observed in 
numerous cancer stem cells (CSCs) from different solid tumours they are 
thereby supposed to withstand chemotherapy.[9-10] According to the tumour 
stem cell hypothesis these surviving cells give rise to the relapse in cancer.[10-11] 
Until now a 2D crystal structure is available showing conformational changes 
upon binding the substrate mitoxantrone.[12] Additionally, several residues within 
or near the transmembrane helices 1, 2 and 6 were identified to be important for 
substrate specificity and the overall transport activity of ABCG2.[13-14] Docking-
calculations and homology modelling predict TMD 2 of ABCG2, along with other 
TMDs, to form the large central binding cavity of multiple substrate binding 
sites.[13] A high resolution 3D structure of ABCG2 is not yet available.[15-16] Since 
a broad variety of structurally different molecules are known as substrates, no 
obvious structure-activity relationships are known until now.[17] Very recently, we 
discovered selective ABCG2 modulators[7] (Figure 2.1) by structural modification 
of the known ABCB1-preferring inhibitor tariquidar.[18] 
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Figure 2.1: Structure of a selective ABCG2 modulator derived from tariquidar.[7] 
 
The shift of the heteroarylcarbonylamino substituent from the ortho to the meta 
position of the benzamide core proved to be crucial for the change in 
selectivity.[7] The mode of interaction with the membrane located transporters is 
still unknown. The observed efflux inhibition may be caused by competing with 
substrates for the same binding side or by allosteric modulation of the 
transporter activity. 
To date, several fluorescent substrates of ABCG2 such as mitoxantrone,[19] 
pheophorbide a,[20] Hoechst 33342,[21] bodipy-prazosin[22] are known and mainly 
used for the analysis of active extrusion. Since, by comparably projects, 
fluorescent pyridinium compounds turned out to be useful pharmacological 
tools[23], a series of fluorescence-labelled compounds were produced to gain 
insight into the mechanism of action. With the objective to retain the activity of 
our previously discovered ABCG2 modulator and to keep the molecular weight 
low, different substructures of the parent molecule were replaced by fluorescent 
pyridinium chromophores. These dyes mimic aromatic substructures of the 
modulator and show spectral properties which are in principle well suited for the 
analysis with flow cytometers and confocal microscopes. We report the 
synthesis of eight luminescent potential ABCG2 modulators and the 
investigation of their spectral and pharmacologic properties. 
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2.2. Results and Discussion 
2.2.1. Synthesis 
For the design of the labelled ABCG2 modulators four different pharmacophore 
substructures 2-5 and three different pyrylium dyes 6-8 (see Figure 2.2) were 
considered to investigate the contribution of the different moieties of the 
molecule to the biological activity. 
 
Figure 2.2: Pharmacophore substructures (2-5) and pyrylium dyes (6-8) used to 
design fluorescence-labelled ABCG2 modulators. 
 
On the one hand, the tetrahydroisoquinoline part of the parent structure 1 was 
exchanged by the pyrylium labels 6-8 giving compounds 9-11. On the other 
hand, the quinaldic acid was replaced by the pyrylium labels 6-8 in meta and 
para position at the central aromatic core leading to compounds 12-14 and 15. 
Finally, 4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)ethyl)aniline (5) 
as a building block was linked to pyrylium label 7 to give compound 16 (Figure 
2.3). As a reference compound in cell assays and confocal microscopy, the 
pyrylium dye 7 was conjugated with benzyl amine giving compound 17. 
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In order to obtain the pyridinium compounds, the primary amines 2-5 were 
treated with the pyrylium dyes 6-8 at a pH of 8-9 at room temperature (Table 
2.1). The course of the reaction is easily monitored by the typical hypsochromic 
shift of the absorption maximum by more than 100 nm as demonstrated for the 
labelling of NPY receptor ligands before.[23] A change in colour from blue to red 
indicated the end of the coupling reaction after 2.5 h. The labelled ABCG2 
modulators were isolated and their purity was determined by analytical HPLC. 
 
Table 2.1: General labelling reaction and obtained yields of synthesised 
compounds (structure cf. Figure 2.3). 
 
 
Amine (R’-NH2) Pyrylium label Product Yield (%) 
2 6 9 81 
2 7 10 86 
2 8 11 90 
3 6 12 80 
3 7 13 80 
3 8 14 76 
4 7 15 73 
5 7 16 66 
benzyl amine 7 17 78 
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Figure 2.3: Structures of the pyrylium-labelled ABCG2 modulators 9-17. 
 
The modulator substructures 2, 3, 4 and 5 were prepared using the established 
synthetic route for tariquidar analogues.[7] Primary amines were Boc-protected 
during the synthesis. The pyrylium dyes 6 and 8 were previously reported for 
protein staining.[24] Dye 7, with an extended conjugation length, was 
synthesised by a Vilsmeier formylation yielding the unsaturated aldehyde 20, 
which was converted by a condensation reaction into the pyrylium dye 7 
(Scheme 2.1). 
 
2. Fluorescently Labelled ABCG2 Modulators 
 
 
37 
 
Scheme 2.1: Synthetic route of the new pyrylium dye 7. 
 
2.2.2. Spectral Properties 
The spectral properties of the labelled modulators were investigated and the 
results are summarized in Table 2.2. Absorption maxima of the pyridinium 
functionalized compounds range between 500 nm and 550 nm. The compounds 
show emission maxima between 610 nm and 710 nm (Figure 2.4). 
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Figure 2.4: Corrected absorption and emission spectra of 9 (10 µM in PBS + 1 
% BSA, T = 22 °C), absorption maximum 525 nm, emission maximum 610 nm. 
 
The relative quantum yields were determined using cresyl violet perchlorate. As 
previously reported, the fluorescence intensity increases significantly in the 
presence of 1 % bovine serum albumin (BSA) and the quantum yields are given 
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for these conditions (PBS buffer BSA solution, pH 7.4).[23] The highest quantum 
yield of Φ = 0.31 was determined for compound 9. 
 
Table 2.2: Spectral properties of the labelled compounds in PBS buffer with 1 
% BSA. 
 
Compound λabs. [nm] λem [nm] Φ [%] ε (MeOH) [cm-1M-1] 
9 525 610 31.2 18199 
10 545 707 3.8 1233 
11 500 637 8.2 4003 
12 520 609 4.1 33457 
13 547 695 13.7 3647 
14 500 650 3.6 1645 
15 546 711 --* 7267 
16 523 675 10.8 2388 
17 558 706 30.9 1941 
 
* precipitation in buffer. 
 
The absorption and emission properties of the pyridinium labelled compounds 
are in principle suitable for confocal microscopy of cells or investigations on 
isolated tissues like brain capillaries. 
 
2.2.3. Inhibition of the ABCG2 Transporter 
The fluorescent compounds 9-17, as well as their amino precursors 2-5 were 
investigated for inhibition of ABCG2 by the Hoechst 33342 assay[25] using 
MCF7 cells/topo cells.[7] The overexpression of ABCG2 transporters by 
topotecan treated MCF7 cells was checked via the flow cytometric (FACS) 
mitoxantrone-efflux assay.[7] The known potent and selective ABCG2 modulator 
1 was used as reference. 
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Table 2.3: Biological activity of the labelled compounds. 
 
Compound IC50 [µM]a Max [%]a,b 
1 0.06 ± 0.01 63 ± 2 (12.5 µM) 
2 1.67 ± 0.59 64 ± 3 (15 µM) 
3 -- 61 ± 2 (50 µM) c 
4 -- 27 ± 1 (50 µM) c 
5 --d -- 
9 4.48 ± 2.51 28 ± 1 (35 µM) 
10 -- 61 ± 4 (15 µM) 
11 2.09 ± 1.59 37 ± 4 (50 µM) 
12 -- 24 ± 7 (5 µM) e 
13 21.30 ± 9.39 51 ± 2 (100 µM) 
14 16.38 ± 13.00 36 ± 1 (15 µM) 
15 -- 15 ± 1 (100 µM) 
16 -- 28 (100 µM) 
 
a Mean values ± SEM, calculated from 2-3 independent 
experiments. b Maximal inhibitory effects (%) are expressed 
as inhibition caused by the highest concentration of the 
compound tested (see parentheses) relative to the inhibitory 
effect caused by 10 µM fumitremorgin C (100 % inhibition). c 
N = 1; d Inactive at concentration up to 50 µM; e N = 3 from 1 
measurement. 
 
The exchange of significant parts of the molecular structure 1 by the fluorescent 
labels markedly decreased the activity at the ABCG2 transporter. The inhibition 
assay shows that the 3-(acylamino)benzoic amide moiety is crucial for biological 
activity. The IC50 values of compounds 9, 11, 13 and 14 were in the range from 
of 2.0 to 21 µM (Table 2.3). The ABCG2 inhibitory potency was less affected by 
the exchange of the tetrahydroisoquinoline portion compared to the 
replacement of the quinoline-2-carboxylic acid moiety (cf. 11 versus 14). This 
observation is in good agreement with investigations of partial structures of the 
non-labelled modulators reported before.[7] 
Surprisingly, the unconjugated amine 2 was found to be cytotoxic. Compounds 
3 and 5 and their pyrylium-labelled derivatives 15 and 16 showed no significant 
effect on the ABCG2 transporter activity. 
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With respect to transporter selectivity, the compounds were investigated for 
ABCB1 modulation in the calcein-AM microtiter assay.[26] Due to low activities of 
these compounds IC50 values could not be calculated (data not shown). The 
most pronounced ABCB1 inhibition was achieved with compound 10 (14.7 % 
maximal response at a concentration of 100 µM). Hence, all fluorescence-
labelled compounds synthesised in this series show selectivity for ABCG2 
compared to ABCB1. 
 
2.2.4. Transport in Rat Brain Capillaries 
The active compounds 1 and 9 were used for transport studies in isolated rat 
brain capillaries to determine the interaction of ABCG2 modulators with the 
transporter expressed at physiological concentrations. Compound 1 represents 
the group of the unlabelled ABCG2 modulators and compound 9 represents the 
group of fluorescent modulators. An increase in luminal fluorescence indicates 
transport of the applied fluorescent substance. Therefore, brain capillaries of 
rats were isolated and co-incubated with the modulator 1 and the known 
ABCG2 substrate prazosin labelled with fluorescent bodipy[27] (Figure 2.5). 
Compound 1 was applied at three different concentrations (0.001 µM, 0.1 µM 
and 1 µM), whereas the concentration of the bodipy-prazosin derivative was 
kept constant at 1 µM. In order to determine relative fluorescence, 4-10 different 
capillaries were analysed for each concentration. Luminal fluorescence intensity 
measurements were made of three areas within the central 2 µm (10 pixels) of 
each segment. The background fluorescence intensity was determined at three 
background areas and the average pixel intensity for each area was calculated. 
Luminal fluorescence intensity was corrected by the background intensity. 
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Figure 2.5: Co-incubation experiment on isolated rat brain capillaries of bodipy-
prazosin (1 µM) without (control) or with increasing concentrations of compound 
1 (0.001 µM, 0.100 µM, 1 µM) in PBS + 1 % BSA after 30 min of incubation; A: 
transmission light and confocal micrograph of decreasing fluorescence of 
bodipy-prazosin with increasing concentration of compound 1; B: quantitative 
analysis of the effect of compound 1 on the transport of bodipy-prazosin. 
 
In the presence of compound 1 the luminal fluorescence of co-incubated 
bodipy-prazosin decreased with increased modulator (1) concentrations, i.e. 
compound 1 inhibits the efflux of the ABCG2 substrate bodipy-prazosin. The 
results from the brain capillaries confirm the data from the Hoechst 33342 
assay. Thus, the modulation of ABCG2 by compound 1 is not restricted to 
overexpressed transporters as on MCF-7/Topo cells, but is corroborated by the 
studies on physiologically expressed ABCG2 transporters in rat brain 
capillaries. Species-dependent differences were not detected in these 
experiments. 
The fluorescent analogue 9 was tested on the same system using three 
different concentrations (1 µM, 10 µM, 50 µM). Due to lower potency of 9, the 
concentrations as high as 50 µM were used for the investigations of the 
pyrylium-labelled compound on the same system. The luminal fluorescence of 
bodipy-prazosin stayed constant (Figure 2.6 A), i.e. the transport of the 
substrate bodipy-prazosin was not affected by compound 9 under these 
conditions. The luminal fluorescence of compound 9 (Figure 2.6 B) rised with 
increasing concentration. Additionally, the luminal fluorescence of 9 could not 
be decreased by co-incubation with the potent ABCG2 inhibitor Ko143, a known 
ABCG2 inhibitor[28] (Figure 2.6 C). 
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Figure 2.6: Co-incubation experiments on isolated rat brain capillaries, 
detection of fluorescence after 30 min of incubation; A: effect of compound 9 on 
the transport of bodipy-prazosin (1 µM) without (control) or with increasing 
concentrations of compound 9 (1 µM, 10 µM, 50 µM) determined by bodipy-
prazosin fluorescence; B: fluorescence of compound 9 increasing 
concentrations (1 µM, 10 µM, 50 µM) without (control) or with bodipy-prazosin 
(1 µM); C: effect of Ko143 on the transport of compound 9 (1 µM) without 
(control) or with increasing concentrations of Ko143 (0.01 µM, 0.1 µM, 1 µM, 5 
µM). 
 
The mode of the interaction between the transporter and the modulators could 
not be identified so far. 
 
2.2.5. Confocal Laser Scanning Microscopy (CLSM) Studies 
Additionally, the fluorescence-labelled compounds were investigated by 
confocal microscopy on MCF7/Topo cells at different incubation periods of time 
and at different concentrations to monitor the penetration through the cell 
membrane. Due to weak potency of the compounds, concentrations high as 10 
µM were used. 
A B 
C
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All examined compounds showed significant accumulation in the cytoplasm and 
gave rinse to intracellular fluorescence. The compounds were not detected in 
the nuclei. Compounds 15 (Figure 2.7 A) and 16, which are almost devoid of 
ABCG2 inhibitory effect, entered the cells within a few minutes, whereas 
compounds 9 and 11 (Figure 2.7 B) penetrated slower and emitted less 
intensely. A selective enrichment within the cell membranes, potentially allowing 
for the localization of ABCG2 transporters, was not observed. Due to the 
positive charge of the molecules and according to previous results on pyrylium-
labelled receptor ligands,[21] the rapid cellular uptake was unexpected and a 
carrier-mediated process, independent from the interaction with the membrane 
located ABCG2 transporter, cannot be ruled out. The used high concentrations 
(10 µM) of the fluorescent compounds may also increase the diffusion through 
the cell membrane. As a control, MCF-7/Topo cells were incubated with a 
pyrylium-labelled benzyl amine, which is considered to be neither a substrate 
nor an inhibitor for ABCG2. We observed for reference compound 17 also a 
rapid penetration of the membrane (data not shown), showing the same 
distribution inside the cells. Thus, the label itself contributes at least in part to 
the cellular uptake. 
 
 
 
Figure 2.7: A: Compound 15, 10 µM, incubated 30 min on MCF7/Topo cells, 
153th passage; B: Compound 11, 10 µM, incubated 11 min on MCF7/Topo 
cells, 177th passage; white pseudo-colour images. 
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2.3. Conclusion 
We synthesised fluorescent analogues of the recently developed ABCG2 
modulator 1, which is chemically derived from the ABCB1 inhibitor tariquidar. 
Structural moieties of the parent structure 1 were exchanged by pyridinium 
chromophores which are accessible by aminolysis of known and newly 
synthesised pyrylium dyes. The derivatives showed emission over 600 nm and 
relative quantum yields up to 31.2 %. The testing for biological activity with the 
Hoechst 33342 assay revealed some structural activity relationship information. 
The ability to inhibit ABCG2 transporters of the compounds was least affected 
by the exchange of the tetrahydroisoquinoline part (compounds 9-11), while the 
heteroarylcarbonylamino substituent in meta-position on the methyl 4-
carbamoylbenzoate core was again proved to be essential for an effective 
interaction with the ABCG2 transporter. All prepared pyrylium derivatives 
showed selectivity for ABCG2 over ABCB1. 
Rat brain capillary studies confirmed biological activity of the unlabelled 
compound 1 for natural expression levels of ABCG2 in rats, identified by 
inhibiting the transport of the substrate bodipy-prazosin. Due to lower potency 
this could not be observed from the pyrylium-labelled compounds. CLSM 
showed time-dependent unspecific cellular uptake of all fluorescent compounds 
in MCF-7/Topo cells. Here, we conclude the low potency as reason for weak 
interactions with the membrane located transporter protein. The hydrophobic 
character of the pyrylium moiety and an additional net charge make this label 
less suitable for mechanistic studies on ABCG2. 
 
2.4. Experimental Section 
General. Commercial reagents and starting materials were purchased from 
Aldrich, Alpha Aesar, Fluka or Acros and used without further purification. Flash 
chromatography was performed on silica gel (Merck silica gel Si 60 40-63 µm); 
products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV-light (λ = 254 nm). 
Melting points were determined with a Optimelt MPA 100 and are uncorrected. 
NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 
MHz, T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 
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K) and Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K) 
instruments. Chemical shifts are reported in δ/ppm relative to external standards 
and coupling constants J are given in Hz. Abbreviations for the characterisation 
of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad 
singlet, dd = double doublet. The relative numbers of protons is determined by 
integration. Error of reported values: chemical shift 0.01 ppm (1H-NMR), 0.1 
ppm (13C-NMR), coupling constant 0.1 Hz. The used solvent for each spectrum 
is reported. Mass spectra were recorded with Finnigan MAT TSQ 7000 (ESI) 
and Finnigan MAT 710 (EI), IR spectra with a Bio-Rad FT-IR-FTS 155 
spectrometer and UV/Vis spectra with a Cary BIO 50 UV/Vis/NIR spectrometer 
(Varian). Analytical HPLC was performed on an Agilent 1100 LC system 
equipped with a Phenomenex Luna C18 (2) column (particle size 3 µm, pore 
size 100 A, 150 mm x 2.00 mm). The column temperature was 25 °C. Gradient 
elution was done with water (0.0059 % w/w TFA) (solvent A) and acetonitrile 
(solvent B) at a constant flow rate of 0.3 mL/min. A gradient profile with the 
following proportions of solvent B was applied: 0 min 5 % B, 20 min 98 % B. 
Compounds were detected with a diode array detector (DAD, 490 nm). The 
compounds were dissolved in methanol. 
 
Synthesis. Methyl 4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl]phenylcarbamoyl}-2-(quinoline-2-carbonylamino)benzoate (1),[7] 4-[2-
(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]aniline (5),[29] 4-[(tert-
butoxycarbonylamino)methyl]benzoic acid,[30] 3-(tert-butoxycarbonyl-
amino)benzoic acid[31] and tert-butyl 4-aminophenethylcarbamate[32] were 
prepared after literature reported procedures. 
 
General procedures: GP 1: Pyridinium formation 
The respective amine (1 eq) and NEt3 (8 eq) were diluted in acetonitrile. A 
solution of the pyrylium dye (1 eq) in acetonitrile was added. The reaction was 
monitored by TLC (CHCl3/MeOH 4:1). After 2.5 h stirring at room temperature 
the solvent was removed yielding a purple solid. 
 
GP 2: Amide coupling over an active ester 
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The respective carboxylic acid (1.1 eq) was dissolved in CH2Cl2. Two 
equivalents of DIPEA, 1.2 eq of each TBTU and HOBt were added at 0 °C. After 
30 minutes the active ester was formed and the respective amine was added. 
The reaction mixture was stirred for 16 h, taken up with water, diluted with 
dichloromethane, washed three times with water (3 x 30 mL) and once with 
saturated NaHCO3 solution (30 mL). The organic layer was dried over Na2SO4 
and the solvent was evaporated giving the crude reaction product. 
 
GP 3: Reduction of the nitro function 
The respective nitro compound (eq) was dissolved in ethyl acetate and 
methanol followed by the addition of Pd/C (10 %/g) suspended in ethyl acetate. 
After stirring the solution under 10 bar of H2 for 15 h at room temperature, the 
catalyst was filtered off and the solvent was removed, to obtain the solid 
product. 
 
GP 4: Boc deprotection 
The respective Boc-protected amine (1 eq) was dissolved in dichloromethane 
and HCl-Ether (15 % /mmol). After stirring 15 h at room temperature the solvent 
was removed under reduced pressure yielding the crude reaction product. 
 
Methyl 4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenylcarbamoyl}-2-nitro-
benzoate 
The compound was prepared following GP 2 using 1.5 g (6.7 mmol) of 4-
(methoxycarbonyl)-3-nitrobenzoic acid and 1.4 g (6.1 mmol of tert-butyl 4-
aminophenethylcarbamate. The product was purified by column 
chromatography (SiO2, MeOH/EE 1:3, Rf = 0.65). The reaction yielded 2.4 g (5.4 
mmol, 88 %) of methyl 4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenyl-
carbamoyl}-2-nitrobenzoate 
as orange solid, mp 135 °C 1H-NMR (300 MHz, CDCl3): δ = 1.42 (s, 9 H), 2.66 
(t, J = 6.9 Hz, 2 H), 3.28-3.35 (m, 2 H), 3.94 (s, 3 H), 7.16 (d, J = 8.2 Hz, 2 H), 
7.57 (d, J = 8.5 Hz, 2 H), 7.79 (d, J = 7.9 Hz, 1 H), 8.20 (dd, J = 7.9 Hz, 1.4 Hz, 
1 H), 8.43 (d, J = 1.4 Hz, 1 H) 13C-NMR DEPT 135 (75 MHz, CDCl3): δ = 28.4(+, 
3 x CH3), 38.6 (+, CH3), 35.7 (-, CH2), 54.1 (-, CH2), 91.4 (Cquat), 95.9 (Cquat), 
111.3 (Cquat), 115.7 (Cquat), 121.0 (+, CHarom), 122.8 (+, CHarom), 129.4 (+, 2 x 
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CHarom), 129.6 (+, CHarom), 129.9 (Cquat), 130.3 (+, CHarom), 131.8 (+, CHarom), 
135.7 (Cquat), 138.5 (Cquat), 148.0 (Cquat), 165.3 (Cquat) MS (-ESI, DCM/MeOH + 
10 mmol/L NH4Ac): m/z (%) = 442 (100) [M -H+]- IR (ATR)ν~ [cm-1] = 1509 (N-O), 
1659 (C=O), 1685 (C=O), 1738 (C=O), 3362 (N-H), 3389 (N-H) MF C22H25N3O7 
MW 443.45 
 
Methyl 2-amino-4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenylcarba-
moyl}benzoate 
Methyl 4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenylcarbamoyl}-2-nitrobenzo-
ate (2.8 g, 6.3 mmol) was reacted according to GP 3, yielding after work-up 2.1 
g (5.15 mmol, 94 %) of methyl 2-amino-4-{4-[2-(tert-butoxycarbonyl-
amino)ethyl]phenyl-carbamoyl}benzoate as orange solid, mp 165 °C 1H-NMR 
(300 MHz, CDCl3): δ = 1.43 (s, 9 H), 2.58-2.68 (m, 2 H), 3.33 (t, J = 6.6 Hz, 2 
H), 3.88 (s, 3 H), 7.00 (dd, J = 1.6 Hz, 8.2 Hz, 1 H), 7.16 (d, J = 8.2 Hz, 2 H), 
7.19 (d, J = 1.64 Hz, 1 H), 7.55 (d, J = 8.2 Hz, 2 H), 7.90 (d, J = 8.5 Hz, 1 H) 
13C-NMR DEPT (75 MHz, CDCl3): δ = 28.4 (+, 3 x CH3), 38.6 (+, CH3), 58.4 (-, 
CH2, 2 x), 111.0 (Cquat), 112.9 (Cquat), 113.6 (+, CHarom), 115.7 (+, CHarom), 155.9 
(Cquat), 120.7 (+, 2 x CHarom), 121.3 (Cquat), 123.7 (Cquat), 129.4 (+, 2 x CHarom), 
129.6 (Cquat), 131.9 (+, CHarom), 150.6 (Cquat), 159.1 (Cquat), 168.0 (Cquat) MS 
(+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 414 (100) [MH+] IR (ATR) 
ν~ [cm-1] = 1684 (C=O), 3319 (N-H), 3372 (N-H), 3481 (NH2) MF C22H27N3O5 MW 
413.47 
 
Methyl 4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenylcarbamoyl}-2-
(quinoline-2-carbonylamino)benzoate 
Methyl 2-amino-4-{4-[2-(tert-butoxycarbonylamino)ethyl]phenylcarbamoyl}-
benzoate (1.8 g, 4.5 mmol) was dissolved in dry DMF, then 1.5 eq of NEt3 (0.67 
g, 0.96 mL, 6.7 mmol) and 0.5 eq of DMAP (0.26 g, 2.2 mmol) were added. 
Under nitrogen atmosphere quinoline-2-carbonyl chloride (1.28 g, 6.7 mmol) 
was added. After two hours at 80 °C the reaction mixture was stirred over night 
at room temperature. Then the DMF was removed, the residue was taken up 
with water and extracted with dichloromethane. The remaining white precipitate 
was collected and washed with acetone. The reaction yielded 0.4 g (0.7 mmol, 
15 %) of methyl 4-{4-[2-(tert-butoxycarbonylamino)ethyl]-phenylcarbamoyl}-2-
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(quinoline-2-carbonylamino)benzoate as white solid, mp > 190 °C 1H-NMR (300 
MHz, CDCl3): δ = 1.44 (s, 9 H), 2.80 (t, J = 6.7 Hz, 2 H), 3.37-3.39 (m, 2 H), 
4.09 (s, 3 H), 7.21 (d, J = 8.2 Hz, 2 H), 7.65 (d, J = 8.5 Hz, 2 H), 7.83 (t, J = 7.7 
Hz, 1 H), 7.91 (d, J = 8.3 Hz, 2 H), 8.21 (d, J = 8.2 Hz, 1 H), 8.29-8.39 (m, 4 H), 
9.45 (s, 1 H), 13.35 (s, CONH) 13C-NMR DEPT 135 (75 MHz, [D6]-DMSO): δ = 
28.2 (+, CH3, three times), 34.8 (-, CH2), 35.7 (+, CH3), 41.5 (-, CH2), 77.4 
(Cquat), 118.5 (+, CHarom), 119.4 (+, CHarom), 120.4 (+, 2 x CHarom), 121.8 (+, 
CHarom), 128.1 (+, CHarom), 128.6 (Cquat), 128.7 (+, 2 x CHarom), 129.0 (Cquat), 
129.2 (+, CHarom), 130.9 (+, CHarom), 131.1 (+, CHarom), 135.0 (Cquat), 136.8 
(Cquat), 138.5 (+, CHarom), 139.7 (Cquat), 140.3 (Cquat), 140.5 (+, CHarom), 145.6 
(Cquat), 149.1 (Cquat), 162.2 (Cquat), 162.7 (Cquat), 164.5 (Cquat), 166.7 (Cquat) MS 
(+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 569 (100) [MH+] IR ν~ (ATR) 
[cm-1] = 1651 (C=O), 1688 (C=O), 3299 (N-H), 3372 (N-H) MF C32H32N4O6 MW 
568.62 
 
Methyl 4-[4-(2-aminoethyl)phenylcarbamoyl]-2-(quinoline-2-carbonyl-
amino)benzoate (2) 
The compound was prepared following GP 4 using methyl 4-{4-[2-(tert-butoxy-
carbonylamino)ethyl]phenylcarbamoyl}-2-(quinoline-2-carbonylamino)benzoate 
(0.4 g, 0.7 mmol) and 4.6 mL HCl/ether. The reaction yielded 0.31 g (0.66 
mmol, 95 %) of compound 2 as yellow solid, mp >200 °C 1H-NMR (300 MHz, 
[D6]-DMSO): δ = 2.97-3.10 (m, 2 H), 3.51-3.60 (m, 2 H), 4.04 (s, 3 H), 7.28 (d, J 
= 8.5 Hz, 1 H), 7.76 (d, J = 8.5 Hz, 2 H), 7.80 (s, 1 H), 7.97 (d, J = 7.7 Hz, 1 H), 
8.07 (s, 2 H), 8.15 (d, J = 8.2 Hz, 1 H), 8.20 (d, J = 8.2 Hz, 1 H), 8.31 (d, J = 8.5 
Hz, 1 H), 8.69 (d, J = 8.8 Hz, 2 H), 9.37 (s, 1 H) 13C-NMR DEPT 135 (75 MHz, 
[D6]-DMSO): δ = 32.3 (-, CH2), 35.7 (+, CH3), 39.9 (-, CH2), 118.4 (+, CHarom), 
119.5 (+, CHarom), 120.6 (+, 2 x CHarom), 121.9 (+, CHarom), 128.1 (+, CHarom), 
128.6 (Cquat), 128.8 (+, 2 x CHarom), 129.0 (Cquat), 129.2 (+, CHarom), 130.9 (+, 
CHarom), 131.1 (+, CHarom), 132.8 (Cquat), 137.4 (Cquat), 138.5 (+, CHarom), 139.7 
(Cquat), 140.1 (Cquat), 141.7 (+, CHarom), 145.6 (Cquat), 149.0 (Cquat), 162.7 (Cquat), 
164.6 (Cquat), 166.7 (Cquat) MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 469 (100) [MH+] IR (ATR) ν~ [cm-1] = 1570 (C=O), 1655 (C=O), 1688 
(C=O), 3300 (N-H), 3406 (N-H) MF C27H24N4O4 MW 468.5 
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tert-Butyl 3-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]-
phenylcarbamoyl}phenylcarbamate 
The compound was prepared following GP 2 using 3-(tert-
butoxycarbonylamino)benzoic acid (0.81g, 3.4 mmol) and 4-[2-(6,7-dimethoxy-
3,4-dihydroisoquinolin-2(1H)-yl)ethyl]aniline (0.99 g, 3.2 mmol). The product 
was purified by column chromatography (MeOH/EE 1:3, Rf = 0.58). The 
reaction yielded 0.61 g (1.1 mmol, 36 %) of tert-butyl 3-{4-[2-(6,7-dimethoxy-
3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenylcarbamoyl}phenylcarbamate as 
yellow solid, mp 177 °C 1H-NMR (300 MHz, CDCl3): δ = 1.50 (s, 9 H), 2.73-2.90 
(m, 8 H), 3.66 (s, 2 H), 3.8 (s, 3 H), 3.82 (s, 3 H), 6.51 (s, 1 H), 6.60 (s, 1 H), 
7.14 (s, 1 H), 7.18 (d, 8.5 Hz, 2H), 7.32 (t, 8.0 Hz, 1 H), 7.51 (t, 8.4 Hz, 1 H), 
7.56 (d, 8.5 Hz, 2 H), 7.97 (s, 1 H) 13C-NMR DEPT 135 (75 MHz, CDCl3): δ = 
28.3 (+, 3 x CH3), 33.2 (-, CH2), 36.5 (-, CH2), 50.9 (-, CH2), 55.5 (-, CH2), 55.8 
(+, CH3), 55.9 (+, CH3), 59.9 (-, CH2), 80.8 (Cquat), 109.4 (+, CHarom), 111.3 (+, 
CHarom), 117.1 (+, CHarom), 120.7 (+, 2 x CHarom), 121.7 (+, CHarom), 121.9 (+, 
CHarom), 125.9 (Cquat), 126.0 (Cquat), 129.2 (+, 2 x CHarom), 129.3 (+, CHarom), 
135.9 (Cquat), 136.2 (Cquat), 136.3 (Cquat), 138.9 (Cquat), 147.2 (Cquat), 147.6 
(Cquat), 153.0 (Cquat), 165.8 (Cquat) MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): 
m/z (%) = 530 (100) [M +] IR (ATR) ν~ [cm-1] = 1667 (C=O), 1716 (C=O), 3238 
(N-H), 3353 (N-H) MF C31H37N3O5 MW 529.67 
 
3-Amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]-
phenyl}benzamide (3) 
The compound was prepared following GP 4 using tert-butyl 3-{4-[2-(6,7-
dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenylcarbamoyl}phenylcarba-
mate (0.5 g, 0.9 mmol) and 6 mL HCl/ether. The reaction gave 0.37 g (0.85 
mmol, 98 %) of compound 3 as yellow solid, mp 160 °C 1H-NMR (300 MHz, 
[D6]-DMSO): δ = 3.00-3.38 (m, 10 H), 3.72 (s, 3 H), 3.73 (s, 3 H), 6.78 (s, 1 H), 
6.81 (s, 1 H), 7.30 (d, J = 8.5 Hz, 2 H), 7.60-7.66 (m, 2 H), 7.76 (d, J = 8.5 Hz, 2 
H), 7.92 (d, J = 7.1 Hz, 1 H), 8.03 (d, J = 7.4 Hz, 1 H) 13C-NMR DEPT 135 (75 
MHz, [D4]-methanol): δ = 20.7 (-, CH2), 26.2 (-, CH2), 31.1 (-, CH2), 51.5 (-, 
CH2), 56.6 (+, CH3), 56.8 (+, CH3), 58.34 (-, CH2), 110.9 (+, CHarom), 112.7 (+, 
CHarom), 120.9 (Cquat), 122.8 (Cquat), 122.9 (+, CHarom), 123.0 (+, CHarom), 123.9 
(+, CHarom), 124.6 (Cquat), 127.7 (Cquat), 129.1 (Cquat), 129.3 (+, CHarom), 131.0 
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(+, CHarom), 131.3 (+, CHarom), 131.6 (+, CHarom), 131.7 (+, CHarom), 132.6 (Cquat), 
149.8 (Cquat), 150.6 (Cquat), 165.5 (Cquat) MS (+ESI, DCM/MeOH + 10 mmol/L 
NH4Ac): m/z (%) = 432 (100) [M +] IR (ATR) ν~ [cm-1] = 3348 (N-H), 3233 (N-H), 
1667 (C=O) MF C26H29N3O3 MW 431.53 
 
tert-Butyl 4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]-
phenylcarbamoyl}benzylcarbamate 
The compound was prepared following GP 2 using 4-[2-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl]aniline (0.9 g, 2.9 mmol) and 4-[(tert-
butoxycarbonylamino)methyl]benzoic acid (0.8 g, 3.2 mmol). The reaction gave 
1.35 g (2.4 mmol, 85 %) of tert-butyl 4-{4-[2-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl]phenylcarbamoyl}benzylcarbamate as orange 
oil, 1H-NMR (300 MHz, CDCl3): δ = 1.33 (s, 9 H), 2.63-2.76 (m, 8 H), 3.52 (s, 2 
H), 3.66 (s, 3 H), 3.68 (s, 3 H), 4.11 (d, J = 5.7 Hz, 2 H), 6.38 (s, 1 H), 6.45 (s, 1 
H), 7.02-7.07 (m, 4 H), 7.54 (d, J = 8.23 Hz, 2 H), 7.66 (d, J = 7.68 Hz, 2 H) 13C-
NMR DEPT 135 (75 MHz, CDCl3): δ = 28.4 (+, 3 x CH3), 33.1 (-, CH2), 43.9 (-, 
CH2), 50.8 (-, CH2), 55.4 (-, CH2), 55.8 (+, CH3), 55.9 (+, CH3), 59.9 (-, CH2), 
109.4 (+, CHarom), 111.3 (+, CHarom), 120.8 (+, CHarom), 125.9 (Cquat), 126.9 (+, 2 
x CHarom), 127.5 (+, 2 x CHarom), 129.0 (+, 2 x CHarom), 130.8 (+, CHarom), 133.6 
(Cquat), 135.8 (Cquat), 136.7 (Cquat), 143.4 (Cquat), 147.1 (Cquat), 147.5 (Cquat), 
156.2 (Cquat), 162.6 (Cquat), 165.6 (Cquat), 166.0 (Cquat) MS (+ESI, DCM/MeOH + 
10 mmol/L NH4Ac): m/z (%) = 546 (100) [M +] IR (ATR) ν~ [cm-1] = 1513 (N-H), 
1612 (C=O), 1663 (C=O) MF C32H39N3O5 MW 545.29 
 
4-Aminomethyl-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-
ethyl]phenyl}benzamide (4) 
The compound was prepared following GP 4 using tert-butyl 4-{4-[2-(6,7-
dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenylcarbamoyl}benzylcarba-
mate (0.3 g, 0.5 mmol) and 3.3 mL HCl/ether. The resulting pale orange solid 
was recrystallised from acetone and water to yield 0.2 g (0.44 mmol, 90 %) of 
compound 4 as yellow solid, mp >190 °C 1H-NMR (300 MHz, [D4]-methanol): δ 
= 2.95-3.39 (m, 10 H), 3.81 (s, 3 H), 3.82 (s, 3 H), 4.22 (s, 2 H), 6.80 (s, 1 H), 
6.83 (s, 1 H), 7.37 (d, J = 8.5 Hz, 2 H), 7.63 (d, J = 8.2 Hz, 2 H), 7.72 (d, J = 8.5 
Hz, 2 H), 8.02 (d, J = 8.2 Hz, 2 H) 13C-NMR DEPT 135 (75 MHz, [D4]-methanol): 
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δ = 26.2 (-, CH2), 31.0 (-, CH2), 43.9 (-, CH2), 51.5 (-, CH2), 54.1 (-, CH2), 56.5 
(+, CH3), 56.6 (+, CH3), 58.3 (-, CH2), 110.8 (+, CHarom), 112.7 (+, CHarom), 
120.8 (Cquat), 122.9 (+, 2 x CHarom), 124.4 (Cquat), 129.5 (+, 2 x CHarom), 130.3 
(+, 2 x CHarom), 130.4 (+, 2 x CHarom), 133.9 (Cquat), 136.8 (Cquat), 138.2 (Cquat), 
139.0 (Cquat), 146.9 (Cquat), 150.8 (Cquat), 168.2 (Cquat) MS (+ESI, DCM/MeOH + 
10 mmol/L NH4Ac): m/z (%) = 446 (100) [M +] IR (ATR) ν~ [cm-1] = 1515 (N-H), 
1612 (C=O), 3380 (NH2) MF C27H31N3O3 MW 445.24 
 
4-[(1E,3E)-4-(1,2,3,5,6,7-Hexahydropyrido[3,2,1-ij]quinolin-9-yl)buta-1,3-
dienyl]-2,6-dimethylpyrylium tetrafluoroborate (7) 
(E)-3-(2,3,6,7-Tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)propenal (20) (50 
mg, 0.21 mmol) and 2,4,6-trimethylpyrylium (60 mg, 0.29 mmol) were diluted in 
methanol with a small amount of chloroform for better solubility. After the 
solution has turned green, the mixture was refluxed for 10 min and then the 
solvent was removed. The crude product was purified by column 
chromatography (SiO2, CHCl3/MeOH 4:1, Rf = 0.65). The reaction yielded 80 mg 
(0.19 mmol, 92 %) of compound 7 as dark blue solid, mp > 200 °C 1H-NMR 
(300 MHz, CDCl3): δ = 1.94-2.00 (m, 4 H), 2.07 (s, 3 H), 2.16 (s, 3 H), 2.75 (t, J 
= 6.6 Hz, 4 H), 3.12 (t, J = 5.6 Hz, 4 H), 6.48-6.56 (m, 1 H), 6.77 (d, J = 7.4 Hz, 
1 H) 6 aromatic protons exchanged to the solvent MS (+ESI, DCM/MeOH + 10 
mmol/L NH4Ac): m/z (%) = 332 (100) [M +] IR (ATR) ν~ [cm-1] = 2927 (C-H) UV 
λmax = 500 nm, ε = 4069 L*mol-1cm-1 (in PBS-buffer) Fluorescence: λem = 679 
nm, Φ  = 12.1 % (in PBS-buffer) MF C23H26BF4NO MW 419.26 
 
(E)-4-[2-(1,2,3,5,6,7-Hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-1-{4-[4-
(methoxycarbonyl)-3-(quinoline-2-carboxamido)benzamido]phenethyl}-
2,6-dimethylpyridinium tetrafluoroborate (9) 
The compound was prepared following GP 1 using 4 mg (0.01 mmol) of 
compound 2 and 3 mg (0.01 mmol) of compound 6. The reaction yielded 5 mg 
(0.006 mmol, 81 %) of compound 9 as purple solid. Due to the small scale, 
purity was checked by HPLC (86 %, tr = 16.8 min), mp 152 °C MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 756 (100) [M+] IR (ATR) ν~ [cm-1] = 
1519 (N-H), 1573 (N-H), 2501 (N+-(C)3) UV λmax1 = 512 nm (MeOH), ε = 18199 
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L*mol-1cm-1, λmax2 = 622 nm (MeOH), ε = 11672 L*mol-1cm-1 MF C48H46N5O4+ 
BF4- MW 843.91 
 
4-[(1E,3E)-4-(1,2,3,5,6,7-Hexahydropyrido[3,2,1-ij]quinolin-9-yl)buta-1,3-
dienyl]-1-{4-[4-(methoxycarbonyl)-3-(quinoline-2-carboxamido)-
benzamido]phenethyl}-2,6-dimethylpyridinium tetrafluoroborate (10) 
The compound was prepared following GP 1 using 17 mg (0.04 mmol) of 
compound 2 and 15 mg (0.04 mmol) of compound 7. The reaction yielded 10 
mg (0.01 mmol, 86 %) of compound 10 as purple solid. Due to the small scale, 
purity was checked by HPLC (80 %, tr = 17.5 min), mp 160 °C MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 782 (100) [M+] IR (ATR) ν~ [cm-1] = 
1474 (N-H), 1573 (N-H), 2457 (N+-(C)3), 2498 (N+-(C)3) UV λmax = 490 nm 
(MeOH), ε = 4004 L*mol-1cm-1 MF C50H48N5O4+ BF4- MW 869.95 
 
4-{[1E,3E]-4-[4-(Dimethylamino)phenyl]buta-1,3-dienyl}-1-{4-[4-(methoxy-
carbonyl)-3-(quinoline-2-carboxamido)benzamido]phenethyl}-2,6-
dimethylpyridinium tetrafluoroborate (11) 
The compound was prepared following GP 1 using 4 mg (0.01 mmol) of 
compound 2 and 5 mg (0.01 mmol) of compound 8. The reaction gave 4 mg 
(0.01 mmol, 90 %) of compound 11 as red solid. Due to the small scale, purity 
was checked by HPLC (85 %, tr = 16.1 min), mp 145 °C MS (+ESI, DCM/MeOH 
+ 10 mmol/L NH4Ac): m/z (%) = 730 (100) [M+] IR (ATR) ν~ [cm-1] = 2359 (N-
(C)3), 2498 (N+-(C)3), 2603 (N+-(C)3) UV λmax = 530 nm (MeOH), ε = 1233 L*mol-
1cm-1 MF C46H44N5O4+ BF4- MW 817.87 
 
(E)-1-{3-[4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)phenylcarbamoyl]phenyl}-4-[2-(1,2,3,5,6,7-hexahydropyrido[3,2,1-
ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium tetrafluoroborate (12) 
The compound was prepared following GP 1 using 5 mg (0.01 mmol) of 
compound 3 and 4 mg (0.01 mmol) of compound 6. The reaction yielded 6 mg 
(0.008 mmol, 80 %) of compound 12 as red solid. Due to the small scale, purity 
was checked by HPLC. (81 %, tr = 12.4 min), mp >190 °C MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 720 (100) [MH+] IR (ATR) ν~ [cm-1] 
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= 1518 (N-H), 2340 (N-(C)3), 2356 (N-(C)3), 2944 (N+-H), 2605 (N+-H) UV λmax = 
520 nm (MeOH), ε = 401 L*mol-1cm-1 MF C47H51BF4N4O3 MW 822.97 
 
1-{3-[4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenylcarbamoyl]phenyl}-4-[(1E,3E)-4-(1,2,3,5,6,7-hexahydropyrido[3,2,1-
ij]quinolin-9-yl)buta-1,3-dienyl]-2,6-dimethylpyridinium tetrafluoroborate 
(13) 
The compound was prepared following GP 1 using 6 mg (0.01 mmol) of 
compound 3 and 6 mg (0.01 mmol) of compound 7. The reaction yielded 10 mg 
(0.01 mmol, 80 %) of compound 13 as purple solid. Due to the small scale, 
purity was checked by HPLC (74 %, tr = 12.0 min), mp 187 °C MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 746 (100) [M +] IR (ATR) ν~ [cm-1] = 
1668 (C=O), 2342 (N-(C)3), 2360 (N-(C)3) UV λmax = 551 nm (MeOH), ε = 3647 
L*mol-1cm-1 MF C49H53BF4N4O3 MW 832.97 
 
1-{3-[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)phenyl-
carbamoyl]phenyl}-4-[(1E,3E)-4-[4-(dimethylamino)phenyl]buta-1,3-dienyl]-
2,6-dimethylpyridinium tetrafluoroborate (14) 
The compound was prepared following GP 1 using 5 mg (0.01 mmol) of 
compound 3 and 3 mg (0.01 mmol) of compound 8. The reaction yielded 6 mg 
(0.008 mmol, 76 %) of compound 14 as red solid. Due to the small scale, purity 
was checked by HPLC. (83 %, tr = 12.6 min), mp >190 °C MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 693 (100) [MH+] IR (ATR) ν~ [cm-1] 
= 1518 (N-H), 1652 (C=O), 2263 (N-(C)3), 2356 (N-(C)3), 2463 (N+-H) UV λmax = 
490 nm (MeOH), ε = 1654 L*mol-1cm-1 MF C45H49BF4N4O3 BF4- MW 780.9 
 
1-{4-[4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenylcarbamoyl]benzyl}-4-[(1E,3E)-4-(1,2,3,5,6,7-hexahydropyrido[3,2,1-
ij]quinolin-9-yl)buta-1,3-dienyl]-2,6-dimethylpyridinium tetrafluoroborate 
(15) 
The compound was prepared following GP 1 using 50 mg (0.11 mmol) of 
compound 4 and 51 mg (0.11 mmol) of compound 7. The reaction gave 70 mg 
(0.08 mmol, 73 %) of compound 15 as purple solid. Due to the small scale, 
purity was checked by HPLC (82 %, tr = 12.0 min), mp >190 °C MS (+ESI, 
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DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 760 (100) [M +] IR (ATR) ν~ [cm-1] = 
1686 (C=O), 3326 (N+-H), 3362 (N-H), 3477 (N-H) UV λmax = 546 nm (MeOH), 
ε = 7267 L*mol-1cm-1 MF C50H55N4O3+ BF4- MW 846.43 
 
1-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl}-4-
[(1E,3E)-4-(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)buta-1,3-
dienyl]-2,6-dimethylpyridinium tetrafluoroborate (16) 
The compound was prepared following GP 1 using 4-(2-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)benzenamine (20 mg, 0.06 mmol), NEt3 (30 
mg, 0.3 mmol) and the pyrylium dye 7 (25 mg, 0.06 mmol) in acetonitrile. The 
reaction yielded 25 mg (0.04 mmol, 66 %) of compound 16 as violet solid. 
HPLC purity (78 %, tr = 11.9 min), mp > 200 °C 1H-NMR (300 MHz, CDCl3): δ = 
1.91-1.99 (m, 4 H), 2.72-2.76 (m, 4 H), 2.80-2.85 (m, 8 H), 2.86 (s, 3 H), 2.97 (s, 
3 H), 3.67 (s, 2 H), 3.82 (s, 3 H), 3.83 (s, 3 H), 6.52 (s, 1 H), 6.59 (s, 1 H), 6.63 
(d, Hz, 2 H), 6.76 (d, Hz, 1 H), 7.02 (d, Hz, 2 H), 8 aromatic protons exchanged 
to the solvent MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 626 (100) 
[M +] IR (ATR) ν~ [cm-1] = 2828 (C-H), 1609 (C-N), 1258 (C-O) UV λmax = 523 nm, 
ε = 2606 L*mol-1cm-1 (in PBS-buffer) Fluorescence: λem = 673 nm, Φ = 10.8 % 
(in PBS-buffer) MF C42H48N3O2+ BF4- MW 713.85 
 
1-benzyl-4-[(1E,3E)-4-(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-
yl)buta-1,3-dienyl]-2,6-dimethylpyridinium tetrafluoroborate (17) 
The compound was prepared following GP 1 using 25 mg (0.2 mmol) of benzyl 
amine and 8 mg (0.02 mmol) of compound 7. The reaction yielded 8 mg (0.01 
mmol, 78 %) of compound 17 as purple solid. Due to the small scale, purity was 
checked by HPLC. (85 %, tr = 14.5 min), mp 59 °C (decomposition) MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 421 (100) [M+] IR (ATR) ν~ [cm-1] = 
2979 (N+-H), 2923 (N+-H) UV λmax = 542 nm (MeOH), ε = 1941 L*mol-1cm-1 MF 
C30H33N2+BF4- MW 508.6 
 
(E)-3-(2,3,6,7-Tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)propenal (20) 
To a solution of 1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline (0.2 g, 1.2 mmol) 
and 3-dimethylaminoacrolein (0.1 g, 0.1 mL, 1.2 mmol) in chloroform a solution 
of phosphorylchloride (0.18 g, 0.11 mL, 1.2 mmol) in chloroform was added 
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dropwise. The red reaction mixture was stirred for 15 h at room temperature 
turning blue and was subsequently heated for two hours to 60 °C before the 
solvent was removed. Under ice-cooling the residue was dissolved in methanol, 
hydrolysed with ice and quenched with 5 mL of a 5 N NaOH. Subsequently the 
product was extracted with chloroform. The organic layer was dried over 
Na2SO4 and the solvent was evaporated. The dark red crude product was 
further purified by recrystallisation from acetone and hexane. The reaction 
yielded 0.1 g (0.4 mmol, 33 %) of compound 20 as red oil. 
1H-NMR (300 MHz, CDCl3): δ = 1.95 (m, 4 H), 2.73 (t, J = 6.3 Hz, 4 H), 3.25 (t, J 
= 5.7 Hz, 4 H), 6.45 (dd, J = 15.6 Hz, J = 7.9 Hz, 1 H), 7.00 (s, 2 H), 7.26 (d, J = 
15.4 Hz, 1 H), 9.52 (d, J = 7.9 Hz, 1 H) 13C-NMR DEPT 135 (75 MHz, CDCl3): δ 
= 20.4 (-, two times CH2), 26.6 (-, 2 x CH2), 48.9 (-, 2 x CH2), 119.6 (2 x Cquat), 
119.9 (Cquat), 121.2 (+, CH), 127.2 (+, 2 x CHarom), 144.7 (Cquat), 153.5 (+, CH), 
192.6 (+, CHO) MS (EI): m/z (%) = 227.2 (100) [M +] IR (ATR) ν~ [cm-1] = 2929 
(C-H), 2839 (C-H), 1637 (C=O) UV (CHCl3) λmax = 412 nm, ε = 15920 L*mol-
1cm-1 MF C15H17NO MW 227.30 
 
Fluorescence and UV measurements of pyrylium dyes. The determination 
of quantum yields and the recording of fluorescence spectra were performed 
with a Cary Eclipse spectrofluorimeter (Varian Inc., Mulgrave, Victoria, 
Australia). The excitation spectrum of antagonist 4 was scanned from 400 nm to 
650 nm (slit = 5 nm), the emission was detected at 660 nm (slit = 10 nm). The 
emission spectrum of antagonist 4 was scanned from 540 nm to 860 nm (slit = 
5 nm), the excitation wavelength was set to 530 nm (slit = 10 nm). For both, 
excitation and emission spectra, the photomultiplier voltage was set to 400 V. 
For the determination of quantum yields, cresyl violet perchlorate was used as a 
standard fluorophore, for which a quantum yield of 54 % in ethanol was 
reported.[33] It is important to take the perchlorate, because only this salt is 
provided with sufficient purity. 
All spectra were recorded in acryl cuvettes. The stock solutions (1 mM) of the 
fluorescent probes and the standard cresyl violet were prepared in DMSO. 
These solutions were diluted to yield a final concentration of 2 µM for 7, 1 µM 
for 9, 50 µM for 10, 10 µM for 11, 50 µM for 12, 50 µM for 13, 50 µM for 14, 100 
µM for 15, 50 µM for 16, 10 µM for 17 and 2.5 µM for the standard. Two 
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solutions were prepared of every fluorescent ligand: one in PBS buffer and the 
other one in PBS and an additional 1 % of BSA in order to determine the 
influence of serum albumin on the quantum yield. The cresyl violet standard 
was diluted in ethanol. For the determination of the reference spectra the pure 
solvents were used with the same protein and DMSO content, but without 
fluorescent compounds. Every solution was maintained in the dark and thermo 
stated to 22 °C. 
The emission spectra were recorded at a temperature of 22 °C using a medium 
scan rate and a photomultiplier voltage of 400 V. The filter settings were “auto” 
for the excitation and “open” for the emission filter. Excitation wavelengths were 
set to 500 nm for 7, 525 nm for 9, 545 nm for 10, 500 nm for 11, 520 nm for 12, 
547 nm for 13, 500 nm for 14, 523 nm for 16, 558 nm for 17 and 600 nm for 
cresyl violet. The excitation slit was set to 10 nm and the emission slit was set 
to 5 nm. A wavelength near the excitation maximum or at a plateau of the 
excitation spectrum was used for excitation. The excitation of the fluorescent 
compounds in the steep part of the excitation spectrum was strictly avoided. In 
addition to every emission spectrum the corresponding reference spectrum was 
subtracted to yield the net spectra, which were multiplied with the corresponding 
lamp correction spectra. The resulting corrected net spectra were integrated in 
the ranges described above. The absorbance at the excitation wavelength was 
determined by recording absorption spectra using a Cary 100 (Varian) UV/Vis 
photometer. Baselines were recorded by using reference solutions and 
subtracted from the raw spectra. The quantum yield was calculated according to 
the following formula: 
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AS and FS are the absorbance and the integral of the emission spectrum of the 
cresyl violet standard solution. AX and FX stand for the absorbance and the 
integral of the emission spectrum of the fluorescent ligand. The refraction 
indices of the solvents for the fluorescent ligands and the cresyl violet standard 
are symbolized by nX and nS, respectively. ΦF(S) is the reported quantum yield of 
cresyl violet, in this case 54 %. 
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Drugs and chemicals used for assays. A Milli-Q system (Millipore, Eschborn, 
Germany) was used for the purification of water in aqueous drug solutions. All 
chemicals used were of analytical grade, if not otherwise mentioned. Hoechst 
33342 (Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to 
produce a 1.6 mM working solution. Test compounds were dissolved in DMSO 
(Merck, Darmstadt, Germany) at a concentration of 10 mM. All stocks were 
stored at -20 °C. Topotecan stocks were prepared by diluting Hycamtin 
(GlaxoSmithKline, Munich, Germany) in 70 % ethanol to a concentration of 0.1 
mM and stored at 4 °C. PBS (phosphate buffered saline) was made of 8.0 g/L 
NaCl, 1.0 g/L Na2HPO4 · 2 H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4 and 0.15 g/L 
NaH2PO4·H2O. The pH-value was adjusted to 7.3 - 7.4 by using a 1 M NaOH or 
HCl solution. Phosphate buffered saline with calcium and magnesium was 
made by dissolving 0.2 g/L KCl, 0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.15 g/L 
Na2HPO4 · 2 H2O in water followed by adding 0.132 g/L of CaCl2 · 2 H2O and 
0.10 g/L of MgCl2 · 6 H2O. Adjusting the pH-value to 7.3 was performed by the 
dropwise addition of a 1 M NaOH solution. Fumitremorgin C (FTC, gift of Dr. 
Susan Bates, NIH) was also dissolved in DMSO and diluted to a concentration 
of 1 mM. A solution of 3 % (m/m) of paraformaldeyde (Merck, Darmstadt, 
Germany) in Ca2+/Mg2+ containing PBS was made by stirring 1.5 g of 
paraformaldehyde per 50 g total solution while heating on a magnetic stirrer for 
approximately 30 min. 
 
Cell lines and culture conditions. MCF-7/Topo cells, an ABCG2 
overexpressing subclone of MCF-7 breast cancer adenocarcinoma cells (ATTC 
HTB-22), were obtained by passaging the MCF-7 cells with increasing 
concentrations of topotecan in the culture medium to a maximum concentration 
of 0.55 µM. Having reached the final concentration of topotecan, the cells were 
passaged after trypsinization using 0.05 % trypsin/0.02 % EDTA (PAA 
Laboratories, Pasching, Austria) every 3-5 days. The treated cells showed 
sufficient quantities of the ABCG2 transporter after three passages in Eagle’s 
minimum essential medium (Sigma, Deisenhofen, Germany) containing L-
glutamine, 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany), 0.11 g/L sodium 
pyruvate (Serva, Heidelberg, Germany), 5 % fetal calf serum (Biochrom, Berlin, 
Germany), and topotecan at a concentration of 0.55 µM. 
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Modulation of ABCG2 in the Hoechst 33342 assay. The standard protocol for 
the performance of Hoechst 33342 was as follows: 3-5 days after passaging 
(70-90 % confluency), MCF-7/Topo cells were seeded into 96-well plates at a 
density of 20000 cells/well (total volume 100 µL). Subsequently, the cells were 
allowed to attach to the surface of the microplates in a water saturated 
atmosphere (95 % air, 5 % carbondioxide) at 37 °C for at least 3 h. In 1.5 mL 
reaction vessels pre-mixtures of the test compounds were prepared by the 
following procedure: 1000 µL of pre-heated (37 °C) EMEM (Eagle’s Minimum 
Essential Medium, Sigma, Munich, Germany) containing L-glutamine, 2.2 g/L of 
NaHCO3
 
and 0.55 g/L of sodium pyruvate, supplemented with 5 % FCS, were 
transferred into the cups. Subsequently, 10 µL of a 1.6 mM Hoechst 33342 dye 
solution was added to the samples. Afterwards 10 µL of DMSO, FTC (10 mM) 
or the test compounds were added to the mixture at increasing concentrations, 
respectively. The samples were immediately vortexed and transferred into 50 
mL polystyrene reagent reservoirs™ (BD, Heidelberg, Germany). By means of 
a multichannel pipette, 100 µL of the pre-mixtures were added to each well of 
the microplate, achieving a final concentration of 50 µM fumitremorgin C 
(positive control) and 8 µM of Hoechst 33342 or 1 µM, respectively. In order to 
get homogenous solutions in each well, the microplates were slightly shaken 
horizontally for a couple of times and placed into an incubator (37 °C, 5 % 
carbondioxide) for 120 min. The supernatants were drained, and the cells were 
fixed for 30 min using 100 µL per well of a 3 % paraformaldehyde solution 
(plates were protected from light by covering with aluminium foil). Finally, MCF-
7/Topo cells were washed twice with 250 µL of calcium and magnesium 
containing PBS for each well. Thereby, the supernatant of the first washing step 
was immediately removed, whereas the second portion of washing buffer was 
added to the cells for another 10 min in order to get rid of residual dye. 
Afterwards, cells were overlaid with 100 µL / well of Ca2+/Mg2+-containing PBS, 
and the relative fluorescence intensities were determined via microplate reader. 
Instruments were set as follows: Measurement mode: fluorescence top; 
excitation filter (Hoechst 33342): 340/35, emission filter (Hoechst 33342): 
485/20, number of reads: 10; integration time: 40 µs; lag time: 0 µs; mirror 
selection: automatic; plate definition file GRE96ft.pdf or GRE96fb.pdf; multiple 
reads per well (circle): 4x4; time between move and flash: 50 ms. On each 
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plate, the optimal gain was calculated by determination of the fluorescence 
intensity in the presence of the control substance, fumitremorgin C. After 
measurements, the microtiter plates were stored at 4 °C for the following cell 
quantification procedures. As a loss of cells and unspecific toxic effects of the 
test compounds during the incubation phase have to be considered, the 
obtained fluorescence values had to be normalized to the cell number of each 
well. Therefore, the microplates were processed with a 0.02 % aqueous crystal 
violet solution (100 µL / well) for 20 min. Excess dye was removed by rinsing 
the trays with water for 20 min. Crystal violet bound by the cells was re-
dissolved in 70 % ethanol (180 µL / well) while shaking the microplates for 2-4 
h. Subsequently, the absorbance was messured as a parameter proportional to 
cell mass at the TECAN plate reader. Normalization of the fluorescence 
intensities to the cell mass was achieved by dividing the detected fluorescence 
values were through the obtained absorbance data of each well. All values were 
corrected to the unspecific uptake of the dye (DMSO control value) and the data 
were referred to the maximal signal caused by 50 µM of the reference 
compound fumitremorgin C. Addition of increasing concentrations of the 
modulators led to sigmoidal concentration response curves. IC50 values were 
calculated using SIGMA PLOT 9.0, four parameter logistic curve fitting. Errors 
were expressed as standard error of the mean (SEM). The required 
concentration of 50 µM fumitremorgin C in the final assay protocol, as a 
reference value for maximal transporter inhibition, was determined via the 
performance of the H33342 assay according to the standard protocol. 
 
Confocal laser scanning microscopy (CLSM) of MCF-7/Topo cells. After 
trypsinization, ABCG2-overexpressing MCF-7/Topo cells were resuspended in 
culture medium supplemented with 5 % fetal calf serum (FCS) and 0.55 µM 
topotecan. 250 µL of the cell suspension were seeded into each well of a sterile 
1 µ-slide 8-well ibiTreat™ microscopy chamber (ibidi, Martinsried, Germany). 
Having reached the appropriate confluency of 70 % (approximately 48 h later), 
the medium was removed by suction, and the cells were washed with 280 µL of 
Leibovitz´s L15 medium containing L-glutamine (Invitrogen, Karlsruhe, 
Germany). Subsequently, the cells were overlaid with 240 µL of Leibovitz´s L15 
medium. On the eve of the experiment, 40 µL of a 7-fold concentrated stock 
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solution of the test compound were pipetted to the cells. Fluorescence imaging 
was performed with a Carl Zeiss Axiovert 200M LSM 510 confocal-laser 
scanning microscope (CLSM) encased by a tempered incubation chamber. 
Instrument settings were as follows: pyrylium-labelled compounds: excitation 
wavelength 543 nm (laser intensity 10 %), emission filter: 659 LP, magnification 
400-fold, (Apochromat 40 x / NA 1.2 W); for bodipy-prazosin: excitation 
wavelength 488 nm (laser intensity 3 %), emission filter: BP 530-600, 
magnification 400-fold, (Apochromat 40 x / NA 1.2 W). For image processing 
the Carl Zeiss LSM Image Examiner and the LSM image browser software were 
used. 
 
Isolation of rat brain capillaries and confocal lacer scanning microscopy 
(CLSM). Rat brain capillaries isolation and confocal microscopy measurements 
were performed as described by Miller et al. (2000).[34] In brief: Capillaries from 
rat (3–6 animals per preparation) brain were isolated using a modification of the 
procedure of Pardridge et al. (1985).[35] All steps in the isolation procedure were 
carried out at 4 °C in pregassed (95 % O2/5 % CO2) solutions. Keeping the 
tissue on ice and in wellgassed buffers was essential for preservation of 
transport function. Briefly, pieces of gray matter were gently homogenized in 
three volumes (v/w) of buffer A (artifical cerebral spinal fluid, commercial ACSF) 
and after addition of dextran (final concentration 30 %), the homogenate was 
centrifuged at low speed (15 min, 7200 mrp). The resulting pellet was 
resuspended in (ACSF+0.5 % BSA) and then filtered through a 150 µM nylon 
mesh. The filtrate was passed over a glass bead column and, after washing 
with 500-mL ACSF + 0.5 % BSA solution, the capillaries adhering to the beads 
were collected by gentle agitation. Capillaries were centrifuged, the pellet 
resuspended in ice-cold ACFS, gassed, BSA-free Krebs-Henseleit buffer and 
immediately used for transport experiments. To measure transport, 10 µL of 
capillary suspension was transferred to a covered, Teflon incubation chamber 
(containing 1.5 mL of pregassed Krebs-Henseleit buffer with fluorescent 
compound and added effectors.) The chamber floor was a glass cover slip to 
which the capillaries adhered and through which capillaries could be viewed by 
means of an inverted confocal laser microscope. Fluorescent compounds and 
inhibitors were added (490 µL) as thinned solutions in PBS + 1 % BSA in 
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different concentrations. The dilution series was prepared from stock solutions 
(in DMSO) and PBS + 1 % BSA. Preliminary experiments showed that the 
concentrations of dimethylsulfoxide used (< 0.5 %) had no significant effects on 
the uptake and distribution of the fluorescent labelled test compounds in brain 
capillaries as measured by confocal microscopy (D.S. Miller, unpublished data). 
Incubation time was set to 30 min. All transport experiments were conducted at 
room temperature (18–20°C). Final concentrations for the test compounds were 
as follows: co-incubation bodipy-prazosin (1 µM) and compound 1 (0.001 µM, 
0.1 µM, 1 µM), co-incubation bodipy-prazosin (1 µM) and compound 9 (1 µM, 
10 µM, 50 µM), co-incubation compound 9 (1 µM) and Ko143 (0.01 µM, 0.1 µM, 
1 µM, 5 µM), co-incubation compound 9 (1 µM) and compound 1 (0.01 µM, 0.1 
µM, 1 µM, 10 µM). 
For image processing and data evaluation Nikon EZ-C1 3.90 and ImageJ 
software were used. Luminal fluorescence intensity measurements were made 
of areas within the central 2 mm (10 pixels) of each segment. The background 
fluorescence intensity was subtracted and the average pixel intensity for each 
area was calculated. Three fluorescent samples and three background samples 
were analysed per capillary, using 4-10 capillaries per concentration. 
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3. Synthesis and Metabolic Stability of New 
Tariquidar-derived ABCG2 Inhibitors 
 
Breast cancer resistance protein (ABCG2) has been studied intensely since its 
discovery one decade ago. The modulation of the membrane located ABC-
transporters is an effective tool for the treatment of multi-drug resistant cancer 
cells. Recently, a new class of tariquidar-like selective ABCG2 inhibitors was 
discovered. By structural variations of this lead structure an improvement of the 
drug-like properties and the potency was attempted. Incubation in mouse 
plasma proved the stability of the ester functionality, but one of the peptide 
bonds was cleaved, also when N-methylated. Structural changes of different 
parts of the molecule decreased the potency only moderately as long as there 
was no negative charge introduced under physiological conditions. The 
phenylbenzamide group is essential for the interaction with the transporter. 
                                                 
∗
 All synthesis were done by Carolin Fischer, inhibition assays for ABCB1 and ABCG2 and 
plasma stability experiments were performed by Peter Höcherl, Matthias Kühnle and Kira 
Bürger. 
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3.1. Introduction 
The ATP-binding cassette (ABC) transporter G2 (BCRP) plays a major role in 
the protection from xenobiotics. Physiological high concentrations are found in 
the blood brain barrier,[1] the gastrointestinal tract, the blood-testis barrier[2] and 
the maternal-fetal[3] barrier to protect the organism and to limit the absorption of 
drugs.[4, 5] ABCG2 overexpression has also been demonstrated in cancer 
cells.[6] On the one hand, cancer cells develop high levels of ABCG2 after the 
treatment with cytostatic agents. On the other hand, cancer stem cells are 
known to express naturally high concentrations of the ABCG2 transporter.[7, 8] 
Here, ABCG2 is supposed to protect the cancer cells against chemotherapeutic 
agents.[9] These properties make the membrane located protein an important 
target to address multi-drug-resistance of cancer cells. In the last few years, the 
list of ABCG2 substrates and inhibitors increased rapidly.[10, 11] Most of the 
identified substances were used in cancer chemotherapy and are large and 
lipophilic molecules, such as mitoxantrone, topotecan, doxorubicin and 
others.[12] Also tyrosine kinase inhibitors (imatinib and gefitinib) and fluorescent 
dyes (Hoechst 33342 and rhodamine 123) have been shown to be 
transported.[13, 14] As the substrate spectrum is highly overlapping with other 
ABC-transporters like ABCB1 (p-glycoprotein) and ABCC1 (MRP1), also many 
inhibitors block more than one ATP-binding cassette transporter.[15] Only few 
specific inhibitors are known for ABCG2. The fungal toxin fumitremorgin C 
(FTC)[16] and its analogue Ko143 are the most commonly used selective 
inhibitors.[17] Novobiocin also displays a selective, but weak inhibitor.[18] 
Structural variation of the ABCB1 inhibitor tariquidar (XR 9576) mostly resulted 
in broad spectrum inhibitors or even preferring ABCB1 inhibition.[19-23] Recently, 
selective ABCG2 inhibitors 1a and 1b (Figure 3.1) were found by changing the 
substitution pattern of the carboxylic acid and the amine functionalities on the 
central aromatic core.[24] Instead of anthranilic acid, 3-aminobenzoic acid was 
used. Additionally, a bicyclic hetero arene gave better inhibitory activity 
compared to monocyclic arenes. In 4-position on the central aromatic core the 
methyl ester was the preferred substituent concerning the potency to modulate 
ABCG2, in comparison to methoxy- and methyl-substituents. 
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Figure 3.1: The parent compound tariquidar and structural modified derivatives 
as specific ABCG2 inhibitors. 
 
In an attempt to improve the potency of the compounds and to identify essential 
structural elements for their inhibitory activity, modifications in the little explored 
tetrahydroisoquinoline part of 1 were made and substructures were synthesised 
and tested. 
Furthermore, with respect to in vivo studies, the metabolic stability of these 
compounds should be high. The ester derivatives 1a and 1b are supposed to be 
cleaved under physiological conditions yielding the corresponding carboxylic 
acid.[25] Therefore, the carboxylic acid and analogues owing a different 
functionality in 4-position on the central aromatic core were synthesised. The 
goal was to retain the activity and at the same time improve the metabolic 
stability. Derivatives bearing hydrogen, a methyl ketone, methyl amide and 
propenyl as substituents were therefore prepared. 
Moreover, amide bonds are also susceptible to enzymatic degradation.[26] The 
quinoline amide bond should be stabilized and protected by intramolecular 
hydrogen bonding in a six-membered ring between the carbonyl oxygen of the 
ester and the NH. The second amide bond was stabilized by N-methylation. The 
method is commonly used to improve the physiological stability of drugs.[27, 28] 
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3.2. Results and Discussion 
3.2.1. Synthesis 
Following the well-established procedures[24, 29] (Scheme 3.1), a library of 
different compounds was synthesised to improve enzymatic stability and to 
investigate the structure-activity-relationship of tariquidar-derived ABCG2 
modulators. The synthetic sequence started with an SN2 reaction converting  
1-(2-bromoethyl)-4-nitrobenzene 2 with different tetrahydroisoquinolines 3a-c. 
The residues on the tetrahydroisoquinolines were hydrogen, methoxy or amine. 
The reaction gave 45-73 % yield of 4a-d. Boc-protection of compound 4b gave 
compound 4c. Consequently, the nitro functionality was reduced with Pd/C and 
hydrogen to the corresponding amine (5a-c). Here, the conversion was nearly 
complete. At this step of the synthesis, 5c was also modified to the acyl (5d), 
the formyl (5e) and the N-methyl derivative (5f). The amide bond formation 
between the 3-nitrobenzoic acid derivatives (6a-c) and compounds 5a-d was 
achieved using classical peptide coupling reagents as HOBt and TBTU, yielding 
20-88 % of 7a-g. Again, the nitro functionality was converted with the help of 
Pd/C and hydrogen gas in good to excellent yields to compounds 8a-h. To 
obtain 8a und 8e, reduction with SnCl2 was necessary. The most sensitive 
reaction was the formation of the second amide bond using the acid chloride 
either of the quinoline-2- or the quinoline-3 carboxylic acid with yields varying 
between 3 % and 69 % for compounds 9a-j. Compound 9c was the product of 
Boc-deprotected derivative 9d, and compound 9f was derived from ester 
cleavage of compound 1b using LiOH. 
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N
R1
R2
N
O
R4
NH2
N
R1
R2
N
O
R4
HN
R5
O
8ae): R1 = H, R2 = H, R3 = H, R4 = CONHCH3
8b: R1 = H, R2 = H, R3 = H, R4 = CO2CH3
8c: R1 = H, R2 = NHBoc, R3 = H, R4 = CO2CH3
8d: R1 = OCH3, R
2 = OCH3, R
3 = CH3, R
4 = CO2CH3
8ee): R1 = OCH3, R
2 = OCH3 R
3 = H, R4 = CONHCH3
8f: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = COCH3
8g: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = CHOHCH2CH3
8hf): R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = H
R6COCl, NEt3, DMF
9a: R1 = H, R2 = H, R3 = H, R4 = CO2CH3, R
5 = 2-quinoline
9b: R1 = H, R2 = H, R3 = H, R4 = CONHCH3, R
5 = 2-quinoline
9c: R1 = H, R2 = NHBoc, R3 = H, R4 = CO2CH3, R
5 = 2-quinoline
9d: R1 = H, R2 = NH2, R
3 = H, R4 = CO2CH3, R
5 = 2-quinoline
9e: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = H, R5 = 2-quinoline
1b: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = CO2CH3, R
5 = 3-quinoline
9f: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = CO2H, R
5 = 3-quinoline
9g: R1 = OCH3, R
2 = OCH3, R
3 = CH3, R
4 = CO2CH3, R
5 = 2-quinoline
9h: R1 = OCH3, R
2 = OCH3, R
3 = H, R4 = CONHCH3, R
5 = 2-quinoline
g)
h)
3-69 %
R3
R3
 
Scheme 3.1: Synthesis of potential ABCG2 inhibitors. a) Boc2O, NEt3, DMF, 99 
%. b) Ac2O, HCO2H, THF, 84 %. c) LiAlH4, THF, 73 % d) acylchloride, NEt3, 
DMAP, DCM, 81 %. e) 5 eq SnCl2, EtOH, 8a: 46 %, 8e: 73 %. f) NHBoc + 
HCl/ether -> NH2, 95 %. g) 15 mol% HCl/ether, 11 %. h) LiOH, DMF, microwave: 
80°C, 300 W, 4 min, 10 %. 
 
For comparison of the biological activitiy only the left part of the parent structure 
1a-b was prepared, starting with a palladium-catalysed reduction of the methyl 
2-nitrobenzoates 10a-b to the corresponding amino compounds 11a-c (Scheme 
3.2). The partial structures 12a-d were derived from the coupling of compounds 
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11a-c to quinoline-2- or the quinoline-3 carbonyl chloride. The Boc-deprotection 
of compound 12d gave compound 12e. 
 
 
Scheme 3.2: Partial structure synthesis. a) 15 mol% HCl/ether, yield: 95 %. 
 
3.2.2. Biological Activity 
The potency of the tariquidar analogues to modulate the ABCG2 transporter 
was determined in the flow cytometric mitoxantrone assay. The red fluorescent 
mitoxantrone is not accumulated in MCF7/Topo cells due to its active efflux by 
overexpressed ABCG2 transporters. Hence, ABCG2 inhibitors can be detected 
by the change of intramolecular mitoxantrone levels. The relative fluorescence 
intensity of the cells was measured. Fumitremorgin C and Ko143 were used as 
positive control compounds, whereas fumitremorgin C was the reference for the 
maximal inhibitory effect of the test compounds. Additionally, all compounds 
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were tested on their activity on the ABCB1 transporter in the calcein-AM 
microtiter assay.[30] 
Table 3.1: ABCG2 inhibition by tariquidar analogues determined by the 
mitoxantrone efflux flow cytometry assay. 
 
No. IC50 [nM] 
Max. effect [%] 
(realtive to 
Fumitremorgin C) 
ABCB1 [nM] 
FTC > 11 000 100 inactive 
Ko143 225 ± 33 82 ± 5 inactive 
1a 60 ± 10 56 ± 6 > 29000 
1b 119 ± 22 41 ± 3 9450 ± 417 
5c inactive a) -- inactive 
5f inactive a) 6 ± 3 > 50000 
9a 297 ± 75 65 ± 2 > 50000 
9b 795 ± 194 39 ± 3 > 50000 
9d 664 ± 249 90 ± 5 > 100000 
9e 555 ± 48 56 ± 2 > 50000 
9f 3414 ± 724 27b) inactive 
9g 1900 ± 700 68 ± 6 6000 ± 2000 
9h 857 ± 122 26 ± 3 > 50000 
9i 622 ± 152 58 ± 3 95308 ± 57364 
9j 1470 ± 420 63 ± 7 103417 ± 48104 
12a inactive a) -- > 50000 
12b inactive a) -- > 50000 
12c 2353 ± 251 105 ± 4 > 50000 
12e 1669 ± 590 b), c) 64 ± 3 > 100000 
 
a)
 no effect up to a concentration of 10 µM. b) N = 1. c) values obtained by Hoechst 33342 assay. 
 
In comparison to the most active compounds 1a and 1b, the methyl keto 
substituted compound 9i (IC50 622 ± 152 nM) gave a good inhibitory effect, 
whereas the potency for the propenyl substituted compound 9j  
(IC50 1470 ± 420 nM) was reduced, potentially due to sterical more demanding 
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residue (Table 3.1). The exchange of the methyl ester to methyl amide (9b IC50 
795 ± 194 nM, 9h IC50 857 ± 122 nM) decreased the IC50 value about one order 
of magnitude. Compound 9f possessing the carboxylic acid in position 4 was 
about 30 times less potent (IC50 3414 ± 724 nM) than the parent ester 
functionalized analogue 1b (IC50 119 ± 22). This observation shows that 
susceptible enzymatic cleavage of the ester would decrease the activity of the 
compound significantly. Without a substituent in 4-position, compound 9e still 
shows acceptable activity (IC50 555 ± 48 nM). The examples indicate that a 
replacement of the methyl ester by other substituents without decrease in 
activity is only possible if they are not charged (9f) or sterically demanding (9j). 
The modifications on the tetrahydroisoquinoline part of the molecule, the 
replacement of the methoxy substituents by hydrogen (9a, IC50 297 ± 75 nM) or 
a primary amine (9d, IC50 795 ± 194 nM) lead to derivatives with IC50 values 
only slightly higher than these for Ko143. Additionally, partial structures of the 
parent compound 1a and 1b were investigated. As shown before, all 
compounds lacking the quinolincarboxamide structure (5c, 5f) are inactive.[23] In 
the absence of the tetrahydroisoquinoline part as in compound 12c (IC50 2353 ± 
251 nM) and 12e (IC50 1669 ± 590 nM) the inhibition activity is still low. 
Compounds 12a and 12b are negatively charged at physiological conditions; 
these compounds show no activity. 
Compound 9g, which was N-methylated at the peptide bond connecting the 
tetrahydroisoquinoline part and the quinolincarboxamide, showed only low 
inhibition activity for ABCG2. However, this was the only compound also 
possessing low activity on ABCB1 with a selectivity factor of 3. As this slight 
structural modification has such strong effect, the phenylbenzamide bond 
seems to play an essential role in the interaction with the transporter. 
In summary, the inhibitory effect of mitoxantrone efflux is more affected by the 
quinoline carboxamide benzoate substructure than by the 
tetrahydroisoquinoline substructure. Structural changes on the 
tetrahydroisoquinoline part are more tolerated in terms of retained inhibition 
activity. All new derivatives are selective ABCG2 inhibitors. 
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3.2.3. Stability in Mouse Plasma 
Before the intented in vivo studies, the biological stability of selected ABCG2 
modulators was investigated. Incubation with mouse plasma showed enzymatic 
degradation of the compounds 1a and 1b within 10 to 30 min by at least  
50 %.[31] Surprisingly, the ester group remained intact, whereas the benzoic 
amide was cleaved rapidly. HPLC-MS analysis confirmed the cleavage of the 
peptide bond into compounds 12a/12b and 5c. To exclude a hydrolytic 
cleavage, control experiments in phosphate buffered saline (PBS) and 
deproteinated plasma revealed the stability of the compounds in the absence of 
enzymes. The products of the cleavage reaction are inactive in the inhibition of 
the ABCG2 transporter. 
Methylation of amide nitrogen atoms is an established strategy to improve the 
stability of peptides against enzymatic cleavage. However, compound 9g with 
the N-methylated amide was again completely degraded within minutes  
(Figure 3.2). 
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Figure 3.2: Stability of compound 9g upon incubation with murine plasma; the 
concentration of 9g was determined by HPLC, N = 2. 
 
Bio-isosteric replacement of the amide bond e.g. by benzimidazole, by different 
oxadiazoles or by -CH2-NH- may improve the stability of derivatives against 
enzymatic cleavage.[32, 33] 
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3.3. Conclusion 
A series of new tariquidar-derived ABC-transporter inhibitors were synthesised 
to investigate the effect of structural changes at the tetrahydroisoquinoline 
substructure and the ester functionality. Furthermore, the effect of N-
methylation on the enzymatic stabililty was examined to increase enzymatic 
stability by N-methylation. Structural variations on the tetrahydroisoquinoline 
part (9a, 9d) decreased the inhibitory effect on ABCG2 only little. Exchanging 
the methyl ester on the central aromatic core by other substituents was 
tolerated well, as long as no additional charge (9f) or a sterical demanding 
residue (9j) was introduced. Partial structures without the tetrahydroisoquinoline 
part (12c, 12e) showed weak inhibitory activity in the testing. This allows the 
conclusion that the tetrahydroisoquinoline part plays only a minor role in the 
interaction between the inhibitor and the transporter protein. N-Methylation of 
the phenylbenzamide moiety as in 9g decreased the inhibitory activity 
compared to the parent compound 1a significantly; the functional group seems 
to be important for the inhibitory activity on ABCG2. 
All new compounds were found to be selective inhibitors for ABCG2 with no 
significant inhibition activity for ABCB1. Among 15 tested derivatives, only 9g, 
the N-methylated analogue of 1a, showed some inhibition activity on ABCB1. 
Although it was not possible to obtain an ABCG2 inhibitor that is stable in 
serum, valuable information on the structure activity-relationship was derived 
from the study. 
 
3.4. Experimental Section 
General. Commercial reagents and starting materials were purchased from 
Aldrich, Fluka or Acros and used without further purification. Flash 
chromatography was performed on silica gel (Merck silica gel Si 60 40-63 µm); 
products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ = 254 nm). 
Melting points were determined with a Büchi SMP 20 and are uncorrected. 
NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz; 13C:  
75.5 MHz; T = 300 K), Bruker Avance 400 (1H: 400.1 MHz; 13C: 100.6 MHz; T = 
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300 K) and Bruker Avance 600 (1H: 600.1 MHz; 13C: 150.1 MHz; T = 300 K) 
instruments. Chemical shifts are reported in δ/ppm relative to external 
standards and coupling constants J are given in Hz. Abbreviations for the 
characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, 
bs = broad singlet, dd = double doublet. The relative numbers of protons is 
determined by integration. Error of reported values: chemical shift 0.01 ppm 
(1H-NMR), 0.1 ppm (13C-NMR), coupling constant 0.1 Hz. The used solvent for 
each spectrum is reported. Mass spectra were recorded with Finnigan MAT 
TSQ 7000 (ESI) and Finnigan MAT 90 (HRMS), IR spectra with a Bio-Rad FT-
IR-FTS 155 spectrometer and UV/vis spectra with a Cary BIO 50 UV/vis/NIR 
spectrometer (Varian). 
 
The following compounds were synthesised following literature-known 
procedures: 1,2,3,4-tetrahydro-7-nitroisoquinoline,[34] 3-(tert-butoxycarbonyl-
amino)benzoic acid,[35] methyl 4-{4-[2-(6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinolin-2-yl)ethylphenyl] aminocarbonyl}-2-nitrobenzoate,[24] 
methyl 2-amino-4-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl)ethyl]phenyl} aminocarbonyl)benzoate,[24] tert-butyl 4-aminophenethyl-
carbamate,[36] methyl 4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl) 
ethyl] phenylcarbamoyl} -2-(quinoline-2-carboxamido) benzoate (1a),[24] methyl 
4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl] phenylcarbamoyl}-
2-(quinoline-3-carboxamido) benzoate (1b),[24] 1,2,3,4-tetrahydroisoquinolin-7-
amine (3b),[37] 4-{2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}aniline 
(5c),[38] 3-amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenyl}benz-amide (8h) (see chapter 2), methyl 4-{4-[2-(tert-
butoxycarbonylamino) ethyl] phenylcarbamoyl}-2-nitrobenzoate (10b) (see 
chapter 2), methyl 2-amino-4-{4-[2-(tert-butoxycarbonylamino)ethyl] 
phenylcarbamoyl} benzoate (11c) (see chapter 2), N-[4-(2-tert-
butoxycarbonylamino-ethyl)-phenyl]-2-[(quinoline-2-carbonyl)-amino]-
terephthalamic acid methyl ester (12d) (see chapter 2), methyl-4-[4-(2-
aminoethyl)phenylcarbamoyl]-2-(isoquinoline-3-carboxamido)-benzoate (12e) 
(see chapter 2), tert-butyl-3-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenylcarbamoyl}phenylcarbamate (see chapter 2) 
General procedures (GP): 
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GP 1: Amide coupling over an active ester 
The respective carboxylic acid (1.1 eq) was dissolved in CH2Cl2. Two 
equivalents of DIPEA, 1.2 eq of each TBTU and HOBt were added at 0 °C. After 
30 minutes the active ester was formed and the respective amine was added. 
The reaction mixture was stirred for 16 h, taken up in water, diluted with 
dichloromethane, washed three times with water (3 x 30 mL) and once with 
saturated NaHCO3 solution (30 mL). The organic layer was dried over Na2SO4 
and the solvent was evaporated giving the crude reaction product. 
 
GP 2: Reduction of the nitro function 
The respective nitro compound (1 eq) was dissolved in ethyl acetate and 
methanol followed by the addition of Pd/C (10 % m/m) suspended in ethyl 
acetate. After stirring the solution under 10 bar of H2 at room temperature for  
15 h, the catalyst was filtered off and the solvent was removed to obtain the 
solid product. 
 
2-(4-Nitrophenethyl)-1,2,3,4-tetrahydroisoquinoline (4a) 
A solution of 4-nitrophenylethyl bromide (1 eq, 4.40 g, 19 mmol), 1,2,3,4-
tetrahydro isoquinoline hydrochloride (1.1 eq, 2.45 g, 18 mmol) and potassium 
carbonate (2.3 eq, 5.53 g, 40 mmol) in 20 mL DMF was heated at 100 °C for 4.5 
h. The mixture was filtered and evaporated. The residue was taken up in water 
and extracted with dichloromethane (3 x 30 mL). The organic layers were dried 
over sodium sulphate and the solvents were removed under reduced pressure. 
The resulting solid was recrystallized from ethanol to give 2-(4-nitrophenethyl)-
1,2,3,4-tetrahydroisoquinoline as orange solid (3.96 g,14 mmol, 73.4 %), mp 
108 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.80 (t, J = 7.2 Hz, 4 H), 2.92 (t, J = 
5.7 Hz, 2 H), 3.02 (t, J = 8.1 Hz, 2 H), 7.02-7.04 (m, 1 H), 7.09-7.15 (m, 3 H), 
7.41 (d, J = 8.8 Hz, 2 H), 8.15 (d, J = 8.8 Hz, 2 H) – 13C-NMR, DEPT 135 (75 
MHz, CDCl3): δ = 29.1 (-, CH2), 33.8 (-, CH2), 50.9 (-, CH2), 56.1 (-, CH2), 59.2 
(-, CH2), 123.7 (+, 2 x CHarom), 125.7 (+, CHarom), 126.3 (+, CHarom), 126.6 (+, 
CHarom), 128.7 (+, 2 x CHarom), 129.6 (+, CHarom), 134.2 (Cquat), 134.4 (Cquat), 
146.5 (Cquat), 148.4 (Cquat) – MS (CI, NH3): m/z (%) = 283 (100) [M-H+] – IR 
(ATR) ν~ [cm-1] = 1339 (N-O), 1519 (N-O) – MF C17H18N2O2 – MW 282.34 
2-(4-Nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-amine (4b) 
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A solution of 4-nitrophenylethyl bromide (1 eq, 1.9 g, 8.5 mmol), 1,2,3,4-
tetrahydroisoquinolinehydrochloride-7-amine (1.2 eq, 1.4 g, 9.3 mmol) and 
potassium carbonate (2.3 eq, 2.7 g, 19.5 mmol) in 10 mL DMF was heated at  
90 °C for five hours under nitrogen. The mixture was filtered and evaporated. 
The residue was taken up in water and extracted with dichloromethane  
(3 x 30 mL). The organic layers were dried over sodium sulphate and the 
solvents were removed under reduced pressure. The resulting solid was 
purified by column chromatography (elution with ethyl acetate, Rf: 0.2) to give 2-
(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-amine as orange solid (1 g, 
3.4 mmol, 45 %), mp 137 °C – 1H-NMR: (300 MHz, CDCl3) δ = 2.75 – 2.80 (m, 6 
H), 2.95 – 3.02 (m, 2 H), 3.62 (s, 2 H), 6.37 (d, J = 2.3 Hz, 1 H), 6.52 (dd, J = 
2.4 Hz, 8.1 Hz, 1 H), 6.90 (d, J = 8.1 Hz, 1 H), 7.40 (d, J = 8.7 Hz, 2 H), 8.14 (d, 
J = 8.7 Hz, 2 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 27.0 (-, CH2), 32.7 
(-, CH2), 50.1 (-, CH2), 54.9 (-, CH2), 58.0 (-, CH2), 111.7 (+, CHarom), 112.3 (+, 
CHarom), 122.6 (+, 2 x CHarom), 123.1 (Cquat), 128.4 (+, CHarom), 128.6 (+, 2 x 
CHarom), 134.0 (Cquat), 143.2 (Cquat), 145.5 (Cquat), 147.4 (Cquat) – MS (CI): m/z 
(%) = 298 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1339 (N-O), 1514 (N-O), 3350 (N-
H), 3453 (N-H) – MF C17H19N3O2 – MW 297.35 
 
tert-Butyl 2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-yl carba-
mate (4c) 
2-(4-Nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-amine (1.0 g, 3.4 mmol) 
was dissolved in DMF before 1.5 eq of NEt3 (0.5 g, 0.7 mL, 5.1 mmol) and 1 eq 
of Boc2O (0.7 g, 3.5 mmol), diluted in a few drops of water, were added. After 
stirring over night at room temperature DMF was evaporated and the residue 
was taken up with diluted HCl and extracted with ethyl acetate. The combined 
organic layers were dried over Na2SO4 and evaporated. The reaction yielded 
1.35 g (3.3 mmol, 99 %) yellow oil, 1H-NMR (300 MHz, CDCl3): δ = 1.50 (s, 9 
H), 2.75-2.85 (m, 6 H), 2.94-3.00 (m, 2 H), 3.66 (s, 2 H), 6.47 (s, 1H), 6.99 (d, J 
= 3.8 Hz, 1 H), 7.21 (s, 1 H), 7.39 (d, J = 8.8 Hz, 2 H), 8.14 (d, J = 8.5 Hz, 2 H) 
– 
13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 28.4 (+, 3 x CH3,), 29.2 (-, CH2), 
33.7 (-, CH2), 51.0 (-, CH2), 56.0 (-, CH2), 59.2 (-, CH2), 80.3 (Cquat), 117.0 (+, 
CHarom), 123.6 (+, 2 x CHarom), 128.8 (+, CHarom), 129.0 (+, CHarom), 129.6 (+, 2 x 
CHarom), 135.1 (Cquat), 136.2 (Cquat), 146.4 (Cquat), 148.5 (Cquat), 153.1 (Cquat), 
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162.7 (Cquat) – MS (CI): m/z (%) = 398 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1341 
(N-O), 1511 (N-O), 1664 (C=O) – MF C22H27N3O4 – MW 397.47 
 
4-{2-[3,4-Dihydroisoquinolin-2(1H)-yl]ethyl}benzenamine (5a) 
The preparation followed GP 2 using 3.75 g (13.3 mmol) 2-(4-nitrophenethyl)-
1,2,3,4-tetrahydroisoquinoline diluted in ethyl acetate. The reaction yielded  
3.02 g (12.0 mmol, 89 %) orange solid, mp 88 °C – 1H-NMR (300 MHz, [D6]-
DMSO): δ = 2.50-2.60 (m, 4 H), 2.68 (t, J = 6.0 Hz, 2 H), 2.79 (t, J = 5.4 Hz, 2 
H), 3.59 (s, 2 H), 6.48 (d, J = 8.2 Hz, 2 H), 6.89 (d, J = 8.2 Hz, 2 H), 7.02-7.11 
(m, 4 H) – 13C-NMR, DEPT 135 (75 MHz, [D6]-DMSO): δ = 28.6 (-, CH2), 32.1 (-
, CH2), 50.4 (-, CH2), 55.4 (-, CH2), 60.2 (-, CH2), 113.9 (+, 2 x CHarom), 125.3 (+, 
CHarom), 125.7 (+, CHarom), 126.3 (+, CHarom), 127.1 (Cquat), 128.3 (+, CHarom), 
128.9 (+, 2 x CHarom), 134.1 (Cquat), 134.9 (Cquat), 146.5 (Cquat) – MS (CI, NH3): 
m/z (%) = 253 (100) [M-H+] – IR (ATR) ν~ [cm-1] = 3308 (N-H), 3432 (N-H) –  
MF C17H20N2 – MW 252.35 
 
tert-Butyl 2-(4-aminophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-ylcarba-
mate (5b) 
The preparation followed GP 2 diluting tert-butyl 2-(4-nitrophenethyl)-1,2,3,4-
tetrahydroisoquinolin-7-ylcarbamate (0.48 g, 1.2 mmol) in ethyl acetate. The 
reaction yielded 0.45 g (1.2 mmol, 100 %) yellow solid, mp 70 °C 
decomposition – 1H-NMR (300 MHz, [D4]-methanol): δ = 1.05 (s, 3 H), 2.33-2.45 
(m, 8 H), 2.89 (s, 2 H), 6.53 (d, J = 8.2 Hz, 2 H), 6.71-6.73 (m, 3 H), 6.75-6.79 
(m, 2 H) – 13C-NMR, DEPT 135 (75 MHz, [D4]-methanol): δ = 28.2 (+, 3 x CH3), 
28.9 (-, CH2), 32.8 (-, CH2), 51.9 (-, CH2), 56.4 (-, CH2), 61.0 (-, CH2), 80.9 
(Cquat), 117.0 (+, 3 x CHarom), 129.9 (+, CHarom), 130.1 (+, CHarom), 130.5 (+, 2 x 
CHarom), 134.1 (Cquat), 138.8 (Cquat), 147.1 (Cquat), 155.3 (Cquat), 164.9 (Cquat) – 
MS (CI): m/z (%) = 368 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1515 (C=O), 3222 
(N-H), 3300 (N-H) – MF C22H29N3O2 – MW 367.48 
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N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}form-
amide (5d) 
Formic acid (1.5 mL) was added to ice-cold acetic anhydride (3 mL) and heated 
to 50-60 °C for two hours. After cooling to room temperature dry THF (5 mL) 
was added. Then a solution of 4-{2-[6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl]ethyl}aniline (0.42 g, 1.3 mmol) in dry THF was added dropwise at  
-20 °C. After 30 min stirring at low temperature the excess of anhydride and 
acid was removed under vacuum. The residue was taken up in ethyl acetate 
and washed twice with 0.1 N NaOH. The organic layer was dried over Na2SO4 
and evaporated. The reaction resulted in pale yellow solid (0.39 g, 1.1 mmol, 84 
%), mp 96 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.72-2.82 (m, 8 H), 3.63 (s, 2 
H), 3.81 (s, 6 H), 6.52 (s, 1 H), 6.58 (s, 1 H), 6.98 (d, J = 8.5 Hz, 1 H), 7.14-7.21 
(m, 2 H), 7.44 (d, J = 8.2 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 
28.65 (-, CH2), 33.3 (-, CH2), 51.0 (-, CH2), 55.7 (+, CH3), 55.9 (+, CH3), 56.0 (-, 
CH2), 60.0 (-, CH2), 109.5 (+, CHarom), 111.3 (+, CHarom), 119.2 (+, CHarom), 
120.2 (+, CHarom), 126.1 (Cquat), 126.4 (Cquat), 129.3 (+, CHarom), 130.0 (+, 
CHarom), 136.9 (Cquat), 137.6 (Cquat), 147.2 (Cquat), 147.6 (Cquat), 162.6 (Cquat) – 
MS (CI): m/z (%) = 341 (100) [MH+] – IR (ATR) ν~ [cm-1] = 1516 (C=O) –  
MF C20H24N2O3 – MW 340.18 
 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}-N-methylaniline 
(5e) 
To a suspension of LiAlH4 (2.6 eq, 30 mg, 0.7 mmol) in dry THF a solution of  
N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}formamide 
(100 mg, 0.3 mmol) was added dropwise at 0 °C. After two hours reaction time 
the mixture was treated with saturated NH4Cl solution to destroy the excess of 
reducing agent. The water layer was then extracted twice with ethyl acetate. 
The combined organic layers were dried over Na2SO4 and evaporated. The 
reaction yielded yellow solid (0.07 g, 0.2 mmol, 73 %), mp 86 °C – 1H-NMR 
(300 MHz, CDCl3): δ = 2.68-2.84 (m, 11 H), 3.64 (s, 2 H), 3.83 (s, 3 H), 3.84 (s, 
3 H), 6.54 (s, 1 H), 6.57 (d, J = 8.2 Hz, 2 H), 6.59 (s, 1 H), 7.06 (d, J = 8.5 Hz, 2 
H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 27.6 (-, CH2), 29.9 (+, CH3), 
32.0 (-, CH2), 50.0 (-, CH2), 54.7 (-, CH2), 54.8 (+, CH3), 54.9 (+, CH3), 59.7 (-, 
CH2), 108.4 (+, CHarom), 110.3 (+, CHarom), 111.5 (+, 2 x CHarom), 125.1 (Cquat), 
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125.5 (Cquat), 127.8 (Cquat), 128.4 (+, 2 x CHarom), 146.1 (Cquat), 146.4 (Cquat), 
146.7 (Cquat) – MS (CI): m/z (%) = 327 (100) [MH+] – IR (ATR) ν~ [cm-1] = 2806 
(C-H), 3400 (N-H) – MF C20H26N2O2 – MW 326.2 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}acet-
amide (5f) 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}aniline (50 mg, 0.16 
mmol) was diluted in dichloromethane before 1.5 eq (20 mg, 30 µL, 0.24 mmol) 
of NEt3, 0.5 eq (0.01 g, 0.08 mmol) of DMAP and 1.5 eq (20 mg, 0.24 mmol) of 
acylchloride were added. After stirring three hours at room temperature the 
mixture was diluted with further dichloromethane and the organic layer was 
washed with NaHCO3 and water. Drying over Na2SO4 and evaporation yielded 
0.05 g (0.13 mmol, 81 %) yellow oil, mp 105 °C – 1H-NMR (300 MHz, CDCl3): 
δ = 2.05 (s, 3 H), 2.81-2.86 (m, 8 H), 3.70 (s, 2 H), 3.74 (s, 3 H), 3.75 (s, 3 H), 
6.45 (s, 1 H), 6.52 (s, 1 H), 7.05 (d, J = 8.5 Hz, 2 H), 7.42 (d, J = 8.8 Hz, 2 H), 
8.72 (s, 1 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 24.4 (+, CH3), 
27.8 (-, CH2), 32.7 (-, CH2), 50.5 (-, CH2), 54.9 (-, CH2), 55.9 (+, CH3), 56.0 (+, 
CH3), 59.3 (-, CH2), 109.4 (+, CHarom), 111.3 (+, CHarom), 120.2 (+, 2 x CHarom), 
125.2 (Cquat), 125.5 (Cquat), 129.1 (+, 2 x CHarom), 135.3 (Cquat), 136.6 (Cquat), 
144.0 (Cquat), 147.4 (Cquat), 147.7 (Cquat), 168.8 (Cquat) – MS (+ESI, DCM/MeOH 
+ 10 mmol/L NH4Ac): m/z (%) = 355 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1514 
(N-H), 1671 (C=O) – MF C21H26N2O3 – MW 354.44 
 
N4-{4-[2-(3,4-Dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-methyl-2-
nitroterephthalamide (7a) 
The preparation followed GP 1 using 4-(methylcarbamoyl)-3-nitrobenzoic acid 
(0.27 g, 1.21 mmol), DIPEA (0.28 g, 0.37 mL, 2.2 mmol), HOBt (0.2 g,  
1.3 mmol), TBTU (0.5 g, 1.3 mmol) and 4-{2-[3,4-dihydroisoquinolin-2(1H)-
yl]ethyl}benzenamine (0.27 g, 1.1 mmol) diluted in dichloromethane with a few 
drops of DMF. The reaction yielded 0.55 g (1.2 mmol, 75 %) orange solid,  
mp 177 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.73-2.87 (m, 11 H), 3.69 (s, 2 H), 
6.95-6.97 (m, 1 H), 7.05-7.08 (m, 3 H), 7.14 (d, J = 8.5 Hz, 2 H), 7.37 (d, J = 8.0 
Hz, 1 H), 7.55 (d, J = 8.2 Hz, 2 H), 7.99 (dd, J = 1.4 Hz, 8.0 Hz, 1 H), 8.34 (d, J 
= 1.4 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 26.7 (+, CH3), 28.5 
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(-, CH2), 32.8 (-, CH2), 50.8 (-, CH2), 55.7 (-, CH2), 59.8 (-, CH2), 121.0 (+, 2 x 
CHarom), 123.4 (+, CHarom), 125.8 (+, CHarom), 126.5 (+, CHarom), 126.6 (+, 
CHarom), 128.7 (+, CHarom), 129.0 (+, CHarom), 129.2 (+, 2 x CHarom), 132.5 (+, 
CHarom), 133.7 (2 x Cquat), 134.8 (Cquat), 135.9 (Cquat), 136.6 (Cquat), 137.2 (Cquat), 
146.0 (Cquat), 163.7 (Cquat), 167.1 (Cquat) – MS (+ESI): m/z (%) = 459 (100) [M-
H+] - IR (ATR) ν~ [cm-1] = 1604 (C=O), 1637 (C=O), 3263 (N-H) –  
MF C26H26N4O4 – MW 458.51 
 
Methyl 4-{4-[2-(3,4-dihydroisoquinolin-2[1H]-yl)ethyl] phenylcarbamoyl}-2-
nitro-benzoate (7b) 
The preparation followed GP 1 using 4-(methoxycarbonyl)-3-nitrobenzoic acid 
(0.6 g, 2.4 mmol), DIPEA (0.56 g, 0.74 mL, 4.4 mmol), HOBt (0.4 g, 2.6 mmol), 
TBTU (1.0 g, 2.6 mmol) and 4-{2-[3,4-dihydroisoquinolin-2(1H)-
yl]ethyl}benzenamine (0.55 g, 2.2 mmol) diluted in dichloromethane with a few 
drops of DMF. The reaction yielded 0.86 g (1.9 mmol, 85 %) yellow solid,  
mp 79 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.74-2.95 (m, 8 H), 3.72 (s, 1 H), 
3.95 (s, 3 H), 7.02-7.04 (m, 1 H), 7.10-7.23 (m, 3 H), 7.24 (d, J = 7.1 Hz, 2 H), 
7.58 (d, J = 8.2 Hz, 2 H), 7.80 (d, J = 7.9 Hz, 1 H), 8.21 (dd, J = 7.9 Hz, 1.4 Hz, 
1 H), 8.43 (d, J = 1.4 Hz, 1 H), 8.63 (s, NH) – 13C-NMR, DEPT 135 (75 MHz, 
CDCl3): δ = 29.1 (-, CH2), 33.4 (-, CH2), 51.0 (-, CH2), 53.5 (+, CH3), 56.1 (-, 
CH2), 60.1 (-, CH2), 121.1 (+, 2 x CHarom), 123.1 (+, CHarom), 125.6 (+, CHarom), 
126.2 (+, CHarom), 126.6 (+, CHarom), 128.7 (+, CHarom), 129.3 (+, 2 x CHarom), 
129.6 (Cquat), 130.0 (+, CHarom), 132.1 (+, CHarom), 134.2 (Cquat), 134.6 (Cquat), 
135.8 (Cquat), 137.3 (Cquat), 138.7 (Cquat), 147.9 (Cquat), 165.4 (Cquat), 165.7 
(Cquat) – MS (+ESI): m/z (%) = 460 (100) [M-H+] – IR (ATR) ν~ [cm-1] = 1348 (N-
O), 1536 (N-O), 1651 (C=O), 1740 (C=O), 3333 (N-H) – MF C26H25N3O5 –  
MW 459.49 
 
Methyl4-{4-[2-(7-[tert-butoxycarbonylamino]-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]-phenyl-carbamoyl}-2-nitrobenzoate (7c) 
The preparation followed GP 1 using 4-(methoxycarbonyl)-3-nitrobenzoic acid 
(0.27 g, 1.21 mmol), DIPEA (0.28 g, 0.37 mL, 2.2 mmol), HOBt (0.2 g, 1.3 
mmol), TBTU (0.5 g, 1.3 mmol) and tert-butyl 2-(4-aminophenethyl)-1,2,3,4-
tetrahydroisoquinolin-7-ylcarbamate (0.4 g, 1.0 mmol) diluted in 
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dichloromethane with a few drops of DMF. The reaction yielded 0.48 g  
(0.8 mmol, 40 %) yellow solid, mp 92 °C – 1H-NMR (300 MHz, CDCl3): δ = 1.50 
(s, 9 H), 2.72-2.86 (m, 8 H), 3.63 (s, 2 H), 3.94 (s, 3 H), 6.49 (s, 1 H), 6.96 (s, 1 
H), 7.15 (s, 1 H), 7.21 (d, J = 8.5 Hz, 2 H), 7.59 (d, J = 8.2 Hz, 2 H), 7.76 (d, J = 
7.9 Hz, 1 H), 8.19 (d, J = 7.9 Hz, 1 H), 8.42 (d, J = 1.4 Hz, 1 H), 8.9 (s, 1 H) – 
13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 28.3 (-, CH2), 28.4 (+, CH3, 3 x), 33.2 
(-, CH2), 51.0 (-, CH2), 53.5 (+, CH3), 55.9 (-, CH2), 59.9 (-, CH2), 116.8 (+, 
CHarom), 117.2 (+, CHarom), 121.1 (+, 2 x CHarom), 123.1 (+, CHarom), 124.9 
(Cquat), 128.9 (Cquat), 129.2 (+, 2 x CHarom), 129.5 (Cquat), 129.9 (+, CHarom), 
130.0 (+, CHarom), 132.1 (+, CHarom), 135.1 (Cquat), 135.9 (Cquat), 137.1 (Cquat), 
138.6 (Cquat), 147.9 (Cquat), 153.2 (Cquat), 162.8 (Cquat), 165.4 (Cquat), 165.7 
(Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 575 (100) [M-
H+]- - IR (ATR) ν~ [cm-1] 1513 (N-O), 1601 (C=O), 1673 (C=O), 1732 (C=O) – MF 
C31H34N4O7 – MW 574.62 
 
Methyl 4-{[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)-
phenyl]-(methyl)-carbamoyl}-2-nitrobenzoate (7d) 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}-N-methylaniline (0.5 
g, 1.5 mmol) and 1.5 eq of NEt3 (0.23 g, 0.32 mL, 2.3 mmol) were dissolved in 
dichloromethane and methyl 4-(chlorocarbonyl)-2-nitrobenzoate (0.56 g,  
2.3 mmol) was added. After stirring the reaction mixture for 15 h at room 
temperature 10 mL dichloromethane were added and the organic layer was 
washed with NaHCO3 and water. Then, the organic layer was dried over 
Na2SO4 and evaporated. Further purification was achieved by column 
chromatography (elution EtOAc > ETOAC/MeOH 6:1, Rf: 0.42). The reaction 
yielded yellow solid (0.47 g, 0.08 mmol, 44 %), mp 57 °C – 1H-NMR (300 MHz, 
CDCl3): δ = 2.70-2.85 (m, 8 H), 3.48 (s, 3 H), 3.63 (s, 2 H), 3.82 (s, 3 H), 3.83 
(s, 3 H), 3.86 (s, 3 H), 6.52 (s, 1 H), 6.58 (s, 1 H), 6.95 (d, J = 8.2 Hz, 2 H), 7.15 
(d, J = 8.2 Hz, 2 H), 7.51 (d, J = 7.9 Hz, 1 H), 7.56 (dd, J = 1.1 Hz, 7.9 Hz, 1 H), 
7.79 (s, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 28.5 (-, CH2), 33.3 (-, 
CH2), 38.6 (+, CH3), 50.9 (-, CH2), 53.4 (+, CH3), 55.6 (-, CH2), 55.9 (+, CH3), 
56.0 (+, CH3), 59.5 (-, CH2), 109.5 (+, CHarom), 111.4 (+, CHarom), 124.4 (+, 
CHarom), 126.0 (Cquat), 126.2 (Cquat), 126.9 (+, 2 x CHarom), 128.0 (Cquat), 129.4 
(+, CHarom), 130.2 (+, 2 x CHarom), 132.9 (+, CHarom), 139.7 (Cquat), 140.2 (Cquat), 
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141.5 (Cquat), 147.3 (Cquat), 147.4 (Cquat), 147.6 (Cquat), 165.3 (Cquat), 166.7 
(Cquat) – MS (CI): m/z (%) = 534 (100) [MH+] – IR (ATR) ν~ [cm-1] = 1514 (C=O), 
1733 (C=O) – MF C29H31N3O7 – MW 533.57 
 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}phenyl4-
(methylcarbamoyl)-3-nitrobenzoate (7e) 
The preparation followed GP 1 using 4-(methylcarbamoyl)-3-nitrobenzoic acid 
(0.3 g, 1.3 mmol), DIPEA (0.31 g, 0.40 mL, 2.4 mmol), HOBt (0.23 g, 1.5 mmol), 
TBTU (0.56 g, 1.5 mmol) and 4-{2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl]ethyl}aniline (0.37 g, 1.2 mmol) diluted in dichloromethane with a few drops of 
DMF. The product was purified with column chromatography (elution with 
MeOH/EE 1:3, Rf: 0.35). The reaction yielded 0.28 g (0.5 mmol, 42 %) of yellow 
solid, mp 178 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.64-2.80 (m, 8 H), 3.28 (s, 
2 H), 3.57 (s, 3 H), 3.72 (s, 3 H), 3.73 (s, 3 H), 6.44 (s, 1 H), 6.51 (s, 1 H), 7.14 
(d, J = 8.2 Hz, 2 H), 7.47 (d, J = 7.7 Hz, 1 H), 7.52 (d, J = 8.2 Hz, 2 H), 8.07 (d, 
J = 7.9 Hz, 1 H), 8.46 (s, 1 H) – 13C-NMR, DEPT 135 (75 MHz, [D6]-DMSO): δ = 
26.0 (+, CH3), 28.2 (-, CH2), 32.3 (-, CH2), 50.5 (-, CH2), 55.0 (-, CH2), 55.3 (+, 
CH3), 55.4 (+, CH3), 59.5 (-, CH2), 109.8 (+, CHarom), 111.6 (+, CHarom), 120.4 
(+, 2 x CHarom), 123.1 (+, CHarom), 125.8 (Cquat), 126.5 (Cquat), 128.8 (+, 2 x 
CHarom), 128.9 (Cquat), 129.2 (+, CHarom), 132.4 (+, CHarom), 134.6 (Cquat), 136.4 
(Cquat), 136.6 (Cquat), 146.7 (Cquat), 146.8 (Cquat), 147.0 (Cquat), 162.4 (Cquat), 
165.1 (Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 519 
(100) [MH+] – IR ν~ [cm-1] = 1516 (N-O), 1600 (C=O), 1640 (C=O), 3300 (N-H) – 
MF C28H30N4O6 – MW 518.55 
 
4-Acetyl-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]-
phenyl}-3-nitro benzamide (7f) 
Preparation following GP 1 using 4-acetyl-3-nitrobenzoic acid (0.74 g,  
3.5 mmol), DIPEA (0.82 g, 1.09 mL, 6.4 mmol), HOBt (0.58 g, 3.8 mmol), TBTU 
(0.38 g, 3.8 mmol) and 4-{2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl]ethyl}aniline (1.0 g, 3.2 mmol) diluted in dichloromethane. The reaction 
yielded 1.42 g (88 %) of a yellow solid, mp > 190 °C – 1H-NMR (300 MHz, [D6]-
DMSO): δ = 2.62 (s, 3 H), 2.78-2.86 (m, 8 H), 3.70 (s, 6 H), 5.76 (s, 2 H), 6.66 
(s, 1 H), 6.68 (s, 1 H), 7.27 (d, J = 8.5 Hz, 2 H), 7.71 (d, J = 8.5 Hz, 2 H), 7.94 
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(d, J = 7.9 Hz, 2 H), 8.41 (dd, J = 7.6 Hz, J = 1.6 Hz, 1 H), 8.64 (d, J = 1.6 Hz, 1 
H), 10.60 (s, 1 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 28.4 (-, 
CH2), 30.1 (+, CH3), 30.9 (+, CH3), 33.2 (-, CH2), 50.9 (-, CH2), 55.5 (-, CH2), 
55.9 (+, CH3), 59.8 (-, CH2), 109.4 (+, CHarom), 111.3 (+, CHarom), 120.9 (+, 
CHarom), 123.2 (+, CHarom), 124.5 (+, CHarom), 125.9 (Cquat), 126.1 (Cquat), 127.7 
(+, CHarom), 129.3 (+, 2 x CHarom), 133.2 (+, CHarom), 135.6 (Cquat), 137.2 (Cquat), 
137.5 (Cquat), 139.9 (Cquat), 145.6 (Cquat), 147.2 (Cquat), 147.5 (Cquat), 199.3 
(Cquat), 208.2 (Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 
504 (100) [MH+] – UV/Vis (CHCl3) λmax [nm] (lg ε): 276 (4.9732) – IR (KBr) ν~  
[cm-1] = 3307 (N-H), 2933 (C-H), 1707 (C=O), 1647 (C=O; amide), 1599 (N-H), 
1518 (N-H) – MF C28H29N3O6 – MW 503.55 g/mol 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-4-(1-
hydroxypropyl)-3-nitrobenzamide (7g) 
Preparation according to GP 1 using 4-(1-hydroxypropyl)-3-nitrobenzoic acid 
(0.25 g, 1.1 mmol), DIPEA (0.26 g, 0.33 mL, 2.0 mmol), HOBt (0.14 g,  
1.2 mmol), TBTU (0.45 g, 1.2 mmol) and 4-(2-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)aniline (0.31 g, 1.0 mmol) diluted in 
dichloromethane and a few drops of DMF. After further purification with column 
chromatography (elution with EtOAc/MeOH, 4:1, Rf: 0.72) and evaporation of 
the solvent the reaction yielded 0.46 g (88 %) of a yellow oil, 1H-NMR  
(300 MHz, CDCl3): δ = 1.03 (t, J = 7.4 Hz, 3 H), 1.59-1.86 (m, 2 H), 2.86-2.94 
(m, 8 H), 3.61 (s, 1 H), 3.79 (s, 3 H), 3.80 (s, 3 H), 5.13-5.19 (m, 1 H), 6.46 (s, 1 
H), 6.54 (s, 1 H), 7.22 (d, J = 8.5 Hz, 2 H), 7.59 (d, J = 8.5 Hz, 2 H), 7.84 (d, J = 
8.2 Hz, 1 H), 8.03 (dd, J = 1.6 Hz, J = 8.2 Hz, 1 H), 8.32 (d, J = 1.6 Hz, 1 H), 
8.55 (s, 1 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 10.5 (+, CH3), 
28.5 (-, CH2), 31.6 (-, CH2), 33.2 (-, CH2), 51.0 (-, CH2), 55.7 (-, CH2), 55.9 (+, 2 
x CH3), 60.0 (-, CH2), 70.1 (+, CH), 109.4 (+, CHarom), 111.3 (+, CHarom), 120.8 
(+, 2 x CHarom), 123.0 (+, CHarom), 126.0 (Cquat), 126.1 (Cquat), 128.8 (+, CHarom), 
129.3 (+, 2 x CHarom), 131.6 (+, CHarom), 134.8 (Cquat), 135.8 (Cquat), 136.9 
(Cquat), 144.2 (Cquat), 147.1 (Cquat), 147.3 (Cquat), 147.5 (Cquat), 165.6 (Cquat) – MS 
(+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 520.2 (100) [M-H+] – IR 
(ATR) ν~ [cm-1] = 3559 (O-H), 1664 (C=O, amide), 1604 (N-H, amide), 1514 (N-
O), 1324 (N-O) – MF C29H33N3O6 – MW 519.59 g/mol 
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2-Amino-N4-{4-[2-(3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-
methylterephthalamide (8a) 
N4-{4-[2-(3,4-Dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-methyl-2-
nitroterephthal-amide (0.5 g, 1.2 mmol) was dissolved in ethanol (p.a.) and 
treated with 5 eq SnCl2 (1.14 g, 6.0 mmol) and then heated under nitrogen to  
70 °C for 30 min. The reaction mixture was poured on ice and the pH was 
adjusted to 9 and extracted with ethyl acetate. Then the organic layer was dried 
over Na2SO4 and evaporated. The reaction yielded 0.38 g (0.88 mmol, 73 %) of 
yellow solid, mp 147 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.79 - 2.88 (m, 8 H), 
2.91 (s, 3 H), 3.70 (s, 2 H), 6.96-7.00 (m, 2 H), 7.07 – 7.09 (m, 3 H), 7.15 (d, J = 
8.5 Hz, 2 H), 7.30 (d, J = 8.1 Hz, 1 H), 7.54 (d, J = 8.4 Hz, 2 H), 7.92 (s, 1 H) – 
13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 26.3 (+, CH3), 28.5 (-, CH2), 32.9 (-, 
CH2), 50.8 (-, CH2), 55.8 (-, CH2), 59.9 (-, CH2), 115.0 (+, CHarom), 115.8 (+, 
CHarom), 118.9 (Cquart), 120.4 (+, CHarom), 120.8 (+, CHarom), 120.9 (Cquart), 125.8 
(+, CHarom), 126.4 (+, CHarom), 126.6 (+, 2 x CHarom), 127.9 (+, CHarom), 128.6 (+, 
CHarom), 129.1 (+, 2 x CHarom), 133.8 (2 x Cquart), 136.2 (Cquart), 138.1 (Cquart), 
148.3 (Cquart), 162.9 (Cquart), 169.7 (Cquart) – MS (+ESI, DCM/MeOH + 10 mmol/L 
NH4Ac): m/z (%) = 429 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1599 (C=O), 1635 
(C=O), 3318 (N-H) – MF C26H28N4O2 – MW 428.53 
 
Methyl 2-amino-4-{4-[2-(3,4-dihydroisoquinolin-[1H]-yl)ethyl]phenyl-
carbamoyl}benzoate (8b) 
The preparation followed GP 2 using methyl 4-{4-[2-(3,4-dihydroisoquinolin-2 
[1H]-yl)ethyl]phenylcarbamoyl}-2-nitro-benzoate (1.1 g, 2.4 mmol) diluted in 
ethyl acetate. The reaction yielded 1.03 g (2.4 mmol, 100 %) yellow solid,  
mp 89 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.55-2.94 (m, 8 H), 3.71 (s, 2 H), 
3.87 (s, 3 H), 5.90 (s, 2 H, NH2), 6.98-7.03 (m, 2 H), 7.09-7.13 (m, 3 H), 7.20-
7.23 (m, 3 H), 7.55 (d, J = 8.2 Hz, 2 H), 7.90 (d, J = 8.2 Hz, 1 H), 8.08 (s, 1H) – 
13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 29.0 (-, CH2), 33.3 (-, CH2), 50.9 (-, 
CH2), 51.8 (+, CH3), 56.0 (-, CH2), 60.2 (-, CH2), 112.7 (Cquat), 113.8 (+, CHarom), 
115.9 (+, CHarom), 120.6 (+, 2 x CHarom), 125.6 (+, CHarom), 126.2 (+, CHarom), 
126.6 (+, CHarom), 128.7 (+, CHarom), 129.2 (+, 2 x CHarom), 131.8 (+, CHarom), 
134.2 (Cquat), 134.6 (Cquat), 136.0 (Cquat), 136.7 (Cquat), 140.0 (Cquat), 150.5 
(Cquat), 165.8 (Cquat), 168.0 (Cquat) – MS (+ESI): m/z (%) = 430 (100) [M-H+] – IR 
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(ATR) ν~ [cm-1] = 1620 (C=O), 1695 (C=O), 3330 (N-H), 3490 (N-H) –  
MF C26H27N3O3 – MW 429.51 
 
Methyl 2-amino-4-{4-[2-(7-[tert-butoxycarbonylamino]-3,4-dihydroiso-
quinolin-2[1H]-yl)ethyl]phenylcarbamoyl}benzoate (8c) 
The preparation followed GP 2 diluting methyl4-{4-[2-(7-[tert-
butoxycarbonylamino]-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]-phenyl-carbamoyl}-
2-nitrobenzoate (0.3 g, 0.52 mmol) in ethanol. The reaction yielded 0.1 g  
(0.2 mmol, 35 %) yellow solid, mp 172 °C – 1H-NMR (300 MHz, CDCl3): δ = 
1.49 (s, 9 H), 2.71-2.85 (m, 8 H), 3.66 (s, 2 H), 3.86 (s, 3 H), 6,58 (s, 1H), 6.96- 
7.01 (m, 2 H), 7.13-7.19 (m, 3 H), 7.53 (d, J = 8.5 Hz, 2 H), 7.86 (d, J = 8.2 Hz, 
1 H), 8.16 (s, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 28.0 (-, CH2), 
28.8 (+, CH3, 3 x), 32.9 (-, CH2), 51.9 (-, CH2),52.2 (+, CH3), 56.2 (-, CH2), 60.3 
(-, CH2), 112.2 (Cquat), 113.2 (Cquat), 114.7 (+, CHarom), 117.0 (+, CHarom), 117.6 
(Cquat), 122.5 (+, 2 x CHarom), 122.8 (+, CHarom), 124.4 (+, CHarom), 126.4 (Cquat), 
128.3 (Cquat), 130.1 (+, CHarom), 130.2 (+, 2 x CHarom), 132.6 (+, CHarom), 133.7 
(Cquat), 136.5 (Cquat), 138.9 (Cquat), 141.4 (Cquat), 152.6 (Cquat), 155.3 (Cquat), 
169.4 (Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 545 
(100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1514 (C=O), 1599 (C=O), 1685 (C=O) –  
MF C31H36N4O5 – MW 544.64 
 
Methyl 2-amino-4-{[4-(2-[6,7-dimethoxy-3,4- dihydroisoquinolin-2(1H)-yl] 
ethyl) phenyl] [methyl] carbamoyl} benzoate (8d) 
The preparation followed GP 2 dissolving methyl 4-{[4-(2-[6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl]ethyl)phenyl](methyl)carbamoyl}-2-nitrobenzoate 
(0.5 g, 0.9 mmol) in methanol and yielded 0.5 g (0.9 mmol, 100 %) yellow solid, 
mp 114 °C – 1H-NMR (300 MHz, CDCl3): δ = 3.27-3.30 (m, 8 H), 3.40 (s, 3 H), 
3.46 (s, 2 H), 3.79 (s, 3 H), 3.81 (s, 3 H), 3.84 (s, 3 H), 6.48 (d, J = 8.23 Hz, 1 
H), 6.52 (s, 1 H), 6.61 (s, 1 H), 6.71 (s, 1 H), 6.99 (d, J = 6.86 Hz, 2 H), 7.13 (d, 
J = 7.68 Hz, 2 H), 7.62 (d, J = 8.2 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, 
CDCl3): δ = 23.8 (-, CH2), 30.0 (-, CH2), 49.2 (-, CH2), 50.4 (+, CH3), 51.7 (+, 
CH3), 52.2 (-, CH2), 55.3 (-, CH2), 56.0 (+, CH3), 56.1 (+, CH3), 109.3 (+, 
CHarom), 111.1 (+, CHarom), 111.7 (Cquat), 117.2 (+, CHarom), 118.1 (Cquat), 122.4 
(Cquat), 127.1 (+, 2 x CHarom), 127.3(+, CHarom), 129.7 (+, 2 x CHarom), 130.9 (+, 
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CHarom), 134.7 (Cquat), 141.2 (Cquat), 143.2 (Cquat), 148.5 (Cquat), 149.0 (Cquat), 
149.1 (Cquat), 167.8 (Cquat), 169.9 (Cquat) – MS (CI): m/z (%) = 504 (100) [MH+] – 
IR (ATR) ν~ [cm-1] = 1518 (C=O), 1690 (C=O), 3445 (N-H) – MF C29H33N3O5 – 
MW 503.24 
 
2-Amino-N4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]-
phenyl}-N1-methylterephthalamide (8e) 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2 (1H)-yl]ethyl] phenyl4- (methyl-
carba-moyl)-3-nitrobenzoate (0.16 g, 0.3 mmol) was dissolved in ethanol (p.a.) 
and treated with 5 eq SnCl2 (0.29 g, 1.5 mmol) and then heated under nitrogen 
to 70 °C for 30 min. The reaction mixture was poured on ice and the pH was 
adjusted to 9 and extracted with ethyl acetate. Then the organic layer was dried 
over Na2SO4 and evaporated. The reaction yielded 0.07 g (0.14 mmol, 46 %) of 
yellow solid, mp 174 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.73 - 2.92 (m, 8 H), 
2.95 (d, 4.7 Hz, 3 H), 3.67 (s, 2 H), 3.80 (s, 3 H), 3.81 (s, 3 H), 6.49 (s, 1 H), 
6.56 (s, 1 H), 6.99 (d, 8.5 Hz, 1 H), 7.13-7.18 (m, 2 H), 7.33 (d, 8.2 Hz, 1 H), 
7.51 (d, 7.9 Hz, 2 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 26.4 (-, CH2), 
27.7 (+, CH3), 32.7 (-, CH2), 50.7 (-, CH2), 55.1 (-, CH2), 55.9 (+, CH3), 55.9 (+, 
CH3), 59.5 (-, CH2), 109.5 (+, CHarom), 111.3 (+, CHarom), 114.5 (Cquat), 115.0 (+, 
CHarom), 115.6 (+, CHarom), 115.9 (+, CHarom), 116.0 (Cquat), 118.9 (Cquat), 120.8 
(+, CHarom), 125.1 (Cquat), 125.5 (Cquat), 127.9 (+, CHarom), 129.2 (+, CHarom), 
129.5 (+, CHarom), 135.8 (Cquat), 136.3 (Cquat), 138.1 (Cquat), 147.4 (Cquat), 147.8 
(Cquat), 148.4 (Cquat) – MS (+ESI): m/z (%) = 489 (100) [M-H+] - IR (ATR) ν~ [cm-
1] = 1531 (C=O), 1637 (C=O), 3197 (N-H), 3263 (N-H) – MF C28H32N4O4 – MW 
488.58 
 
4-Acetyl-3-amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-
ethyl]phenyl} benzamide (8f) 
Preparation according to GP 2 with 4-acetyl-N-{4-[2-(6,7-dimethoxy-3,4-
dihydroiso-quinolin-2[1H]-yl)ethyl]phenyl}-3-nitro benzamide (0.4 g, 0.8 mmol). 
Evaporation of the solvents yielded 0.3 g of a yellow solid. The substance was 
purified by column chromatography on silica gel (elution with MeOH/ETOAC, 
1:2, Rf: 0.55). The yield was 0.2 g (0.4 mmol, 50 %), mp > 190 °C – 1H-NMR 
(300 MHz, CDCl3): δ = 2.57 (s, 3 H), 2.93-3.10 (m, 8 H), 3.79 (s, 3 H), 3.81 (s, 3 
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H), 4.00 (s, 2 H), 6.45 (s, 1 H), 6.54 (s, 1 H), 7.02 (d, J = 8.5 Hz, 2 H), 7.17 (d, J 
= 8.5 Hz, 2 H), 7.57 (d, J = 7.4 Hz, 1 H), 7.73 (d, J = 8.5 Hz, 1 H), 8.39 (s, 1 H) 
– MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 474 (100) [MH+] –  
MF C28H31N3O4 – MW 473.56 g/mol 
 
3-Amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]-
phenyl}-4-(1-hydroxypropyl)benzamide (8g) 
Preparation following GP 2 with N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2[1H]-yl)ethyl]phenyl}-4-(1-hydroxypropyl)-3-nitrobenzamide (30 mg,  
0.06 mmol) diluted in ethyl acetate/methanol 1:1. Evaporation of the solvents 
yielded 20 mg (0.04 mmol, 56 %) of a yellow solid, mp 132 °C – 1H-NMR (300 
MHz, CDCl3): δ = 0.9 (t, J = 7.3 Hz, 3 H), 1.75-1.88 (m, 2 H), 2.70-2.90 (m, 8 H), 
3.82 (s, 3 H), 3.83 (s, 3 H), 4.58 (t, J = 7.0 Hz, 1 H), 6.5 (s, 1H), 6.6 (s, 1 H), 
7.06 (d, J = 5.7 Hz, 2), 7.12 (s, 1 H), 7.17 (s, 1 H), 7.19 (s, 1 H), 7.55 (d, J = 8.5 
Hz, 2 H), 7.98 (s, 1 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 3.1 (+, 
CH3), 10.7 (+, 2 x CH3,), 19.4 (-, CH2), 27.0 (-, CH2), 27.9 (-, CH2), 31.8 (-, CH2), 
32.5 (-, CH2), 42.8 (-, CH2), 43.7 (+, CH), 89.4 (+, CHarom), 109.3 (+, CHarom), 
111.2 (+, CHarom), 113.0 (Cquat), 116.1 (Cquat), 120.8 (+, 2 x CHarom), 127.8 (+, 
CHarom), 129.1 (+, 2 x CHarom), 131.2 (+, CHarom), 134.3 (Cquat), 136.7 (Cquat), 
136.9 (Cquat), 137.4 (Cquat), 145.5 (Cquat), 147.6 (Cquat), 148.0 (Cquat), 166.3 
(Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 490 (100) [M-
H+] – IR (ATR) ν~ [cm-1] = 3310 (O-H), 3057 (N-H, amine), 1602 (N-H, amine), 
1522 (C=O, amide) – MF C29H35N3O4 – MW 489.61 g/mol 
 
Methyl 4-{4-[2-(3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenylcarbamoyl}-2-
(quinoline-2-carboxamido)benzoate (9a) 
Methyl 2-amino-4-{4-[2-(3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenylcarbamoyl} 
benzoate (0.28 g, 0.65 mmol) was dissolved in dry DMF before 1.5 eq of NEt3 
(0.1 g, 0.14 mL, 1.0 mmol) and 0.5 eq of DMAP (40 mg, 0.32 mmol) were 
added. Under nitrogen atmosphere the acid chloride (0.18 g, 1.0 mmol) was 
added. After two hours at 80 °C the reaction mixture was stirred over night at 
room temperature. Then the DMF was removed, the residue was taken up with 
water and extracted with dichloromethane. The organic layer was dried over 
Na2SO4 and the solvent was evaporated. Parts of the product were purified with 
3. Synthesis and Metabolic Stability of New Tariquidar-derived ABCG2 
Inhibitors 
 
 
90 
HPLC to get 1 mg pale yellow solid for pharmacological studies. Due to the 
small scale, purity was checked with HPLC, mp 145 °C (decomposition) –  
MS (+ ESI): m/z (%): 585.2 (100 %) [M-H+] – MF C36H32N4O4 – MW 584.66 
 
N4-{4-[2-(3,4-Dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-methyl-2-
(quinoline-2-carboxamido)terephthalamide (9b) 
2-Amino-N4-{4-[2-(3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-
methylterephthal-amide (0.36 g, 0.85 mmol) was dissolved in dry DMF before 
1.5 eq of NEt3 (0.13 g, 0.18 mL, 1.3 mmol) and 0.5 eq of DMAP (50 mg,  
0.43 mmol) were added. Under nitrogen atmosphere the acid chloride (0.24 g, 
1.3 mmol) was added. After two hours at 80 °C the reaction mixture was stirred 
over night at room temperature. Then the DMF was removed, the residue was 
taken up with water and extracted with dichloromethane. The organic layer was 
dried over Na2SO4 and the solvent was evaporated. Parts of the product were 
purified with HPLC to get 1 mg pale yellow solid for pharmacological studies. 
Due to the small scale, purity was checked with HPLC, MS (+ESI, DCM/MeOH 
+ 10 mmol/L NH4Ac): m/z (%) = 584 (100) [M-H+]- – MF C36H33N5O3 –  
MW 583.68 
 
Methyl 4-{4-[2-(7-amino-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenylcarba-
moyl}-2-(quinoline-2-carboxamido)benzoate (9d) 
Methyl 2-amino-4-{4-[2-(7-[tert-butoxycarbonylamino]-3,4-dihydroisoquinolin-
2[1H]-yl)ethyl]phenylcarbamoyl}benzoate (100 mg, 0.36 mmol) was dissolved in 
dry DMF, 1.5 eq NEt3 (54 mg, 77 µL, 0.54 mmol), 0.5 eq DMAP (21 mg,  
0.18 mmol) and 1.5 eq quinoline-2 carboyl chloride (103 mg, 0.54 mmol) were 
added. The reaction mixture was stirred for two hours at 80 °C and for further 
15 h at room temperature. Then, the solution was diluted with dichloromethane 
and washed twice with saturated NaHCO3 solution. The organic layer was dried 
over Na2SO4 and the solvent was evaporated. Without further purification 
methyl 4-{4-[2-(7-[tert-butoxycarbonylamino]-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenylcarbamoyl}-2-(quinoline-2-carboxamido)benzoate (0.01 g,  
0.01 mmol, 1 eq) was dissolved in dichloromethane and  HCl-Ether (15 % 
/mmol, 0.1 mL). After 15 h stirring at room temperature the solvent was 
removed. The product was then purified with preparative HPLC to get 1 mg pale 
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yellow solid for pharmacological studies. Due to the small scale, purity was 
analyzed with HPLC, MS (ESI): m/z (%) = 600 (100) [MH+] – MF C36H33N5O4 – 
MW 599.68 
 
N-{3-[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)-
phenylcarbamoyl]phenyl}quinoline-2-carboxamide (9e) 
3-Amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenyl}benzamide (100 mg, 0.2 mmol) was dissolved in dry DMF before 
1.5 eq of NEt3 (30 mg, 0.04 mL, 6.7 mmol) and 0.5 eq of DMAP (12 mg,  
0.1 mmol) were added. Under nitrogen atmosphere the acid chloride (60 mg, 
0.34 mmol) was added. After two hours at 80 °C the reaction mixture was 
stirred over night at room temperature. Then the DMF was removed, the 
residue was taken up with water and extracted with dichloromethane. The 
organic layer was dried over Na2SO4 and the solvent was evaporated. The 
product was purified with column chromatography (elution with MeOH/ETOAC 
1:9, Rf: 0.48). The reaction yielded 20 mg (0.03 mmol, 17 %) of a pale yellow 
solid, mp 180 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 2.78-2.93 
(m, 8 H), 3.69 (s, 2 H), 3.82 (s, 6 H), 6.52 (s, 1 H), 6.58 (s, 1 H), 7.23 (d, J = 8.5 
Hz, 2 H), 7.51 (t, J = 7.8 Hz, 1 H), 7.65 (d, J = 7.7 Hz, 2 H), 7.68 (s, 1 H), 7.74 
(d, J = 7.7 Hz, 1 H), 7.82 (t, J = 6.7 Hz, 2 H), 7.91 (d, J = 8.0 Hz, 1H), 8.18 (d, J 
= 8.5 Hz, 1 H), 8.35-8.40 (m, 3 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 
32.1 (-, CH2), 37.0 (-, CH2), 54.8 (-, CH2), 59.4 (-, CH2), 59.7 (+, CH3), 59.8 (+, 
CH3), 63.9 (-, CH2), 95.1 (Cquat), 113.3 (+, CHarom), 115.2 (+, CHarom), 122.4 (+, 
CHarom), 122.5 (+, CHarom), 124.7 (+, CHarom), 127.0 (Cquat), 148.0 (+, CHarom), 
129.8 (Cquat), 129.9 (Cquat), 131.8 (+, CHarom), 132.4 (+, CHarom), 133.0 (+, 2 x 
CHarom), 133.2 (Cquat), 133.4 (+, CHarom), 133.5 (+, 2 x CHarom), 134.5 (+, 
CHarom), 140.0 (Cquat), 140.4 (Cquat), 141.3 (+, CHarom), 142.0 (+, CHarom), 150.2 
(Cquat), 151.1 (Cquat), 151.5 (Cquat), 152.8 (Cquat), 160.7 (Cquat), 169.9 (Cquat) – MS 
(+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 587 (100) [M +] – IR (ATR) 
ν~ [cm-1] = 1651 (C=O), 1668 (C=O), 2342 (N-(C)3), 2360 (N-(C)3), 3344 (N-H) – 
MF C36H34N4O4 – MW 586.68 
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4-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenylcarba-
moyl}-2-(quinoline-3-carboxamido)benzoic acid (9f) 
Compound methyl 4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenylcarbamoyl}-2-(quinoline-3-carboxamido)benzoate (50 mg,  
0.077 mmol) was dissolved in 5 mL of DMF and 3 eq of LiOH dissolved in a 
small amount of water were added. The reaction was carried out in the 
microwave (80 °C, 300 W, 4 min). To work-up the product, the solution was 
acidified with diluted HCl and extracted with dichloromethane. The crude 
product was purified by column chromatography on silica gel (elution with 
chloroform/methanol 10:7, Rf: 0.38) and preparative HPLC (acetonitrile/water 
(TFA 0.0059 %)) and yielded 5 mg (0.007 mmol, 10 %) of a yellow solid, mp 
185 °C – 1H-NMR (300 MHz, [D6]-DMSO): δ = 2.65-3.38 (m, 8 H), 3.76 (s, 6 H), 
3.85-4.05 (m, 2 H), 6.79 (d, J = 4.9 Hz, 1 H), 7.30 (d, J = 8.5 Hz, 2 H), 7.68-7.78 
(m, 4 H), 7.91 (t, J = 2.27, 1 H), 8.11-8.20 (m, 3 H), 8.96 (s, 1 H), 9.19 (s, 1 H), 
9.46 (s, 1 H), 10.47 (s, 1 H) – 13C-NMR, DEPT 135 (75 MHz, [D6]-DMSO): δ = 
25.4 (-, CH2), 33.0 (-, CH2), 34.2 (-, CH2), 39.8 (-, CH2), 42.8 (-, CH2), 56.4 (+, 
CH3), 56.5 (+, CH3), 109.9 (+, CHarom), 114.3 (Cquat), 117.8 (+, CHarom), 118.2 (+, 
CHarom), 120.6 (+, CHarom), 122.0 (+, CHarom), 122.8 (+, CHarom), 125.6 (Cquat), 
129.2 (+, CHarom), 134.2 (+, CHarom), 134.7 (+, CHarom), 135.1 (+, CHarom), 137.7 
(+, CHarom), 138.6 (+, CHarom), 138.7 (Cquat), 139.3 (Cquat), 139.5 (Cquat), 141.8 
(+, CHarom), 142.3 (Cquat), 142.4 (+, CHarom), 143.0 (Cquat), 145.0 (Cquat), 146.9 
(Cquat), 147.8 (Cquat), 148.6 (Cquat), 150.8 (+, CHarom), 151.2 (Cquat), 164.0 (Cquat), 
174.1 (Cquat), 177.1 (Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 631 (100) [MH+] – UV/Vis (DMSO) λmax [nm]: 245 – IR (ATR) ν~ [cm-1] = 
3359 (O-H, acid), 1631 (C=O, amide) – MF C37H34N4O6 – MW 630.69 g/mol 
 
Methyl 4-{[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)-
phenyl][methyl] carbamoyl}-2-(quinoline-2-carboxamido)benzoate (9g) 
Methyl 2-amino-4-{[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl] ethyl)-
phenyl][methyl]carbamoyl} benzoate (0.5 g, 0.99 mmol) was dissolved in 
dichloromethane before 1.5 eq of NEt3 (0.15 g, 0.2 mL, 1.5 mmol) were added. 
Under nitrogen atmosphere the acid chloride (0.28 g, 1.5 mmol) was added. 
After two hours at 40 °C the reaction mixture was stirred over night at room 
temperature. The residue was taken up with water and extracted with 
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dichloromethane and washed with saturated NaHCO3 solution. The organic 
layer was dried over Na2SO4 and evaporated. Further purification was achieved 
with column chromatography (elution EtOAc > MeOH, Rf: 0.35). The reaction 
yielded 0.45 g (0.7 mmol, 69 %) yellow solid, mp 65 °C – 1H-NMR (300 MHz, 
CDCl3): δ = 2.60-2.77 (m, 8 H), 3.39 (s, 2 H), 3.75 (s, 3 H), 3.76 (s, 3 H), 3.79 
(d, J = 1.6 Hz, 3 H), 3.96 (s, 3 H), 6.39 (s, 1 H), 6.48 (s, 1 H), 6.55 (s, 1 H), 6.66 
(d, J = 1.4 Hz, 1 H), 6.92 (d, J = 7.9 Hz, 1 H), 7.02-7.15 (m, 5 H), 7.58 (t, J = 6.9 
Hz, 1 H), 7.74 (t, J = 6.9 Hz, 1 H), 7.83 (d, J = 8.2 Hz, 1 H), 7.92 (d, J = 8.2 Hz, 
1 H), 8.23 (d, J = 8.5 Hz, 1 H), 8.93 (s, 1H, NH), 13.09 (s, 1H, NH) – 13C-NMR, 
DEPT 135 (75 MHz, CDCl3): δ = 21.0 (+, CH3), 28.4 (-, CH2), 33.3 (-, CH2), 50.8 
(-, CH2), 52.5 (+, CH3), 55.5 (-, CH2), 55.8 (+, CH3), 55.9 (+, CH3), 59.6 (-, CH2), 
109.4 (+, CHarom), 111.2 (+, CHarom), 111.3 (+, CHarom), 118.9 (+, CHarom), 122.4 
(+, CHarom), 125.9 (Cquat), 126.0 (Cquat), 126.2 (Cquat), 126.6 (+, CHarom), 127.0 
(+, CHarom), 127.6 (+, CHarom), 128.3 (+, CHarom), 129.3 (Cquat), 129.5 (+, CHarom), 
129.6 (+, CHarom), 130.1 (+, CHarom), 130.2 (+, CHarom), 130.9 (+, CHarom), 137.6 
(+, CHarom), 139.0 (Cquat), 139.2 (Cquat), 140.3 (Cquat), 142.0 (Cquat), 146.5 (Cquat), 
147.2 (Cquat), 147.5 (Cquat), 149.9 (Cquat), 163.2 (Cquat), 167.4 (Cquat), 169.6 
(Cquat) – MS (CI): m/z (%) = 659 (100) [MH+] – IR (ATR) ν~ [cm-1] = 1568 (C=O), 
1643 (C=O), 1687 (C=O) – MF C39H38N4O6 – MW 658.74 
 
N4-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-N1-
methyl-2-(quinoline-2-carboxamido)terephthalamide (9h) 
2-Amino-N4-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-
N1-methylterephthalamide (70 mg, 0.14 mmol) was dissolved in dry DMF 
before 1.5 eq of NEt3 (20 mg, 0.03 mL, 0.2 mmol) and 0.5 eq of DMAP (8 mg, 
0.07 mmol) were added. Under nitrogen atmosphere the acid chloride (40 mg, 
0.2 mmol) was added. After two hours at 80 °C the reaction mixture was stirred 
over night at room temperature. Then the DMF was removed under reduced 
pressure, the residue was taken up with water and extracted with 
dichloromethane. The organic layer was dried over Na2SO4 and evaporated. 
Parts of the product were purified with HPLC to get 1 mg pale yellow solid for 
pharmacological studies. Due to the small scale, purity was checked with 
HPLC, MS (+ESI): m/z (%) = 644 (100) [M-H+] – MF C38H37N5O5 – MW 643.73 
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N-{2-Acetyl-5-[4-(2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)-
phenylcarbamoyl] phenyl} quinoline-3-carboxamide (9i) 
4-Acetyl-3-amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]-
phenyl} benzamide (0.12 g, 0.25 mmol), Et3N (1.5 eq, 0.14 g, 0.5 mmol, 0.2 mL) 
and DMAP (0.5 eq, 15 mg, 0.12 mmol) were dissolved in dry DMF and under 
nitrogen atmosphere quinoline-3-carbonyl chloride (0.1 g, 0.5 mmol) was 
added. The reaction mixture was heated for two hours at 90 °C. After stirring 
another 16 h at room temperature it was diluted with water and extracted with 
dichloromethane. The organic layer was dried with Na2SO4 and the solvent was 
evaporated. The reaction yielded 70 mg (0.12 mmol, 50 %) of an orange solid, 
mp > 190 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 2.51 (s, 3 H), 
3.06-3.26 (m, 6 H), 3.36-3.43 (m, 2 H), 3.77 (s, 3 H), 3.78 (d, 3 H), 4.11 (s, 2H), 
6.48 (s, 1 H), 6.56 (s, 1 H), 7.02 (dd, J = 1.3 Hz, J = 8.2 Hz, 1 H), 7.16 (d, J = 
8.5 Hz, 2 H), 7.55 (t, J = 7.5 Hz, 1 H), 7.58-7.63 (m, 3 H), 7.76 (dt, J = 1.3 Hz, J 
= 7.0 Hz, 1 H), 7.87 (d, J = 7.9 Hz, 1 H), 8.13 (d, J = 8.5 Hz, 1 H), 8.71 (s, 1 H), 
8.82 (d, J = 1.6 Hz, 1 H), 9.49 (d, J = 1.9 Hz, 1 H) – 13C-NMR, HSQC (75 MHz, 
CDCl3): δ = 27.9 (+, CH3), 31.5 (-, CH2), 44.9 (-, CH2), 49.5 (-, CH2), 53.4 (-, 
CH2), 55.8 (+, CH3), 55.9 (+, CH3), 57.2 (-, CH2), 100.1 (+, CHarom), 109.3 (+, 
CHarom), 111.2 (+, CHarom), 112.9 (Cquat), 113.3 (+, CHarom), 113.9 (Cquat), 116.3 
(+, CHarom), 120.6 (+, CHarom), 120.7 (+, CHarom), 121.0 (Cquat), 122.2 (+, CHarom), 
125.2 (Cquat), 126.9 (+, CHarom), 127.3 (Cquat), 128.8 (+, CHarom), 129.0 (+, 
CHarom), 129.3 (+, CHarom), 130.9 (+, CHarom), 132.5 (+, CHarom), 136.8 (+, 
CHarom), 138.3 (Cquat), 148.0 (Cquat), 148.4 (Cquat), 148.7 (Cquat), 151.1 (+, 
CHarom), 157.5 (Cquat), 162.2 (Cquat), 170.1 (Cquat), 170.3 (Cquat), 171.2 (Cquat) – 
MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 629 (100) [MH+] – IR 
(ATR) ν~ [cm-1] = 1651 (C=O, ketone), 1602 (C=O, amide), 1573 (N-H, amide), 
1520 (N-H, amide) –MF C38H36N4O5 – MW 628.72 g/mol 
 
(E)-N-{5-[4-(2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl)phenyl 
carbamoyl]-2-[prop-1-enyl]phenyl}quinoline-3-carboxamide (9j) 
3-Amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-4-
(1-hydroxypropyl)benzamide (20 mg, 0.03 mmol) and 15 eq Et3N (40 mg, 0.05 
mL, 0.5 mmol) were dissolved in a few mL dry DMF. The acid chloride 15 was 
added (10 eq, 60 mg, 0.3 mmol) before the solution was heated by microwave 
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irradiation for 5 min at 160 °C. DMF was removed under reduced pressure and 
the substance was extracted with dichloromethane and water. The organic layer 
was dried with Na2SO4 and the solvent was evaporated. For further purification 
the substance was separated by preparative TLC. The reaction yielded 8 mg 
(0.012 mmol, 42 %) of an orange solid, mp > 190 °C – 1H-NMR (300 MHz, 
CDCl3): δ = 2.14-2.24 (m, 3 H), 3.20-3.22 (m, 8 H), 3.72 (s, 6 H), 3.55-3.59 (m, 
2 H), 4.25-4.30 (m, 1 H), 5.47 (d, J = 5.2 Hz, 1 H), 6.50 (s, 1 H), 6.55 (s, 1 H), 
7.07 (d, J = 8.2 Hz, 2 H), 7.12-7.22 (m, 3 H), 7.30 (s, 1 H), 7.56 (d, J = 5.7 Hz, 2 
H), 7.70 (s, 1 H), 7.88 (d, J = 7.4 Hz, 1 H), 8.03 (d, J = 7.4 Hz, 1 H), 8.79 (s, 1 
H), 9.46 (s, 1 H) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 627 
(100) [M-H+] – MF C39H38N4O4 – MW 626.74 g/mol 
 
Methyl 4-(methylcarbamoyl)-2-nitrobenzoate (10a) 
4-(Methoxycarbonyl)-3-nitrobenzoic acid (0.6 g, 2.6 mmol) was dissolved in 
dichloromethane and a few drops of DMF. Subsequently, 1.2 eq (0.14 g,  
0.1 mL, 1.1 mmol) oxalyl dichloride were added dropwise. After two hours 
stirring at room temperature methylamine (0.1 mL of 40 % solution in water) 
was added over 5 min to the clear solution. The resulting white precipitate was 
collected and washed with water and finally re-dissolved in dichloromethane. 
Remaining starting material was removed by washing with aqueous NaHCO3. 
The reaction yielded 0.32 g (1.3 mmol, 50 %) white solid, mp 140 °C – 1H-NMR 
(300 MHz, CDCl3): δ = 3.02 (d, J = 4.6 Hz, 3 H), 3.92 (s, 3 H), 7.74 (d, J = 7.9 
Hz, 1 H), 8.07 (dd, J = 1.6 Hz, 7.9 Hz, 1 H), 8.28 (d, J = 1.4 Hz, 1 H) – 13C-
NMR, DEPT 135 (75 MHz, CDCl3): δ = 26.1 (+, CH3), 52.5 (+, CH3), 121.5 (+, 
CHarom), 128.6 (Cquat), 129.2 (+, CHarom), 130.4 (+, CHarom), 137.0 (Cquat), 146.9 
(Cquat), 164.0 (Cquat), 164.3 (Cquat) – MS (EI): m/z (%) = 238 (100) [M+•] – IR 
(ATR) ν~ [cm-1] = 1639 (C=O), 1728 (C=O), 3337 (N-H) – MF C10H10N2O5 – MW 
238.20 
 
Methyl 2-amino-4-(methylcarbamoyl)benzoate (11a) 
The preparation followed GP 2 diluting methyl 4-(methylcarbamoyl)-2-
nitrobenzoate (0.3 g, 1.2 mmol) in ethanol. The reaction yielded 0.23 g  
(1.1 mmol, 92 %) pale yellow solid, mp 134 °C – 1H-NMR (300 MHz, CDCl3): δ 
= 2.93 (d, J = 4.6 Hz, 3 H), 3.84 (s, 3 H), 7.64 (d, J = 7.9 Hz, 1 H), 8.00 (dd, J = 
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1.4 Hz, 7.9 Hz, 1 H), 8.24 (d, J = 1.4 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, 
CDCl3): δ = 27.1 (+, CH3), 53.5 (+, CH3), 122.7 (+, CHarom), 129.5 (Cquat), 130.1 
(+, CHarom), 131.6 (+, CHarom), 138.0 (Cquat), 147.9 (Cquat), 165.2 (Cquat), 165.4 
(Cquat) – MS (CI): m/z (%) = 209 (100) [MH+] – IR (ATR) ν~ [cm-1] = 1638 (C=O), 
1731 (C=O), 3334 (N-H) – MF C10H12N2O3 – MW 208.21 
 
4-(Methoxycarbonyl)-3-(quinoline-2-carboxamido)benzoic acid (12a) 
3-Amino-4-(methoxycarbonyl)benzoic acid (100 mg, 0.5 mmol) was dissolved in 
dry DMF before 1.5 eq of NEt3 (80 mg, 0.11 mL, 0.8 mmol) and 0.5 eq of DMAP 
(30 mg, 0.25 mmol) were added. Under nitrogen atmosphere the acid chloride 
(0.14 g, 0.75 mmol) was added. After two hours at 80 °C the reaction mixture 
was stirred over night at room temperature. Then the DMF was removed, the 
residue was taken up with dichloromethane. A pale yellow solid precipitated 
which was collected. The reaction yielded 0.01 g (0.03 mmol, 6 %), mp 255 °C 
– 
1H-NMR (300 MHz, [D6]-DMSO): δ = 2.08 (s, 1 H, NH), 4.03 (s, 3 H), 7.74-
7.77 (m, 2 H), 7.91-7.96 (m, 1 H), 8.12-8.19 (m, 3 H), 8.28 (d, 8.5 Hz, 1 H), 8.66 
(d, 8.5 Hz, 1 H), 9.47 (d, 1.4 Hz, 1 H), 13.06 (s, 1 H, COOH) – 13C-NMR, DEPT 
135 (75 MHz, [D6]-DMSO): δ = 52.8 (+, CH3), 118.5 (+, CHarom), 119.4 (Cquat), 
120.7 (+, CHarom), 123.5 (+, CHarom), 128.1 (+, CHarom), 128.6 (+, CHarom), 129.0 
(Cquat), 129.2 (+, CHarom), 130.9 (+, CHarom), 131.3 (+, CHarom), 135.8 (Cquat), 
138.5 (+, CHarom), 139.7 (Cquat), 145.6 (Cquat), 149.0 (Cquat), 162.7 (Cquat), 166.4 
(Cquat), 166.6 (Cquat) – MS (+ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 
351 (100) [M-H+]- – IR (ATR) ν~ [cm-1] = 1523 (C=O), 1574 (C=O), 1698 (C=O) – 
MF C19H14N2O5 – MW 350.32 
 
4-(Methoxycarbonyl)-3-(quinoline-3-carboxamido) benzoic acid (12b) 
3-Amino-4-(methoxycarbonyl)benzoic acid (150 mg, 0.8 mmol) was dissolved in 
dry DMF, then 1.5 eq of NEt3 (120 mg, 0.15 mL, 1.2 mmol) and 0.5 eq of DMAP 
(40 mg, 0.4 mmol) were added. Under nitrogen atmosphere the acid chloride 
(230 mg, 1.2 mmol) was added. After two hours at 80 °C the reaction mixture 
was stirred over night at room temperature. DMF was removed under reduced 
pressure and the residue was taken up with dichloromethane. A pale yellow 
solid precipitated which was collected. The reaction yielded 0.09 g (0.3 mmol, 
37 %), mp 241 °C – 1H-NMR (300 MHz, [D6]-DMSO): δ = 3.89 (s, 3 H), 7.75 (t, 
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J = 7.27 Hz, 1 H), 7.82 (dd, J = 1.6 Hz, 8.2 Hz, 1 H), 7.94 (t, J = 8.4 Hz, 1 H), 
8.06 (d, J = 8.2 Hz, 1 H), 8.14 (d, J = 8.2 Hz, 1 H), 8.20 (d, J = 7.9 Hz, 1 H), 
8.85 (d, J = 1.4 Hz, 1 H), 8.97 (d, J = 2.2 Hz, 1 H), 9.38 (d, J = 2.2 Hz, 1 H), 
11.53 (s, 1 H, COOH) – 13C-NMR, DEPT 135 (75 MHz, [D6]-DMSO): δ = 52.8 
(+, CH3), 123.0 (+, CHarom), 123.3 (Cquat), 124.6 (+, CHarom), 126.5 (Cquat), 126.9 
(Cquat), 127.7 (+, CHarom), 128.8 (+, CHarom), 129.4 (+, CHarom), 130.8 (+, CHarom), 
131.8 (+, CHarom), 135.2 (Cquat), 136.1 (+, CHarom), 138.8 (Cquat), 148.4 (+, 
CHarom), 148.7 (Cquat), 163.7 (Cquat), 166.3 (Cquat), 167.1 (Cquat) – MS (+ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 351 (100) [M-H+]- – IR (ATR) 
ν~ [cm-1] = 1527 (C=O), 1547 (C=O), 1691 (C=O) – MF C19H14N2O5 - MW 350.32 
 
Methyl 2-(2-naphthamido)-4-(methylcarbamoyl)benzoate (12c) 
The amine (0.2 g, 0.9 mmol) was dissolved in dry DMF, then 1.5 eq of NEt3 
(0.13 g, 0.18 mL, 1.3 mmol) and 0.5 eq of DMAP (0.08 g, 0.5 mmol) were 
added. Under nitrogen atmosphere the acid chloride (0.23 g, 1.2 mmol) was 
added. After two hours at 80 °C the reaction mixture was stirred over night at 
room temperature. DMF was removed under reduced pressure, the residue was 
taken up with dichloromethane and washed with NaHCO3 and water. The 
organic layer was dried over Na2SO4 and evaporated. The reaction yielded  
0.09 g (0.3 mmol, 33 %), mp 202 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.96 (d, 
J = 4.6 Hz, 3 H), 4.00 (s, 3 H), 7.61 (t, J = 8.1 Hz, 1 H), 7.66 (dd, J = 1.4 Hz, 8.2 
Hz, 1 H), 7.77 (t, J = 7.1 Hz, 1 H), 7.85 (d, J = 8.2 Hz, 1 H), 8.12 (d, J = 8.5 Hz, 
1 H), 8.22-8.33 (m, 3 H), 9.06 (s, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): 
δ = 26.9 (+, CH3), 52.7 (+, CH3), 117.8 (+, CHarom), 118.7 (+, CHarom), 118.8 
(Cquat), 122.9 (+, CHarom), 127.7 (+, CHarom), 128.5 (+, CHarom), 129.5 (+, CHarom), 
130.2, 130.4 (+, CHarom), 131.8 (+, CHarom), 137.9 (+, CHarom), 139.7 (Cquat), 
140.0 (Cquat), 146.6 (Cquat), 149.4 (Cquat), 163.9 (Cquat), 167.4 (Cquat), 167.5 
(Cquat) – MS (CI): m/z (%) = 364 (100) [MH+] – IR (ATR) ν~ [cm-1] = 1569 (C=O), 
1633 (C=O), 1686 (C=O) – MF C21H18N2O4 – MW 363.37 
 
4-(1-Hydroxypropyl)-3-nitrobenzoic acid 
Ethyl 3-nitro-4-propionylbenzoate (0.30 g, 1.2 mmol) was dissolved in methanol. 
A portion of 3 eq LiOH (80 mg, 3.5 mmol) was added in a suspension of water. 
The mixture was stirred at room temperature for two hours. Then it was acidified 
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with diluted HCl and extracted with ethyl acetate. The organic layer was dried 
over Na2SO4 and the solvent was removed under reduced pressure. The 
reaction yielded brown oil (0.26 g, 1.1 mmol, 96 %), 1H-NMR (300 MHz, CDCl3): 
δ = 1.06 (t, J = 7.4 Hz, 3 H), 1.80 (m, 2 H), 5.26 (dd, J = 3.8 Hz, J = 8.2 Hz, 1 
H), 7.9 (d, J = 8.2 Hz, 1 H), 8.32 (dd, J = 1.6 Hz, J = 8.2 Hz, 1 H), 8.59 (d, J = 
1.6 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 10.2 (+, CH3), 31.3 (-, 
CH2), 70.6 (+, CH), 126.0 (+, CHarom), 128.7 (+, CHarom), 134.2 (+, CHarom), 
145.5 (Cquat), 160.9 (Cquat), 168.4 (Cquat), 177.5 (Cquat) – MS (CI -MS, NH3): m/z 
(%) = 226.0 (100) [M-H+] – IR (ATR) ν~ [cm-1] = 3334 (O-H, acid), 3090 (O-H), 
1686 (C=O, acid), 1529 (N-O), 1345 (N-O), 1251 (C-O, acid) – MF C10H11NO5 – 
MW 225.2 g/mol 
 
Modulation of ABCB1 and ABCG2 was performed as described.[30], [24] 
 
Stability investigations in mouse plasma. Preparation of mouse plasma and 
determination of esterase activity: Blood of BL6 mice was collected by heart 
puncture in deep anesthesia using heparin-coated syringes. Samples were 
immediately centrifuged for 7 min at 7000 rpm (Eppendorf centrifuge 5415R, 
Eppendorf, Hamburg, Germany) and the supernatant was carefully removed. 
After pooling, the plasma was fractioned into small aliquots for long-term 
storage at -80 °C. The enzymatic activity of esterases in the plasma samples 
was measured spectrophotometrically. The coloured product o-nitrophenol, 
formed by enzymatic cleavage of the chromogenic substrate nitrophenyl 
butyrate was determined as a function of time. Absorbance was plotted against 
time, the linear slope at the beginning of the reaction was determined and used 
for the calculation of volume activity: 
vd
t
VA
VA
⋅⋅
⋅∆
=
ε
 
The abbreviations of the present equation define the following parameters: 
VA = volume activity [U · mL-1] multiplied with 1000 for [U · L-1], ∆A = 
absorbance of o-nitrophenol at 414 nm, t = time [min], V = total volume [mL],  
εo-nitrophenol = 3190 [L · mol-1 · cm-1], d = path length [cm], v = plasma volume [mL] 
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The test compounds were dissolved in DMSO at a concentration of 1.5 mM. 
Subsequently, test compound stocks, mouse plasma, deproteinated plasma, 
culture medium and phosphate buffered saline were equilibrated on a Wealtec 
heat plate (Wealtec, Sparks, USA) to 37 °C for approximately 15 min. 
Thereafter, a 1:50 dilution of the substances with the corresponding medium 
was prepared in 1.5-mL polypropylene reaction vessels (Eppendorf, Hamburg, 
Germany). The samples were shortly vortexed and immediately incubated at  
37 °C. After increasing periods of time, aliquots were taken, and the reaction 
was stopped by the addition of two parts of ice-cold acetonitrile. For quantitative 
precipitation of the denatured proteins, the samples were efficiently vortexed 
and stored at 4 °C for 30 min. Finally, samples were centrifuged for 5 min at 
17000 g, using an Eppendorf MiniSpin plus centrifuge, and the supernatants 
were transferred into new plastic cups. For HPLC analysis the samples were 
further diluted (1:2) with acetonitrile and stored at -80 °C until the measurement. 
For HPLC analysis samples were unfrozen at room temperature and injected 
into the HPLC system (Waters, Eschborn, Germany). Analysis was 
accomplished by gradient elution with water containing TFA (0.05 %) and 
acetonitrile (0 min, 15 %; 19 min, 60 %; 20 min, 95 %; 24.5 min, 95 %; 25 min, 
15 %; 38 min, 15 %), at a constant flow rate of 0.8 mL/min. The HPLC system 
was equipped with a Luna RP-18 (2), 3 µm, 150 mm x 4.6 mm column. Analysis 
was carried out via UV-detection at a wavelength of 210 nm. 
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4.  Photochromic Tariquidar Derivatives as 
Potential ABCG2 Modulators 
Despite the wide spectrum of substrates and inhibitors known for the multi-drug-
resistance causing ABCG2 transporter mechanistic details are not yet clear. 
Photochromic tariquidar-derived compounds as potential ABCG2 modulators 
may be useful as tool in mechanistic investigation. The synthetic approach was 
focused on the replacement of characteristic structural moieties of a potent and 
selective ABCG2 inhibitor by photochromic dithienylethenes. Photochemical 
properties, thermostability, cycle performance, photostationary state and 
photostability at assay conditions are suitable for all four compounds for 
pharmacological in vitro investigations. 
                                                 
∗
 All synthesis and spectroscopical investigations were done by Carolin Fischer, compounds 3 
and 8 were synthsisized by Natascha Kuzmanović, inhibition assay for ABCB1 and ABCG2 
were performed by Maria Beer-Krön. 
* 
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4.1. Introduction 
The ABCG2 transporter (BCRP, breast cancer resistance protein) has been 
shown to play a protective role due to blocking absorption of xenobiotics. As it is 
a member of the ABC (ATP-binding cassette) transporter family, they can be 
found in increased concentrations in different biological barriers like the blood-
brain-barrier[1], the blood-testis-barrier[2], the maternal-fetal-barrier[3] and the 
apical membrane of the intestine.[4] Also high levels of ABCG2 are found in 
cancer cells of acute myeloid leukemia and breast cancer causing multi-drug-
resistance of cytostatic there.[5] Since its discovery in 1998, the list of substrates 
and inhibitors continuously grew. Most of the substrates are chemotherapeutic 
agents such as mitoxantrone, topotecan, methotrexate, flavopiridol and 
others.[6] Also fluorescent dyes like Hoechst 33342, rhodamine 123, bodipy-
prazosin have been found to be substrates.[7-8] Fumitremorgin C[9] was the first 
selective ABCG2 inhibitor described and the class of selective inhibitors was 
supplemented by the highly potent analog Ko143[10], novobiocin[11], tariquidar 
derivatives[12] and 4-(2-hydroxyethyl)phenyl 2-acylaminobenzoates[13] in the last 
years. Beside the specific inhibitors, the class of broad spectrum inhibitors like 
elacridar (GF120918) and cyclosporine a, which are also modulating ABCB1 (p-
gp, p-glycoprotein) or ABCC1 (MRP1), the family of natural occurring flavonoids 
and tyrosine kinase inhibitors were identified to inhibit ABCG2.[14-16] Despite the 
remarkable number of substrates and inhibitors, no clear structure-function-
relationship has been identified yet. Mechanistic knowledge is still lacking. 
Although there is no 3-dimensional structure reported, this broad range of 
substrates and inhibitors indicates that the transporter contains more than one 
distinct binding pocket. Matsson et al. also predict a large binding surface where 
several compounds can bind simultaneously instead of docking into defined 
binding sites.[14] 
In this study, four new ABCG2 modulators containing a photoswitchable unit 
were synthesised. Upon irradiation with 312 nm, an electrocyclization of the 
photochromic unit occurs turning the flexible molecule into a more rigid structure 
(Figure 4.1). This reversible interconversion of two isomers can be monitored by 
different absorption spectra. Diarylethens have been intensively studied 
concerning their properties and their use as optical memory media.[15] Also, 
successful applications for molecular light switches in medicinal chemistry have 
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already been shown.[16] In particular, dithienylethenes (DTE) were applied for 
the inhibition of human carbonic anhydrase.[17-18] Targeting the structure-
activity-relationship between the membrane-located ABCG2 transporter and its 
ligands, different shapes may result in different biological activity and therefore 
provide information about essential interactions between the modulator and the 
transporter. 
 
 
Figure 4.1: Photochromism of dithienylethenes. 
 
The synthetic strategy towards new photoswitchable ABCG2 inhibitors was the 
exchange of molecular parts of the parent compound 1 to the photochromic unit 
(Figure 4.2). With this approach three different aims should be achieved: 
retention of the potency, determination of the essential molecular structures and 
similarity of the size and the molecular weight to the parent ABCG2 inhibitor. To 
obtain photochromic ABCG2 inhibitors the quinoline moiety, the 
tetrahydroisoquinoline moiety and the central aromatic core were replaced by 
dithienylethenes. 
 
 
 
Figure 4.2: Potent and selective ABCG2 inhibitor, parent compound. 
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4.2. Results and Discussion 
4.2.1. Synthesis 
Compound 4o was accessible replacing the quinoline moiety by the 
photoswitchable DTE unit. The amine 2 was reacted with phenyl-substituted 
dithienylethene 3 by first generating the acid chloride. In the same way 
compound 6o was synthesised in one step from compound 3 and 5. For the 
preparation of the symmetrically substituted compound 9o two equivalents of 
quinoline-2-amine 7 were coupled with the diacid dithienylethene 8. The 
synthesis of the non-symmetrically substituted compound 11o was achieved 
using 0.3 equivalents of compound 10 and 1 equivalent of compound 7 
(Scheme 4.1). All photoswitchable ABCG2 modulators were purified by 
preparative HPLC and obtained in moderate isolated yields. 
 
NH
N
H
O
N
O
O
S
S
O
NH2
N
H
O
N
O
O
S
S
O
HO
+
1. SOCl2, THF, DMF
2. NEt3, THF
16 %
2 3
4o
 
4. Photochromic Tariquidar Derivatives as Potential ABCG2 Modulators 
 
 
107 
4. Photochromic Tariquidar Derivatives as Potential ABCG2 Modulators 
 
 
108 
HN
N
S
S
O
N
O
OO
N
H
N
O
O
H2N
+
NH2
N +
1. SOCl2, THF, DMF
2. NEt3, THF
7 10 8
11o
12 %
S
S
O
O
HO
OH
 
Scheme 4.1: Synthesis of potential photoswitchable ABCG2 modulators. 
 
With the intention to prepare an ABCG2 modulator containing a heteroaromatic 
moiety instead of the central aromatic core, the synthetic sequence was started 
with the coupling of 5-nitrothiophene-2-carboxylic acid 12 and the amine 10. 
The reduction of the nitrofunction of compound 13 to the corresponding amine 
was performed with SnCl2 in good yield. The synthesis of the thiophene 
compound 16 was completed by the second amid bond formation (Scheme 
4.2). 
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Scheme 4.2:Synthesis of thiophene containing ABCG2 modulator. 
 
4.2.2. Photochemical Properties 
Irradiating solutions of 4o, 6o, 9o and 11o in methanol (c = 10-5 mol/L) with  
312 nm resulted in immediate changes of the UV/VIS absorption spectra that 
are typical for photo-responsive dithienylethenes.[17] Depending on the different 
compounds, the high energy band around λmax = 270 nm decreased in intensity 
and a new absorption band in the visible spectral region appeared (λmax = 530-
560 nm). For compounds 4c, 9c and 11c additional absorption bands appeared 
at λmax = 378 nm (4c), λmax = 370 nm (9c) and λmax1 = 239 nm, λmax2 = 358 nm 
(11c). The solution changed its colour from colourless to purple upon ring-
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closure. These spectral changes were complete after several seconds of 
irradiation (compound 4: 40 s; compound 6: 20 s; compound 9: 10 s; compound 
11: 14 s). Longer irradiation led, in some cases, to destruction of the molecules 
(see Figure 4.3). 
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Figure 4.3: Electrocyclization upon irradiation with 312 nm, concentration  
10-5 mol/L in methanol, irradiation periods: A: 4o: 0, 10, 22, 33, 53 s; B: 6o: 0, 
10, 22, 40, 60, 120 s; C: 9o: 0, 5, 10, 15, 20 s; D: 11o: 0, 2, 4, 6, 8, 10, 12, 14 s. 
 
Thermal stability of the ring-closed derivatives could be proven for all 
compounds at least for 10 h in the dark (Figure 4.4). 
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Figure 4.4: Thermal stability in the dark for 10 h, spectra taken each hour, A: 
compound 4c, B: compound 6c, C: compound 9c, D: compound 11c. 
 
In order to study the durability, the photoswitchable compounds 4, 6, 9 and 11 
were alternately irradiated with 312 nm and with visible light > 420 nm. The 
absorption band as well as the visible light band were followed and plotted 
against the cycle number. Compound 4 showed a fast loss of performance and 
therefore a high tendency of photo-degradation. After nine cycles the absorption 
intensity decreased about 50 %. The performance was improved for 
compounds 6 and 9. The intensity of the visible band drops by 32 % for 
compound 6 and only 10-12 % for compounds 9 and 11 after ten cycles  
(Figure 4.5). 
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Figure 4.5: A :Cycle performance of 4, changes in absorption at 270 nm (open 
scares) and 531 nm (blue circles) during an alternated irradiation of a solution in 
methanol (10-5 mol/L) with 312 nm light for 40 s and greater than 420 nm light 
for 7 min., B: Cycle performance of 6, changes in absorption at 266 nm (open 
scares) and 530 nm (blue circles) during an alternated irradiation of a solution in 
methanol (10-5 mol/L) with 312 nm light for 120 s and greater than 420 nm light 
for 5 min; C: Cycle performance of 9, changes in absorption at 272 nm (open 
scares) and 555 nm (blue circles) during an alternated irradiation of a solution in 
methanol (10-5 mol/L) with 312 nm light for 10 s and greater than 420 nm light 
for 2 min; D: Cycle performance of 11, changes in absorption at 275 nm (open 
scares) and 547 nm (blue circles) during an alternated irradiation of a solution in 
methanol (10-5 mol/L) with 312 nm light for 30 s and greater than 420 nm light 
for 5 min. 
 
The photostationary state was investigated by 1H-NMR exemplarily for 
compound 9c. Irradiating a 35 µM solution of 9o in CDCl3 60 min with light of a 
312 nm lamp resulted in a photostationary state containing 86 % of the ring-
closed isomer 9c. 
 
In preparation for biological activity investigations, the photostability of the 
photoswitchable modulators was tested in the opened and in the closed form 
upon irradiation with 340 nm. This irradiation wavelength is applied for assay 
using the Hoechst 33342 dye. The ring-opened and ring-closed isomers of all 
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four compounds, dissolved in methanol (c = 10-5 mol/L) turned out to be stable 
to irradiation for several minutes (Figure 4.6 and Figure 4.7). 
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Figure 4.6: Irradiation of the open derivatives with 340 nm, A: compound 4o, B: 
compound 6o, C: compound 9o, D: compound 11o. 
 
A B 
C D 
4. Photochromic Tariquidar Derivatives as Potential ABCG2 Modulators 
 
 
114 
 
4c
0.0
0.1
0.2
0.3
0.4
0.5
200 400 600 800
wavelength [nm]
ab
so
rb
an
ce
0 min
2 min
4 min
6 min
8 min
6c
0.0
0.1
0.2
0.3
0.4
200 400 600 800
wavelength [nm]
ab
so
rb
an
ce
 0 min
 2 min
 4 min
 6 min
 8 min
 
9c
0.0
0.1
0.2
0.3
0.4
0.5
0.6
200 400 600 800
wavelength [nm]
ab
so
rb
an
ce
0 s
30 s
60 s
90 s
120 s
150 s
11c
0.0
0.2
0.4
0.6
0.8
1.0
1.2
200 400 600 800
wavelength [nm]
ab
so
rb
an
ce
120 s
240 s
360 s
480 s
500 s
 
Figure 4.7: Irradiation of the closed derivatives with 340 nm, A: compound 4c, 
B: compound 6c, C: compound 9c, D: compound 11c. 
 
Daylight exposure resulted in immediate conversion into the ring-opened 
isomer. Within 10 min the long wavelength absorption intensity already dropped 
about 50 % (Figure 4.8). 
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Figure 4.8: Daylight exposure for 0 min (blue), 10 min (purple), 20 min (green), 
30 min (yellow), 60 min (orange), 120 min (red) of the ring-closed derivatives, A: 
compound 4c, B: compound 6c, C: compound 9c, D: compound 11c. 
 
Switching of the photochromic compounds in aqueous PBS-buffer containing  
1 % of BSA and EMEM + 5 % FCS was hampered by a very small extinction 
coefficients for compounds 6 and 11. It was not possible to monitor the 
conversion between the open and the closed isomer after irradiation with  
312 nm (data no shown). However, the ring-closed 11c isomer was detectable 
by UV-spectroscopy in aqueous buffer after switching the molecule in the 
DMSO stock solution (Figure 4.9). 
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Figure 4.9: UV-absorbance of compound 11c (c = 10-5 M) in different aqueous 
media, all samples prepared in 1 : 100 ratio (DMSO/aqueous media). 
 
4.2.3. Biological Activity 
The potency of the photochromic compounds to modulate the ABCG2 
transporter was determined in the fluorescent based Hoechst 33342 (H33342) 
microtiter plate assay. The blue fluorescent Hoechst 33342 is not accumulated 
in MCF7/Topo cells due to its active efflux by overexpressed ABCG2 
transporters. Hence, ABCG2 inhibitors can be detected by the change of 
intramolecular H33342 levels. The relative fluorescence intensity of the cells 
was measured. Fumitremorgin C and Ko143 were used as positive control 
compounds, whereas fumitremorgin C was the reference for the maximal 
inhibitory effect of the test compounds. This assay was suitable since there was 
no interference between the spectral properties of the analyte H33342 and the 
test compound. As shown above, all photochromic compounds remain as open 
or closed isomer upon exiting H33342 at 340 nm. 
 
4. Photochromic Tariquidar Derivatives as Potential ABCG2 Modulators 
 
 
117 
Table 4.1: Inhibitory effect of photoswitchable compounds on the transport of 
ABCG2. 
 
Compound IC50 [µM] Max. inhibition [%]b) 
4o 0.433 ± 0.034 42 ± 2 (10 µM) 
6o -a) 14 ± 2 (50 µM) 
9o -c) 31 ± 2 (30 µM) 
11o -c) 25 ± 1 (30 µM) 
16 0.625 ± 0.051 34 ± 2 (7 µM) 
 
a)
 no significant inhibitory effect, b) N = 3, c) plateau not reached. 
 
Until now only the ring-opened isomers were tested on their biological activity 
and resulted in weak or no inhibitory effect (Table 4.1). Compound 16 was 
additionally tested on its inhibitory effect on ABCB1, was found to be inactive. 
4.3. Conclusion 
Potential modulators of the ABCG2 transporter containing a photoswitchable 
dithienylethene unit were prepared. The replacement of parts of the parent 
inhibitor 1 to DTE led to four photochromic compounds. The investigation of the 
photochemical properties resulted in a fast conversion into the ring-closed 
isomer after 10-40 s of irradiation with 312 nm light, monitored by changes in 
the UV/Vis spectra. All ring-closed isomers remained stable in the dark for at 
least 10 h. Cycle performance revealed high stabilities for compounds 9 and 11, 
even after 10 cycles. The photostationary state was determined to be 86 % for 
compound 9c. 
The photostability at the pharmacological assay conditions using irradiation of 
340 nm to detect the analyte Hoechst 33342, was shown for all compounds, 
either in the ring-opened or the ring-closed isomer. Daylight exposure led to 
immediate ring-opening and must be avoided during assays. The 
photoconversion into ring-closed isomers was not possible in aqueous media, 
but in the DMSO stock solution before.  
Preliminary pharmacological tests showed low activity of the ring-opened 
isomers. 
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4.4. Experimental Section 
General. Commercial reagents and starting materials were purchased from 
Aldrich, Fluka or Acros and used without further purification. Flash 
chromatography was performed on silica gel (Merck silica gel Si 60 40-63 µm); 
products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ = 254 nm). 
Melting points were determined with a Optimelt MPA 100 and are uncorrected. 
NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz; 13C:  
75.5 MHz; T = 300 K), Bruker Avance 400 (1H: 400.1 MHz; 13C: 100.6 MHz; T 
= 300 K), and Bruker Avance 600 (1H: 600.1 MHz; 13C: 150.1 MHz; T = 300 K) 
instruments. Chemical shifts are reported in δ/ppm relative to external 
standards and coupling constants J are given in Hz. Abbreviations for the 
characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, 
bs = broad singlet, dd = double doublet. The relative numbers of protons is 
determined by integration. Error of reported values: chemical shift 0.01 ppm 
(1H-NMR), 0.1 ppm (13C-NMR), coupling constant 0.1 Hz. The used solvent for 
each spectrum is reported. Mass spectra were recorded with Finnigan MAT 
TSQ 7000 (ESI) and Finnigan MAT 90 (HRMS), IR spectra with a Bio-Rad FT-
IR-FTS 155 spectrometer and UV/vis spectra with a Cary BIO 50 UV/vis/NIR 
spectrometer (Varian). 
 
Photochemistry. Standard hand-held lamps used for visualizing TLC plates 
(Herolab, 6 W) were used to carry out the ring-closing reactions at 312 nm. The 
ring-opening reactions were carried out using the light of a 200 W tungsten 
source that was passed through a 420 nm cut-off filter to eliminate higher 
energy light. The power of the light source is given based on the specifications 
supplied by the company where the lamps were purchased. A light detector was 
not used to measure the intensity during the irradiation experiments. 
 
The following compounds were prepared following known procedures: 3-amino-
N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}benzamide 
(2) (see chapter 2), 5-methyl-4-[2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-
enyl]thiophene-2-carboxylic acid (3),[23] methyl 4-[4-(2-
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aminoethyl)phenylcarbamoyl]-2-(quinoline-2-carboxamido)benzoate (5) (see 
chapter 2), 4,4'-(cyclopentene-1,2-diyl)bis(5-methylthiophene-2-carboxylic acid) 
(8),[20-21] 4-{2-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}aniline 
(10),[19] 5-nitrothiophene-2-carboxylic acid (12)[24], quinoline-2-carbonyl chloride 
(15)[22] 
 
N-{3-[4-(2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl]ethyl)phenylcarbamoyl] phenyl}-5-methyl-4-[2-(2-methyl-5-
phenylthiophen-3-yl)cyclopent-1-enyl]thiophene-2-carboxamide (4o) 
5-Methyl-4-[2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-enyl]thiophene-2-
carboxylic acid (1.5 eq, 100 mg, 0.24 mmol) was dissolved in 5 mL dry THF and 
4 trops of DMF were added followed by SOCl2 (2 eq, 60 mg, 0.04 mL, 0.5 
mmol) and stirred at room temperature for one hour. Then, the solvent was 
removed under reduced pressure; the residue was dried in high vacuo for two 
hours and was taken up with dry THF. Triethylamine (1.5 eq, 40 mg, 0.05 mL; 
0.36 mmol) was added in one portion followed by solid 3-amino-N-{4-[2-(6,7-
dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}benz-amide (1 eq,  
70 mg, 0.16 mmol) and the resulting mixture was stirred at room temperature 
for 20 h. The solvent was evaporated in vacuo and the residue was purified by 
preparative HPLC affording compound 4o (20 mg, 0.03 mmol, 16 %) as pale 
yellow solid, mp 189 °C – 1H-NMR (300 MHz, CDCl3): δ = 1.91 (s, 3 H), 1.94 (s, 
3 H), 1.98-2.02 (m, 2 H), 2.75-2.77 (m, 6 H), 2.88- 2.93 (m, 4 H), 3.06-3.14 (m, 
4 H), 3.73 (s, 3 H), 3.75 (s, 3 H), 6.37 (s, 1 H), 6.48 (s, 1 H), 6.93-6.96 (m, 2 H), 
7.14 (t, J = 6.9 Hz, 2 H), 7.23-7.26 (m, 3 H), 7.41 (d, J = 7.3 Hz, 2 H), 7.48-7.52 
(m, 3 H), 7.56 (s, 1 H), 7.74 (d, J = 8.0 Hz, 1 H), 8.01 (s, 1 H), 8.66 (s, 1 H, N-
H), 8.86 (s, 1 H, N-H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 14.4 (+, 
CH3), 14.8 (+, CH3), 22.9 (-, CH2), 24.1 (-, CH2), 29.7 (-, CH2), 30.0 (-, CH2), 
38.4 (-, CH2), 38.5 (-, CH2), 49.3 (-, CH2), 52.2 (-, CH2), 55.9 (+, CH3), 56.0 (+, 
CH3), 109.0 (+, CHarom), 111.0 (+, CHarom), 118.2 (+, CHarom), 118.3 (+, CHarom), 
118.7 (+, CHarom), 121.4 (+, 2 x CHarom), 122.3 (+, CHarom), 123.1 (+, CHarom), 
123.5 (Cquat), 123.8 (+, CHarom), 125.2 (+, 2 x CHarom), 127.1 (+, CHarom), 128.8 
(+, 2 x CHarom), 129.1 (2 x Cquat), 129.2 (Cquat), 130.4 (Cquat), 131.7 (Cquat), 133.8 
(+, CHarom), 134.2 (Cquat), 134.3 (Cquat), 134.4 (Cquat), 135.1 (Cquat), 135.8 (Cquat), 
136.4 (+, CHarom), 137.3 (Cquat), 138.4 (Cquat), 140.0 (Cquat), 141.7 (Cquat), 148.5 
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(Cquat), 149.2 (Cquat), 160.5 (Cquat), 165.7 (Cquat) – MS (+ESI): m/z (%) = 794 
(100) [MH+] – IR ν~ [cm-1] = 1600 (C=O), 1656 (C=O), 3466 (N-H) –  
MF C48H47N3O4S2 – MW 794.03 
 
Methyl 4-{4-[2-(5-methyl-4-[2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-
enyl]thiophene-2-carboxamido)ethyl]phenylcarbamoyl}-2-(quinoline-2-
carboxamido)benzoate (6o) 
5-Methyl-4[2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-enyl]thiophene-2-
carboxylic acid (1.3 eq, 32 mg, 0.08 mmol) was dissolved in dry THF and one 
drop of DMF. Thionylchloride (2 eq, 18 mg, 11 µL, 0.16 mmol) was added; the 
mixture was stirred for one hour at room temperature and evaporated to 
dryness. Then the residue was taken up with dry THF, triethylamine (1.5 eq,  
13 mg, 20 µL, 0.13 mmol) and methyl 4-[4-(2-aminoethyl)phenylcarbamoyl]-2-
(quinoline-2-carboxamido)benzoate (1.0 eq, 30 mg, 0.06 mmol) were added 
and the solution was stirred for 15 h at room temperature. The solvent was 
evaporated under reduced pressure and the residue was further purified by 
preparative HPLC to yield compound 6o (12 mg, 0.014 mmol, 24 %) as 
colourless solid, mp 180 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 
1.93 (s, 3 H), 1.99 (s, 3 H), 2.05 (t, J = 7.4 Hz, 2 H), 2.76-2.80 (m, 4 H), 2.86 (t, 
J = 6.9 Hz, 2 H), 3.59-3.65 (m, 2 H), 4.08 (s, 3 H), 5.94-5.97 (m, 1 H, NH), 6.99 
(s, 1 H), 7.17-7.22 (m, 4 H), 7.31 (t, J = 7.8 Hz, 2 H), 7.47 (d, J = 7.4 Hz, 2 H), 
7.61 (d, J = 8.2 Hz, 2 H), 7.66-7.72 (m, 2 H), 7.79-7.85 M, 1 H), 7.90 (d, J = 8.2 
Hz, 1 H), 8.20 (d, J = 8.5 Hz, 1 H), 8.30 (s, 1 H), 8.33-8.35 (m, 3 H), 9.43 (s, 1 
H, NH), 13.3 (s, 1 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 14.4 (+, 
CH3), 14.7 (+, CH3), 22.9 (-, CH2), 35.3 (-, CH2). 38.4 (-, CH2), 38.5 (-, CH2), 
41.1 (-, CH2), 52.7 (+, CH3), 117.9 (+, CHarom), 118.7 (+, CHarom), 118.9 (Cquat), 
120.9 (+, CHarom), 122.6 (+, CHarom), 123.8 (+, CHarom), 125.3 (+, 2 x CHarom), 
127.0 (+, CHarom), 127.7 (+, CHarom), 128.4 (+, CHarom), 128.8 (+, 2 x CHarom), 
129.3 (+, 3 x CHarom), 129.4 (+, CHarom), 129.5 (Cquat), 130.2 (+, CHarom), 130.3 
(+, CHarom), 131.9 (+, CHarom), 133.8 (Cquat), 134.0 (Cquat), 134.3 (Cquat), 134.5 
(Cquat), 135.4 (Cquat), 135.5 (Cquat), 136.2(Cquat), 136.3(Cquat), 136.7 (Cquat), 137.8 
(+, CHarom), 139.9 (Cquat), 140.0 (Cquat), 140.1 (Cquat), 140.8 (Cquat), 146.6 (Cquat), 
149.5 (Cquat), 161.9 (Cquat), 163.9 (Cquat), 164.7 (Cquat), 167.3 (Cquat) –  
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MS (+ESI): m/z (%) = 832 (100) [MH+] – IR ν~ [cm-1] = 1568 (C=O), 1621 (C=O), 
1654 (C=O), 1696 (C=O) – MF C49H42N4O5S2 – MW 831.01 
 
4,4'-(Cyclopentene-1,2-diyl)bis[5-methyl-N-(quinolin-2-yl)thiophene-2-
carboxamide] (9o) 
4,4'-(Cyclopentene-1,2-diyl)bis(5-methylthiophene-2-carboxylic acid) (0.5 g,  
1.4 mmol) was dissolved in dry THF (10 mL) and treated with 4 drops of DMF 
followed by SOCl2 (0.67 g, 0.41 mL, 5.7 mmol). The solution was stirred at room 
temperature for 15 h and then evaporated to dryness. The residue was taken up 
in dry THF and under nitrogen atmosphere NEt3 (3.3 eq, 0.46 g, 0.66 mL,  
4.62 mmol) was added in one portion, followed by solid quinolin-2-amine  
(0.40 g, 2.8 mmol). After stirring at room temperature for additional 50 h, 
insoluble materials were filtered off, washed with THF and the filtrate was 
evaporated to dryness. Further purification was achieved by column 
chromatography (elution with EtOAc/PE 3:7, Rf: 0.8) and yielded compound 9o 
(70 mg, 0.1 mmol, 8.3 %) as purple solid, – mp 130 °C (decomposition) – 1H-
NMR (300 MHz, CDCl3): δ = 1.85 (s, 6 H), 1.91 (t, J = 7.2 Hz, 2 H), 2.55 (t, J = 
7.4 Hz, 4 H), 7.36 (t, J = 7.9 Hz, 2 H), 7.40 (s, 2 H), 7.54 (t, J = 8.4 Hz, 2 H), 
7.72 (d, J = 8.8 Hz, 4 H), 8.12 (d, J = 9.0 Hz, 2 H), 8.46 (d, J = 8.8 Hz, 2 H), 
9.38 (s, 2 H, NH) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 14.6 (+, CH3), 
14.8 (+, CH3), 22.7 (-, CH2), 38.4 (-, 2 x CH2), 125.2 (+, 4 x CHarom), 126.2 (2 x 
Cquat), 127.6 (+, 4 x CHarom), 128.0 (2 x Cquat), 130.0 (+, 2 x CHarom), 130.4 (+, 2 
x CHarom), 134.7 (2 x Cquat), 136.3 (2 x Cquat), 136.7 (2 x Cquat), 138.7 (+, 2 x 
CHarom), 146.3 (2 x Cquat), 151.3 (2 x Cquat), 160.5 (2 x Cquat) – MS (+ESI): m/z 
(%) = 601 (100) [MH+] – IR ν~ [cm-1] = 1597 (C=O), 1655 (C=O), 3505 (N-H) – 
MF C35H28N4O2S2 – MW 600.75 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-5-
methyl-4-{2-[2-methyl-5-(quinolin-2-ylcarbamoyl)thiophen-3-yl]cyclopent-
1-enyl}thiophene-2-carboxamide (11o) 
4,4'-(Cyclopentene-1,2-diyl)bis(5-methylthiophene-2-carboxylic acid) (0.5 g,  
1.4 mmol) was dissolved in dry THF (10 mL) and treated with 4 drops of DMF 
followed by SOCl2 (0.67 g, 0.41 mL, 5.7 mmol). The solution was stirred at room 
temperature for 15 h and then evaporated to dryness. The residue was taken up 
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in dry THF and under nitrogen atmosphere NEt3 (3.3 eq, 0.46 g, 0.66 mL,  
4.62 mmol) was added in one portion, followed by a solution of 4-{2-[6,7-
dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}aniline (0.14 g, 0.45 mmol) in 
dry THF dropwise over 4 h. After stirring at room temperature for 1.5 h, solid 
quinolin-2-amine (0.40 g, 2.8 mmol) was added in one portion. After stirring at 
room temperature for additional 50 h, insoluble materials were filtered off, 
washed with THF and the filtrate was evaporated to dryness. Parts of the 
residue (80 mg) were further purified with preparative HPLC (Rt 13.39 min) and 
yielded compound 11o (9 mg, 0.01 mmol, 12 %) as yellow solid. 
mp 179 °C – 1H-NMR (300 MHz, CDCl3, HSQC, HMBC): δ = 2.10-2.13 (m, 5 
H), 2.25 (s, 3 H), 2.76 (t, J = 7.0 Hz, 2 H), 2.82 (t, J = 7.0 Hz, 2 H), 2.91-2.94 
(m, 1 H), 3.11-3.16 (m, 2 H), 3.24-3.32 (m, 4 H), 3.67-3.72 (m, 1 H), 3.82 (s, 3 
H), 3.85 (s, 3 H), 3.98 (d, J = 14.7 Hz, 1 H), 4.57 (d, J = 14.7 Hz, 1 H), 6.50 (s, 1 
H), 6.62 (s, 1 H), 7.10 (d, J = 8.2 Hz, 2 H), 7.69-7-75 (m, 4 H), 7.93-7.98 (m, 3 
H), 8.22 (s, 1 H), 8.55 (d, J = 9.3 Hz, 1 H), 8.78 (d, J = 9.3 Hz, 1H), 9.23 (s, 1H, 
NH) – 13C-NMR (75 MHz, CDCl3): δ = 14.2 (+, CH3), 14.9 (+, CH3), 23.0 (-, 
CH2), 23.9 (-, CH2), 30.2 (-, CH2), 37.6 (-, CH2), 38.2 (-, CH2), 49.2 (-, CH2), 52.3 
(-, CH2), 55.9 (-, CH2), 56.0 (+, CH3), 56.1 (+, CH3), 109.2 (+, CHarom), 111.1 (+, 
CHarom), 114.7 (+, CHarom), 117.3 (Cquat), 118.1 (Cquat), 119.5 (+, CHarom), 120.9 
(+, 2 x CHarom), 122.4 (Cquat), 124.2 (Cquat), 128.2 (+, CHarom), 128.6 (+, CHarom), 
128.9 (+, 2 x CHarom), 130.0 (Cquat), 130.5 (+, CHarom), 131.0 (Cquat), 134.5 (+, 
CHarom), 135.3 (+, CHarom), 135.4 (Cquat), 135.8 (Cquat), 135.9 (Cquat), 136.3 
(Cquat), 137.0 (Cquat), 138.0 (Cquat), 140.9 (Cquat), 145.9 (+, CHarom), 146.3 (Cquat), 
148.6 (Cquat), 149.2 (Cquat), 150.5 (Cquat), 160.8 (Cquat), 162.6 (Cquat) – HR-MS 
calcd for C45H44N4O4S2 768.2804 [M⋅+], found: 768.2788 – IR ν~ [cm-1] = 1598 
(C=O), 1644 (C=O) – MF C45H44N4O4S2 – MW 768.99 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-5-
nitrothio-phene-2-carboxamide (13) 
5-Nitrothiophene-2-carboxylic acid (0.5 g, 2.9 mmol) was refluxed for 30 min in 
5 mL SOCl2. The solvent was evaporated to complete dryness, then the residue 
was taken up with dichloromethane. Triethylamine (1.5 eq, 0.29 g, 0.41 mL; 2.9 
mmol) was added in one portion followed by solid 4-{2-[6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl]ethyl}aniline (0.56 g, 1.9 mmol) and the resulting 
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mixture was stirred at room temperature for 15 h. The yellow precipitate was 
filtered off and washed with DCM, yielding 0.42 g (0.90 mmol, 47 %) yellow 
solid, mp 220 °C (decomposition) – 1H-NMR (300 MHz, d-6 DMSO): δ = 3.04-
3.51 (m, 6 H), 3.34-3.37 (m, 2 H), 3.73 (s, 3 H), 3.74 (s, 3 H), 4.31 (s, 2 H), 6.77 
(s, 1 H), 6.80 (s, 1 H), 7.31 (d, J = 8.2 Hz, 2 H), 7.77 (d, J = 8.5 Hz, 2 H), 8.19 
(d, J = 4.4 Hz, 1 H), 8.27 (d, J = 4.4 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, 
d-6 DMSO: δ = 24.7 (-, CH2), 29.2 (-, CH2), 48.9 (-, CH2), 51.5 (-, CH2), 55.4 (+, 
CH3), 55.5 (+, CH3), 55.9 (-, CH2), 109.5 (+, CHarom), 111.4 (+, CHarom), 120.3 
(Cquat), 120.8 (+, 2 x CHarom), 123.4 (Cquat), 128.5 (+, CHarom), 128.9 (+, 2 x 
CHarom), 130.0 (+, CHarom), 133.3 (Cquat), 136.6 (Cquat), 146.4 (Cquat), 147.5 
(Cquat), 148.1 (Cquat), 153.2 (Cquat), 158.1(Cquat) – MS (+ESI): m/z (%) = 468 
(100) [MH+] – IR ν~ [cm-1] = 1317 (N-O), 1509 (N-O), 1601 (C-O) – MF 
C24H25N3O5S – MW 467.54 
 
5-Amino-N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-
yl)ethyl]phenyl}thio-phene-2-carboxamide (14) 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)ethyl]phenyl}-5-nitrothio-
phene-2-carboxamide (0.4 g, 0.85 mmol) was dissolved in 5 mL DMF and 5 eq 
of SnCl2 (0.8 g, 4.2 mmol) were added. The reaction mixture was heated to 70 
°C for 30 min and then poured on ice. After neutralisation with diluted NaOH the 
solution was extracted with dichloromethane (3 x 30 mL). The combined organic 
layers were dried over Na2SO4 and the solvent was evaporated under reduced 
pressure. The reaction yielded compound 14 (0.15 g, 0.34 mmol, 59 %) as red 
solid, mp 200 °C (decomposition) – 1H-NMR (300 MHz, d-6 DMSO): δ = 2.78-
2.87 (m, 8 H), 3.68 (s, 2 H), 3.80 (s, 3 H), 3.82 (s, 3 H), 6.52 (s, 1 H), 6.58 (s, 1 
H), 7.11 (d, J = 6.0 Hz, 2 H), 7.35 (d, J = 3.6 Hz, 1 H), 7.50-7.55 (m, 3 H) – 13C-
NMR, DEPT 135 (75 MHz, d-6 DMSO: δ = 27.9 (-, CH2), 32.7 (-, CH2), 50.6 (-, 
CH2), 55.1 (-, CH2), 55.7 (+, CH3), 55.8 (+, CH3), 59.5 (-, CH2), 109.4 (+, 
CHarom), 111.3 (+, CHarom), 115.3 (+, CHarom), 120.5 (+, 2 x CHarom), 122.6 
(Cquat), 125.6 (Cquat), 129.0 (+, 2 x CHarom), 129.4 (+, CHarom), 135.0 (Cquat), 
136.5 (Cquat), 136.6 (Cquat), 150.9 (Cquat), 158.8 (Cquat), 160.2 (Cquat), 161.0 
(Cquat) – MS (+ESI): m/z (%) = 438 (100) [MH+] – IR ν~ [cm-1] = 1517 (N-H), 3320 
(N-H) – MF C24H27N3O3S – MW 437.55 
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N-{5-[4-(2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl]ethyl)phenylcarbamoyl] thiophen-2-yl}quinoline-2-carboxamide (16) 
4-{2-[6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}aniline (150 mg, 0.34 
mmol) was dissolved in 2 mL dry DCM. Triethylamine (1.5 eq, 50 mg, 0.07 mL, 
0.5 mmol) and quinoline-2-carbonyl chloride (1.5 eq, 98 mg, 0.5 mmol) were 
added. The reaction mixture was stirred for 15 h at room temperature and then 
washed with NaHCO3. The aqueous phase was extracted with dichloromethane 
(3 x 20 mL). The combined organic layers were dried over Na2SO4 and the 
solvent was evaporated. Further purification was achieved with preparative 
HPLC (Rt 8.87 min) affording compound 16 (5 mg, 0.008 mmol, 2 %) as yellow 
solid, mp 48 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.82-2.98 (m, 2 H), 3.02-3.15 
(m, 2 H), 3.20-3.38 (m, 4 H), 3.81 (s, 3 H), 3.83 (s, 3 H), 3.98-4.02 (m, 2 H), 
6.49 (s, 1 H), 6.60 (s, 1 H), 6.92 (s, 1 H), 7.13 (d, J = 6.8 Hz, 2 H), 7.57 (d, J = 
6.8 Hz, 2 H), 7.64-7.68 (m, 2 H), 7.81 (t, J = 7.8 Hz, 1 H), 7.91 (d, J = 8.5 Hz, 1 
H), 8.18 (d, J = 7.7 Hz, 2 H), 8.35 (q, J = 7.6 Hz, 2 H), 10.91 (s, 1 H) – IR ν~ [cm-
1] = 1519 (C=O), 1669 (C=O) – HR-MS calcd for C34H32N4O4S 592.2144 [M⋅+], 
found: 592.2130– MF C34H32N4O4S – MW 592.71 
 
Photochemical synthesis of the ring-closed isomer 9c. A solution of 
compound 9o (15 mg, mmol) in CDCl3 (0.7 mL) was irradiated for 60 min with 
312 nm lamp in a silica glass NMR tube, yielding a purple solution of a 
photostationary state containing 86 % of the ring closed isomer according to the 
1H-NMR spectra. The remaining 36 % were assigned to the ring-open isomer 
9o. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.92 (t, J = 7.1 Hz, 2 H), 2.08 (s, 6 H), 
2.48 (t, J = 7.4 Hz, 4 H), 6.85 (s, 2 H), 7.47 (t, J = 6.9 Hz, 2 ), 7.68 (t, J = 7.0 Hz, 
2 H), 7.78-7.82 (m, 4 H), 8.02 (d, J = 9.0 Hz, 2 H) 
 
Modulation of ABCB1 and ABCG2 was performed as described.[25] 
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5. Stereoselective Synthesis of alpha-
disubstituted Secondary Amines as 
Potential ACE Inhibitors 
 
Secondary amines containing two carbon stereocentres in both α-positions are 
a typical substructure of ACE inhibitors and other biological active compounds. 
Their stereoselective synthesis was aspired in different approaches, but 
industrial applications mostly still apply the separation of diastereomers. Here, 
two synthetic routes for the conversion of natural amino acids into the target 
structures using an SN2 reaction or an oxazolidine mediated reaction sequence 
as key steps were compared concerning their diastereoselectivity. Synthesis via 
the oxazolidine gave only one entantiomer for the substituted secondary amine. 
The synthesised compounds showed weak or no cytotoxicity. Selected 
compounds were tested as inhibitors of ACE-2, but revealed no biological 
activity. 
                                                 
∗
 All synthesis were done by Carolin Fischer, the MTT-assay was done by Gabriele Brunner and 
the ACE-2 assay was done by the company CEREP (France). 
* 
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5.1. Introduction 
The angiotensin I converting enzyme (ACE) plays a key role in the control of the 
renin-angiotensin-aldosterone system (RAAS). The biologically inactive 
angiotensin I is converted into the active vasoconstrictor angiotensin II and the 
vasodilatory bradykinin is inactivated. The membrane-bound zinc 
metalloprotease, a dipeptidyl carbopeptidase cleaves the C-terminal dipeptide 
His-Leu from the decapeptide angiotensin I and the dipeptide Phe-Arg from the 
nonapeptide bradykinin.[1] The recently discovered related homolog 
angiotensin-converting enzyme 2 (ACE-2) converts angiotensin I into 
angiotensin 1-9, which has no effect on blood vessels, but is then converted by 
ACE to the blood vessel dilator angiotensin 1-7.[2-3] These activities explain the 
predominant role of ACE and ACE-2 in the regulation of cardic function and 
blood pressure and justify the use of ACE inhibitors in antihypertensive 
therapy.[4-5] Based on isolated potent peptides of snake venom a huge number 
of peptidomimetic ACE inhibitors were developed and released to the market in 
the 1980s and 1990s. Since the crystal structure of the human angiotensin 
converting enzyme was published in 2003 by Natesh et al., ACE has become a 
popular target for structure based drug design.[6] Most of the known inhibitors 
contain an iminodiaceticacid structure substituted in both alpha positions to the 
carboxylic acids. The stereocenters are either (S)/(S) or (S)/(R) configured. One 
of the carboxylic acids is in most cases linked to proline or an alternative 
rigidified ring structure (see Figure 5.1).[7] 
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Figure 5.1: Common clinically used ACE inhibitors. 
 
For the synthesis of the secondary amine substructures owning two defined 
stereocentres in both α-positions, several different approaches were reported 
resulting in no or low excess for one of the two possible diastereomers: 
reductive amination using Raney nickel or NaCNBH3,[8-11] aza-Michael 
reaction,[12] SN2 reaction applying bromide, mesylate, tosylate or triflate as 
leaving groups [9, 13-15] and the palladium-catalysed asymmetric reductive 
alkylation.[19] Only one diastereomer was detected for the synthesis via a β-
lactam intermediate,[16] stereoselective alkylation[20] and for microbial 
reduction.[9, 21] Only few of these reactions resulted in high stereoselectivity. As 
the defined stereochemistry is important for the biological activity, HPLC 
separation of the two diastereomers was necessary in most cases. 
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Improved diastereoselective synthesis of α-disubstituted secondary amines 
would be of advantage for the commercial production of ACE inhibitors, but also 
interesting for other fields of medicinal chemistry where e.g. acyclic amine 
inhibitors are used as phosphorylase or nucleosidase inhibitors[22] or secondary 
amine derivatives are found in naturally occurring opines. These α-substituted 
2,2'-azanediyldiacetic acids are formed by the condensation of an amino acid 
and a keto acid by parasitic bacteria of the genus Agrobacterium.[23] 
We have investigated two methods for the synthesis of chiral secondary amines 
of the general structure 1 starting from natural amino acids and compare their 
diastereoselectivity. SN2 reactions using triflate as leaving group are often 
described to give high diastereoselectivity.[13, 24] The second approach proceeds 
via an oxazolidine intermediate and was not used before for the synthesis of 
ACE inhibitors. The cytotoxic properties and the inhibitory effect on human 
ACE-2 of the synthesised derivatives were tested. 
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5.2. Results and Discussion 
5.2.1. Synthesis 
The natural amino acid valine 2 was converted by formylation and reduction into 
the corresponding N-methyl alcohol 4a. Additionally, the N-methylated alcohol 
of glycine (4b) was used (Scheme 5.1). 
 
 
Scheme 5.1: Oxazolidine-mediated diastereoselective synthesis of amines 8. 
 
Conversion with 2-(benzyloxy)acetaldehyde 5 gave oxazolidines 6a and 6b. 
The attack of the benzylmagnesium chloride (7) was now only possible from the 
convex side of the molecule and gave one diastereomer of compounds 8a and 
8b as confirmed by HPLC analyses. The synthetic strategy was used previously 
for the diastereoselective synthesis of analgesic compounds[25] and the 
antidepressant cericlamine.[26] Heyns oxidation condition (Pt/C, O2) with the 
intention to oxidise the hydroxy function to the corresponding acid was not 
successful and gave only a small yield of the demethylated compound 9. 
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The second synthetic strategy used an SN2 substitution of a triflate group. Two 
different triflate compounds were prepared possessing methyl or isopropyl 
substituents in α-position. The diastereomeric excess for the (S,S) isomer was 
31 % de (12a) and 71 % de (12b) (Scheme 5.2), respectively, as determined by 
HPLC. The basic cleavage of the ester groups was incomplete for the isopropyl-
substituted compound 13a. 
 
 
Scheme 5.2: Synthesis of amines 12 via SN2 reaction; a) de [%] derived by 
HPLC analysis. 
 
5.2.2. Cytotoxicity and ACE-2 Inhibition 
The cytotoxicity of compounds 8, 9, 12 and 13 was tested using the 
colourimetric MTT assay. The assay takes advantage of the cleavage of the 
tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolin 
bromide) into the blue coloured formazan by the mitochondrial enzyme 
succinate-dehydrogenase.[27-29] The conversion takes only place in living cells 
and the amount of the red formazan is proportional to the number of cells alive. 
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Table 5.1: Cytotoxicity determined by the colourimetric MTT-assay. 
 
Compound IC50 [mM] logPa) 
8a 51.89 ± 4.24 4.53 
8b 173.48 ± 3.80 3.30 
9 78.56 ± 1.68 4.40 
12a 114.91 ± 6.39 3.58 
12b -b) 3.24 
13a -b) 3.07 
13b -b) 0.90 
N-methylimino-
diaceticacid 
-
b)
 -1.22 
 
a) logP values calculated by ACD/labs 12.0, b) no cytotoxic effect determined 
 
The tested compounds showed weak or even no toxicity. Their toxicity 
correlates with the calculated logP values: more lipophilic compounds of this 
series are more toxic (Table 5.1). 
 
Compound 13b was previously considered as a potential ACE-2 inhibitor.[30] 
Therefore selected compounds covering different structural elements were 
tested on their inhibitory effect on human ACE-2.1 The assay reference 
compound was Ac-GG-26-NH2 with an IC50 value of 610 nM and nH = 1.5. All 
compounds were investigated at 10 µM final concentration. However, the tested 
compounds did not show significant inhibition of the human ACE-2 function. 
 
5.3. Conclusion 
Di-substituted secondary amines 1 are potential ACE inhibitors and were 
prepared from natural amino acids via an oxazolidine-intermediate 6 or via a 
SN2 reaction. While the first route gave the target compounds in high 
diastereoselectivity, SN2 conditions showed only moderate selectivity of 71 % 
                                                 
1
 The ACE-2 inhibition assay was performed by the company CEREP (Celle l’Evescault, 
France). 
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de or 31 % de depending on the triflate reagent. Compounds 8, 9, 12 and 13 
are not or very weakly cytotoxic in an MTT assay, but have no inhibitory effect 
on human ACE-2. 
 
5.4. Experimental Section 
General. Commercial reagents and starting materials were purchased from 
Aldrich, Fluka or Acros and used without further purification. Flash 
chromatography was performed on silica gel (Merck silica gel Si 60 40-63 µm); 
products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ = 254 nm). 
Melting points were determined with Optimelt MPA 100 and are uncorrected. 
NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz; 13C:  
75.5 MHz; T = 300 K), Bruker Avance 400 (1H: 400.1 MHz; 13C: 100.6 MHz; T = 
300 K) and Bruker Avance 600 (1H: 600.1 MHz; 13C: 150.1 MHz; T = 300 K) 
instruments. Chemical shifts are reported in δ/ppm relative to external 
standards and coupling constants J are given in Hz. Abbreviations for the 
characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, 
bs = broad singlet, dd = double doublet. The relative numbers of protons is 
determined by integration. Error of reported values: chemical shift 0.01 ppm (1H 
NMR), 0.1 ppm (13C NMR), coupling constant 0.1 Hz. The used solvent for each 
spectrum is reported. Mass spectra were recorded with Finnigan MAT TSQ 
7000 (ESI) and Finnigan MAT 90 (HRMS), IR spectra with a Bio-Rad FT-IR-
FTS 155 spectrometer and UV/vis spectra with a Cary BIO 50 UV/vis/NIR 
spectrometer (Varian), optical rotation was determined with Krüss P8000. 
Compounds prepared after literature known procedures: (S)-N-(1-hydroxy-3-
methylbutan-2-yl)formamide (3),[31] (S)-3-methyl-2-(methylamino)butan-1-ol 
(4a),[31] (S)-2-(methylamino)-3-phenylpropan-1-ol (4b),[32] (S)-ethyl 2-
(trifluoromethylsulfonyloxy)propanoate (11b),[33] (S)-methyl 2-[1-ethoxy-1-
oxopropan-2-ylamino]-3-phenylpropanoate (12b) [13] and (S)-2-[1-
carboxyethylamino]-3-phenylpropanoic acid (13b)[13] 
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(2S,4S)-2-(Benzyloxymethyl)-4-isopropyl-3-methyloxazolidine (6a) 
N-Methylvalinol was dissolved under nitrogen atmosphere in DMSO. Freshly 
distilled 2-(benzyloxy)acetaldehyde (0.1 g, 0.68 mmol) was added. The reaction 
was stirred over night at room temperature. The mixture was then diluted with 
dichloromethane and washed with water. After evaporating the solvent, the 
reaction yielded (2S,4S)-2-(benzyloxymethyl)-4-isopropyl-3-methyloxazolidine 
(0.12 g, 0.48 mmol, 72 %) as yellow oil, 1H-NMR (300 MHz, CDCl3): δ = 0.87 (d, 
6.9 Hz, 3 H), 0.91 (d, 6.9 Hz, 3 H), 1.70-1.77 (m, 1 H), 2.49-2.55 (m, 1 H), 2.58 
(s, 3 H), 3.72-3.75 (m, 1 H), 3.84-3.90 (m,1 H), 4.21-4.24 (m, 1 H), 4.53-4.68 
(m, 4 H), 7.29-7.36 (m, 5 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 17.2 
(+, CH3), 19.7 (+, CH3), 30.4 (+, CH), 39.8 (+, CH3), 67.4 (-, CH2), 70.5 (+, CH), 
72.4 (-, CH2), 73.5 (-, CH2), 97.3 (+, CH), 127.6 (+, CHarom), 127.7 (+, 2 x 
CHarom), 128.4 (+, 2 x CHarom), 138.3 (Cquat) – MS (CI): m/z (%) = 250 (100) 
[MH+] – IR ν~ [cm-1] = 1023 (C-O), 1064 (C-O), 1449 (C-N) – MF C15H23NO2 – 
MW 249.35 
 
2-(Benzyloxymethyl)-3-methyloxazolidine (6b) 
Freshly distilled 2-(methylamino)ethanol (0.75 g, 10 mmol) was dissolved at 0 
°C in DMSO under nitrogen atmosphere. Molecular sieves (3 Å) and freshly 
distilled 2-(benzyloxy)acetaldehyde (1.5 g, 10 mmol) were added. The reaction 
was stirred over night at room temperature. The mixture was then diluted with 
dichloromethane and washed with water. After evaporating the solvent, the 
reaction yielded 2-(benzyloxymethyl)-3-methyloxazolidine (1.82 g, 8.8 mmol, 88 
%) as pale oil, 1H-NMR (300 MHz, CDCl3): δ = 2.32 (s, 3 H), 3.03-3.10 (m, 1 H), 
3.35-3.54 (m, 3 H), 3.68-3.77 (m, 2 H), 4.05 (t, J = 4.6 Hz, 1 H), 4.53 (s, 2 H), 
7.27-7.34 (m, 5 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 43.9 (+, CH3), 
59.2 (-, CH2), 69.2 (-, CH2), 76.9 (-, CH2), 77.6 (-, CH2), 100.8 (+, CH), 132.5 (+, 
2 x CHarom), 132.6 (+, CHarom), 133.4 (+, 2 x CHarom), 143.6 (Cquat) – MS (CI): 
m/z (%) = 208 (100) [MH+] – IR ν~ [cm-1] = 1027 (C-O), 1059 (C-O), 1454 (C-N) 
– [α]D20 -13.9 ° (c: 1.0, CHCl3) – MF C12H17NO2 – MW 207.27 
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(S)-2-{[(S)-1-(Benzyloxy)-3-phenylpropan-2-yl](methyl)amino}-3-methyl-
butan-1-ol (8a) 
(4S)-2-(Benzyloxymethyl)-4-isopropyl-3-methyloxazolidine (0.25 g, 1 mmol) was 
dissolved in dry THF and benzylmagnesium chloride (5 eq, 2.5 mL of a 2 M 
solution in THF; 5.00 mmol) was added dropwise. After stirring the mixture 3-4 h 
at room temperature the reaction was treated with diethyl ether and washed 
with water. The organic layer was dried over sodium sulphate and evaporated. 
The reaction yielded 0.2 g (0.58 mmol, 58 %) yellow oil. LC-MS analysis 
showed only one diastereomer, 1H-NMR (300 MHz, CDCl3): δ = 0.97 (d, 6.6 Hz, 
3 H), 1.05 (d, 6.8 Hz, 3 H), 1.90-1.97 (m, 1 H), 2.55 (s, 3 H), 2.62-2.67 (m, 1 H), 
2.90-3.02 (m, 3 H), 3.28-3.35 (m, 4 H), 4.56 (s, 2 H), 7.15-7.24 (m, 10 H) – 13C-
NMR, DEPT 135 (75 MHz, CDCl3): δ = 17.2 (+, CH3), 19.8 (+, CH3), 34.7 (-, 
CH2), 38.0 (-, CH2), 38.2 (-, CH2), 39.4 (-, CH2), 39.9 (+, CH3), 56.2 (+, CH), 
65.9 (+, CH), 76.3 (+, CH), 126.0 (+, CHarom), 126.1 (+, CHarom), 126.2 (+, 
CHarom), 127.1 (+, CHarom), 128.4 (+, CHarom), 128.5 (+, CHarom), 128.6 (+, 
CHarom), 128.7 (+, CHarom), 129.3 (+, CHarom), 131.1 (+, CHarom), 136.7 (Cquat), 
139.1 (Cquat) – MS (+ESI): m/z (%) = 342 (100) [MH+] – [α]D20 -15.3 ° (c: 1.0, 
CHCl3) – IR ν~ [cm-1] = 1454 (C-N), 3375 (O-H) – MF C22H31NO2 – MW 341.49 
 
(S)-2-{[1-(Benzyloxy)-3-phenylpropan-2-yl][methyl]amino}ethanol (8b) 
(4S)-2-(Benzyloxymethyl)-4-isopropyl-3-methyloxazolidine (1 eq, 2.1 g, 10 
mmol) was dissolved in dry THF and benzylmagnesium chloride (5 eq, 25 mL of 
a 2 M solution in THF; 50.0 mmol) was added dropwise. After stirring the 
mixture 3-4 h at room temperature the reaction was treated with diethyl ether 
and washed with water. The organic layer was dried over sodium sulphate and 
evaporated. The reaction yielded (S)-2-{[1-(benzyloxy)-3-phenylpropan-2-
yl][methyl]amino}ethanol (1.8 g, 6 mmol, 63 %) as yellow oil, 1H-NMR (300 
MHz, CDCl3): δ = 2.36 (s, 3 H), 2.64-2.74 (m, 4 H), 3.06-3.15 (m, 1 H), 3.38-
3.61 (m, 4 H), 4.48 (d, J = 2.19 Hz, 2 H), 7.15-7.32 (m, 10 H) – 13C-NMR, DEPT 
135 (75 MHz, CDCl3): δ = 34.5 (-, CH2), 36.1 (+, CH3), 56.0 (-, CH2), 58.1 (-, 
CH2), 64.9 (+, CH), 69.8 (-, CH2), 73.2 (-, CH2), 126.2 (+, CHarom), 127.6 (+, 
CHarom), 127.7 (+, 2 x CHarom), 128.4 (+, 2 x CHarom), 128.5 (+, 2 x CHarom), 
129.0 (+, 2 x CHarom), 138.2 (Cquat), 139.8 (Cquat) – MS (+ESI): m/z (%) = 300 
5. Stereoselective Synthesis of alpha-disubstituted Secondary Amines as 
Potential ACE Inhibitors 
 
 
137 
(100) [MH+] – IR ν~ [cm-1] = 1028 (C-O), 1453 (C-N), 3440 (O-H) – [α]D20 -58.5 ° 
(c: 1.0, CHCl3) – MF C19H25NO2 – MW 299.41 
 
(S)-2-[(S)-1-(Benzyloxy)-3-phenylpropan-2-ylamino]-3-methylbutan-1-ol (9) 
(S)-2-{[(S)-1-(Benzyloxy)-3-phenylpropan-2-yl][methyl]amino}-3-methylbutan-1-
ol (50 mg, 0.14 mmol) was dissolved in acetone. NaHCO3 (60 mg, 0.7 mmol) 
and Pt/C (14 mg of a 100 g/mol batch) were added. The flask was closed with 
an oxygen balloon and the reaction mixture was stirred for 15 h at 60 °C. The 
solid Pt/C was filtered off over celite and washed with acetone. After 
evaporation the residue was taken up in ethyl acetate and washed with water. 
Lyophilisation of the aqueous layer resulted in 7 mg (0.02 mmol, 7.3 %) of (S)-
2-((S)-1-(benzyloxy)-3-phenylpropan-2-ylamino)-3-methylbutan-1-ol as yellow 
oil. Due to small amount, purity was checked by HPLC-MS (Rt: 5.63 min), MS 
(+ESI): m/z (%) = 328 (100) [MH+] – MF C21H29NO2 – MW 327.46 
 
(S)-Methyl 3-methyl-2-(trifluoromethylsulfonyloxy)butanoate (11a) 
Methyl 2-hydroxy-3-methylbutanoate (0.55 g, 4.1 mmol) was added to a solution 
of trifluoromethanesulfonic anhydride (1 eq, 1.17 g, 41. mmol) and pyridine (1 
eq, 0.33 g, 0.33 mL, 4.1 mmol) in dichloromethane at 0 °C. The solution was 
warmed up to room temperature and evaporated. The remaining residue was 
taken up with pentane and washed with water. Then the organic layer was dried 
over sodium sulphate and the solvent was removed under reduced pressure. 
The reaction yielded methyl 3-methyl-2-(trifluoromethylsulfonyloxy)butanoate 
(0.9 g, 3.4 mmol, 83 %) as purple liquid, 1H-NMR (300 MHz, CDCl3): δ = 0.91 
(d, J = 6.9 Hz, 3 H), 1.00 (d, J = 6.9 Hz, 3 H), 2.28-2.34 (m, 1 H), 3.74 (s, 3 H), 
4.91 (d, J = 3.84 Hz, 1 H) – 13C-NMR, DEPT 135 (75 MHz, CDCl3): δ = 15.9 (+, 
CH3), 17.8 (+, CH3), 30.9 (+, CH), 52.5 (+, CH3), 88.0 (+, CH), 116.3 (Cquat), 
167.02 (Cquat) – MS (CI): m/z (%) = 282 (100) [MNH4+] – IR ν~ [cm-1] = 1145 
(S=O), 1213 (C-F), 1736 (C=O), 2966 (C-H) – [α]D20 -13.5 ° (c: 1.0, CHCl3) – 
MF C7H11F3O5S – MW 264.22 
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Methyl 2-[(S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino]-3-methyl-
butanoate (12a) 
Phenylalaninmethylester (0.34 g, 1.8 mmol, 1 eq) was dissolved in a mixture of 
dichloromethane and 1.1 eq of Et3N (0.2 g, 0.3 mL, 2 mmol) and a solution of 
(S)-ethyl 3-methyl-2-(trifluoromethylsulfonyloxy)butanoate (0.50 g, 1.8 mmol,  
1 eq) in dichloromethane was added at 0 °C. The reaction was stirred for 15 h 
at room temperature and then washed with water. The organic layers were 
dried over sodium sulphate and the solvents were removed under reduced 
pressure. Further purification was achieved by column chromatography (elution 
with ethyl acetate, Rf = 0.75). The reaction yielded methyl 2-[(R)-1-methoxy-1-
oxo-3-phenylpropan-2-ylamino]-3-methylbutanoate (0.17 g, 0.58 mmol, 32 %) 
as yellow oil, 1H-NMR (300 MHz, CDCl3): δ = 0.90 (d, J = 6.86 Hz, 3 H), 0.99 (d, 
J = 7.1 Hz, 3 H), 1.70-1.78 (m, 1 H), 2.73-2.90 (m, 2 H), 3.30 (t, J = 6.7 Hz, 1 
H), 3.52 (s, 3 H), 3.55 (s, 3 H), 7.08-7.15 (m, 5 H) – 13C-NMR, DEPT 135 (75 
MHz, CDCl3): δ = 18.2 (+, CH3), 19.1 (+, CH3), 31.9 (+, CH), 39.9 (-, CH2), 51.5 
(+, CH3), 51.7 (+, CH3), 63.0 (+, CH), 66.6 (+, CH), 126.5 (+, CHarom), 128.2 (+, 
2 x CHarom), 129.4 (+, 2 x CHarom), 137.7 (Cquat), 174.5 (Cquat), 175.0 (Cquat) – MS 
(CI): m/z (%) = 294 (100) [MH+] – IR ν~ [cm-1] = 1734 (C=O), 2955 (C-H) – MF 
C16H23NO4 – MW 293.36 
 
(2S)-2-(1-Methoxy-3-methyl-1-oxobutan-2-ylamino)-3-phenylpropanoic 
acid (13a) 
Methyl 2-[(R)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino]-3-methylbutanoate 
(50 mg, 0.17 mmol) was dissolved in methanol. After the addition of LiOH (6 eq, 
24 mg, 1.0 mmol) the reaction mixture was stirred for 15 h at room temperature. 
To work-up the reaction the pH was adjusted to 2 with diluted HCl and extracted 
with ethyl acetate. The organic layer was dried over sodium sulphate and the 
solvent was evaporated. The reaction yielded the mono-ester (5 mg, 0.02 mmol, 
9 %) as yellow oil. Due to small amount, purity was checked by HPLC-MS (Rt: 
5.66 min), 1H-NMR (300 MHz, CDCl3): δ = 0.68 (d, 6.6 Hz, 3 H), 0.75 (d, 6.9 Hz, 
3 H), 1.88-1.92 (m, 1 H), 2.89-2.96 (m, 2 H), 3.26-3.32 (m, 1 H), 3.40-3.44 (m, 1 
H), 3.70 (s, 3 H), 7.23-7.33 (m, 5 H) – MS (+ESI): m/z (%) = 280 (100) [MH+] – 
MF C14H19NO4  – MW 265.30 
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Cell Lines and Cell Culture Conditions. 
The human epithelial cervical cancer cell line HeLa [CCL-2, American Type 
Culture Collection (ATCC)] was cultured in MEM Earle’s medium. An amount of 
500 mL MEM was supplemented with 0.8 mL amphotericin B (250 µg/mL), 5 mL 
penicillin/streptomycin (10,000 U/mL/ 10,000 µg/mL), 5 mL L-glutamine (200 
mM), 5 mL NEA (100×), and 50 mL fetal bovine serum (all from Biochrom AG, 
Berlin, Germany). Cells were split in 1:6 ratio twice a week. All cells were 
cultured in a humidified incubator at 37 °C in a 5 % CO2 atmosphere. 
 
Determination of Cytotoxicity via MTT assay. 
The cytotoxic effect of 8a, 8b, 9, 12a, 12b, 13a and 13b, respectively, was 
determined using the non-metabolizing HeLa (ATCC CCL-2) cell line. For 
evaluation of cytotoxicity on HeLa cells, the colourimetric MTT (tetrazolium) 
assay was conducted as previously described by Mosmann[27] in a modified 
manner according to Heilmann[29] et al. In brief, following trypsinization, HeLa 
cells were counted and 11250 cells/well were seeded into a 96 well plate 
(Techno Plastic Products AG, Trasadingen, Switzerland). Afterward, the cells 
were exposed to the compounds (final concentrations) 8a (12.5 µM, 25 µM, 50 
µM, 75 µM, 100 µM), 8b (25 µM, 50 µM, 75 µM, 100 µM, 150 µM, 200 µM, 300 
µM), 9 (25 µM, 50 µM, 75 µM, 100 µM, 150 µM, 200 µM), 12a (25 µM, 50 µM, 
75 µM, 100 µM, 150 µM, 200 µM, 300 µM), 12b (12.5 µM, 25 µM, 50 µM, 75 
µM, 100 µM), 13a (12.5 µM, 25 µM, 50 µM, 75 µM, 100 µM) and 13b (12.5 µM, 
25 µM, 50 µM, 75 µM, 100 µM) dissolved in 30 % of EtOH for 72 h at 37 °C and 
5 % CO2. For quantification of viability, cells were incubated with 15 µL/well 
MTT (tetrazolium) solution (4 mg/mL) for four hours, which was then converted 
into insoluble, violet formazan. After removal of the supernatant, 150 µL SDS 
solution (10 %) was added to dissolve the formazan crystals. The next day, 
absorption was measured at 560 nm using a SpectraFluorPlus microplate 
reader (Tecan GmbH, Crailsheim/Germany). All tests were performed in 
sextuplicates. Solvent control was set to 100 %. 
Human ACE-2 inhibition. Assay was done by the company CEREP (Le Bois 
l'Evêque BP 30001 - 86600 Celle l’Evescault, France). The assay reference 
compound was Ac-GG-26-NH2 with IC50 = 610 nM and nH = 1.5. All compounds 
were tested at 10 µM final concentration. 
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5.5. Supporting Information 
Spectra. 
Compound 6a 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
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Compound 6b 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
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Compound 8a 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
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Compound 8a HPLC analysis 
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Compound 8b 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
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Compound 9 LC-MS analysis 
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Compound 11a 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
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Compound 12a 1H NMR (300 MHz, CDCl3), 13C NMR (75 MHz, CDCl3) 
 
 
5. Stereoselective Synthesis of alpha-disubstituted Secondary Amines as 
Potential ACE Inhibitors 
 
 
148 
Compound 12a HPLC analysis 
 
 
Compound 12b HPLC analysis  
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Compound 13a LC-MS analysis 
 
Inhibition of human angiotensin-converting enzyme (ACE-2) at 10 µM final 
concentration. 
 
Compound % inhibition of 
control values* 
8a  3 
8b  4 
12a  0 
12b  3 
13b  5 
*reference compound: Ac-GG-26-NH2 
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6. Summary 
Chapter 1 reviews the copper- and palladium-mediated aryl-N bond formations 
used in the synthesis of biological active compounds. Examples using the 
palladium-catalysed Buchwald-Hartwig method, the copper-mediated Ullmann-
Goldberg method and the Cham-Lan method were compared concerning their 
reaction conditions, their scope for a wide spectra of substituent and functional 
groups and their scale-up prospects. The discussed examples show that 
palladium-catalysed reactions are favoured for large scale applications and 
tolerate sterical demanding substituents on the coupling partners better than 
Cham-Lan conditions. Cham-Lan N-arylations are particular mild and do not 
require the addition of ligands, which facilitates the work-up. However, reaction 
times can be very long. Ullmann- and Buchwald-Hartwig-type reactions have 
been used in intramolecular reactions giving access to complex ring structures. 
All three N-arylation methods have specific advantages and disadvantages that 
should be considered when selecting the reaction conditions for a desired C-N 
bond formation in the course of a total synthesis or drug synthesis. 
 
Chapters 2, 3 and 4 deal with the modulation of the membrane located ABC-
transporter ABCG2, which is an effective tool for the treatment of multi-drug 
resistant cancer cells. Starting from the recently discovered tariquidar-derived 
selective ABCG2 modulator (lead structure), in chapter 2 different fluorescent 
labelled ABCG2 modulators were synthesised. The modified modulators show 
emission in the red part of the spectrum and reveal quantum yields up to  
31.2 %. Moderate potency was obtained by the replacement of the 
tetrahydroisoquinoline part of the tariquidar-derived lead-structure by a pyrylium 
label. All synthesised derivatives showed selectivity for ABCG2 over ABCB1. 
Studies at the physiological expressed ABCG2 concentrations on rat brain 
capillaries revealed that the parent lead structure is also influencing the rat 
ABCG2 transporter, confirming the results of previous in vitro experiments with 
MCF-7/Topo cells and Hoechst 33342 as substrate. Due to lower affinity of the 
fluorescent labelled compounds, this could not be proven for the fluorescent 
modulators. 
Chapter 3 shows structural variations of the lead structure to improve the drug-
like properties and the potency. Incubation in mouse plasma proved the stability 
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of the ester functionality, but one of the peptide bonds was cleaved, also if N-
methylated. Structural changes of different parts of the molecule decreased the 
potency only moderately as long as there was no negative charge introduced 
under physiological conditions. The phenylbenzamide group turned out to be 
essential for the interaction with the transporter. 
Chapter 4 discribes photochromic tariquidar-derived compounds as potential 
ABCG2 modulators which may be useful as tool in mechanistic investigation. 
The synthetic approach was focused on the replacement of characteristic 
structural moieties of a potent and selective ABCG2 inhibitor by photochromic 
dithienylethenes. Photochemical properties, thermostability, cycle performance, 
photostationary state and photostability at assay conditions are suitable for all 
four compounds for pharmacological in vitro investigations. 
 
Chapter 5 reports the synthesis of secondary amines containing two carbon 
stereocentres in both α-positions. These are typical substructure of ACE 
inhibitors and other biological active compounds. The stereoselective synthesis 
was aspired in different approaches, but industrial applications still mostly apply 
the separation of diastereomers. Here, two synthetic methods, a SN2 reaction 
and an oxazolidine mediated reaction sequence, were compared concerning 
their selectivity. The oxazolidine intermediate-mediated amine formation gave 
only one entantiomer for the substituted secondary amine. The synthesised 
compounds showed weak or no cytotoxicity. Selected compounds were tested 
as inhibitors of ACE-2, but revealed no biological activity. 
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7. Zusammenfassung 
Kapitel 1 vermittelt einen Überblick über die kupfer- und palladiumvermittelte 
Aryl-N Bindungsbildung die bei den Synthesen biologisch aktiver Substanzen 
verwendet wird. Beispiele, die die palladiumkatalysierte Buchwald-Hartwig 
Methode, die kupfervermittelte Ullmann-Goldberg Methode und die Cham-Lan 
Methode verwenden, wurden bezüglich ihrer Reaktionsbedingungen, ihrer 
Toleranz gegenüber verschiedener Substituenten und funktionellen Gruppen 
und ihrer Up-Scale Möglichkeiten verglichen. Die diskutierten Beispiele zeigen, 
dass die palladiumkatalysierten Reaktionen für Anwendungen im größeren 
Maßstab bevorzugt werden und dass sie gleichzeitig sterisch anspruchsvolle 
Substituenten an den Kupplungspartern besser tolerieren als bei Cham-Lan 
Bedingungen. Cham-Lan N-Arylierungen sind besonders mild und benötigen 
keine Liganden, was die Aufarbeitung deutlich vereinfacht. Jedoch können die 
Reaktionszeiten sehr lang sein. Ullmann- und Buchwald-Hartwig Reaktionen 
wurden in intramolekularen Reaktionen zum Aufbau von komplexen 
Ringstrukturen verwendet. Alle drei N-Arylierungsmethoden haben ihre 
spezifischen Vor- und Nachteile. Dies spielt bei der Wahl der 
Reaktionsbedingungen für die gewünschte C-N Bindungsbildung in der Planung 
einer Totalsynthese oder einer Wirkstoffsynthese eine wichtige Rolle. 
 
Kapitel 2, 3 und 4 beschäftigen sich mit der Hemmung des membranständigen 
ABC-Transporters ABCG2, die ein effektives Instrument für die Behandlung 
multiwirkstoffresistenter Krebszellen ist. Ausgehend von dem kürzlich 
entdeckten, von Tariquidar abgeleiteten, selektiven ABCG2 Inhibitor 
(Leitstruktur) wurden in Kapitel 2 verschiedene fluoreszenzmarkierte ABCG2 
Inhibitoren hergestellt. Die modifizierten Modulatoren zeigten Emission im roten 
Bereich des Lichtspektrums und ergaben Quantenausbeuten bis zu 31,2 %. 
Moderate biologische Aktivität wurde für die von Tariquidar abgeleitete 
Leitstruktur erhalten, die an Stelle des Tetrahydroisoquinolinteils ein 
Pyryliumlabel besitzt. Alle hergestellten Derivate zeigten eine gute selektive 
Wirksamkeit für ABCG2 gegenüber ABCB1. Untersuchungen an ABCG2 in 
physiologisch expremierten Konzentrationen an Rattengehirnkapillaren 
machten deutlich, dass die ursprüngliche Leitstruktur auch die ABCG2 
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Transporter in Ratten beeinflusst und somit die Ergebnisse der vonangehenden 
in vitro Experimente mit MCF7/Topo Zellen und Hoechst 33342 als Substrat 
bestätigten. Auf Grund der niedrigeren Affinität der fluoreszenzmarkierten 
Verbindungen konnte dies für die fluoreszenten Modulatoren nicht bewiesen 
werden.  
Kapitel 3 zeigt strukturelle Veränderungen der Leitstruktur zur Verbesserung 
potentieller Wirkstoffeigenschaften und der Wirksamkeit. Inkubation mit Mäuse-
plasma bewies die Stabilität der Esterfunktionalität, jedoch wurde eine der 
Peptidbindungen, trotz Methylierung gespalten. Strukturelle Veränderungen an 
verschiedenen Teilen des Moleküls verringerte die Wirksamkeit nur geringfügig, 
solange unter physiologischen Bedingungen keine negative Ladung vorlag. Die 
Phenylbenzamid-Funktionalität stellte sich als essentiell für die Wechselwirkung 
mit dem Transporter heraus. 
In Kapitel 4 werden von Tariquidar abgeleitete, photochrome Verbindungen als 
potentielle ABCG2 Modulatoren, die nützlich für mechanistische 
Untersuchungen sein können, beschrieben. Die synthetische Strategie 
konzentrierte sich auf den Austausch charakteristischer Strukturteile eines 
potenten und selektiven ABCG2 Hemmers durch photochrome Dithienylethene. 
Die photochemischen Eigenschaften, die Thermostabilität, die Lebensdauer, 
der photostationäre Zustand und die Photostabilität bei den Testbedingungen 
zeigten für alle vier Substanzen die Eignung für pharmakologische in vitro 
Untersuchungen. Erste pharmakologische Untersuchungen zeigten eine 
niedrige Affinität der ringgeöffneten Isomere. 
In Kapitel 5 wird die Synthese sekundärer Amine mit zwei Stereozentren in 
beiden α-Positionen vorgestellt. Diese Substrukturen sind typisch für ACE 
Hemmer und andere biologisch aktive Substanzen. Die stereoselektive Syn-
these wurde bereits in verschiedenen Ansätzen angestrebt, aber für industrielle 
Anwendungen wird meistens noch die Auftrennung der Diastereomere ver-
wendet. Hier wurden zwei synthetische Methoden bezüglich ihrer Selektivität 
verglichen: Eine SN2 Reaktion und eine Reaktionssequenz über eine Oxazoli-
din-Zwischenstufe. Dabei ergab die oxazolidin-vermittelte Reaktion nur ein 
Enantiomer für das substituierte sekundäre Amin. Die hergestellten Substanzen 
zeigten schwache oder keine Toxizität. Ausgewählte Verbindungen wurden als 
Hemmstoffe für ACE-2 getestet, zeigten aber keine biologische Aktivität. 
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8. Abbreviations 
 
ABC  ATP binding cassette 
ABCB1 ABC transporter B1, p-
gylocoprotein 170 
ABCG2 ABC transporter G2, 
 breast cancer 
resistance protein 
ABCP  ACB transporter  
  expressed in placenta 
Ac  Acetyl 
ADHD Attention deficit 
hyperactivity disorder 
Aq  Aqueous 
ATP  Adenosine  
  triphosphate 
ATR  Attenuated total 
reflection 
BBB  Blood brain barrier  
BCRP  Breast cancer 
resistance protein 
BINAP 2,2´–Bis(diphenyl-
phosphino)-1,1´-
binaphthyl 
Boc  t-Butyloxycarbonyl 
BSA  Bovine serum  
  albumine 
Bu  Butyl 
Calcein-AM Calcein- 
  acetoxymethylester 
calcd  Calculated 
CI  Chemical ionisation 
CNS  Central nervous 
system 
CSC  Cancer stem cell 
COSY  Correlated  
  spectroscopy 
CLSM  Confocal laser  
  scanning microscopy 
DAD  Diode array detector 
DCM  Dichloromethane 
DEPT Distortionless enhance- 
ment by polarization 
transfer 
DIPEA Diisopropylethylamine 
DMAP Dimethylaminopyridine 
DME  1,2-Dimethoxyethan 
DMEDA Dimethylethylendiamin 
DMF  Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA  Desoxyribonucleic acid 
DPPF  1,1'-Bis(diphenyl- 
  phosphino)ferrocen 
DtBPF Di-tert-butyl phosphate 
DTE  Dithienylethene 
EMEM Eagels minimum  
  essential medium 
eq  Equivalent 
EI-MS Electron-impact 
ionization mass 
spectrometry 
ESI  Electronspray  
  ionisation 
Et  Ethyl 
EtOAc Ethyl acetate 
EtOH  Ethanol 
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FACS Fluorescence 
activated cell 
FCS  Fetal calf serum 
FTC  Fumitremorgin C 
FT  Fourier transformed 
HB  Hydrogen bond 
HOBt  1-Hydroxy-
benzotriazole 
HPLC  High pressure liquid  
  chromatography 
HR-MS High resolution mass 
spectrometry 
5-HT 5-Hydroxytryptamin 
IC50 Half maximal inhibitory 
concentration 
IR  Infrared spectroscopy 
J  Coupling constant 
Log P Partition coefficient 
between n-octanol and 
water 
MCF-7/Topo Topotecan resistant  
human breast cancer 
cells 
MDR  Multidrug resistance 
Me  Methyl 
MeOH Methanol 
MF  Molecular formula 
Mp  Melting point 
MMP  matrix metalloprotease 
MS  Mass spectrometry 
MRP  Multidrug-related 
protein 
MXR  Mitoxantrone  
  resistance-associated  
  protein 
MW  Molecular weight 
NET  Norepinephrine  
  transporte 
NHC  N-heterocyclic carbene 
NIR  Near infrared 
NMR  Nuclear magnetic  
  resonance 
NPY  Neuropeptide Y 
PBS  Phosphate buffered  
  saline 
PE  Petrol ether (hexanes) 
P-gp  P-glycoprotein 
Ph  Phenyl 
PPAR  Peroxisome  
  proliferators-activated  
  receptor 
Rf  Retention factor 
RFU  Relative fluorescent 
units 
RP  Reversed phase 
RT  Room temperature 
SAR  Structur activity  
  relationship 
SEM  Standard error of the  
  mean 
SERGPHOS 5,5′-Bis(diphenyl-
phosphino)-4,4′-bi-1,3-
benzodioxole 
SNP  Single nucleotide  
  polymorphism 
SN2 nucleophilic 
substitution type 2 
TBTU O-Benzotriazol-1-yl-
N,N,N',N'-tetramethyl-
uroniumtetrafluoroborate 
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TFA  Trifluorous acetic acid 
THF  Tetrahydrofuran 
TLC Thin layer 
chromatography 
TMD Trans membrane 
domaines 
TMEDA Tetramethyl-
ethylendiamin 
Topo  Topotecan 
tr  Retention time 
UV  Ultraviolett 
Vis  Visible 
XANTPHOS 4,5-Bis(diphenyl-
phosphino)-9,9-
dimethylxanthene
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